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Preface
This thesis presents the research work carried out from March 2008 to July 2011 in the 
laboratories of Unidade de Retrovírus e Infeções Associadas (URIA) – Centro de 
Patogénese Molecular (CPM) and Instituto de Medicina Molecular (IMM), under the 
supervision of Prof. João Gonçalves. 
The thesis is divided in four sections. The first one is the introduction, which contains 
an overview of the gene therapy subjects relevant to this study. The second section 
describes the materials and methods used throughout this work. In the third one, the 
results and discussion, it is presented the data obtained during this research work and it 
is also described and discussed all the trials and attempts necessary to achieve the final
results. Finally, in the fourth section it is presented the conclusions and perspectives. 
The results shown here are included in a manuscript that is being prepared for 
submission. 
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Abstract
A crucial factor for successful gene therapy is the efficacy of specific gene transfer, 
which is usually done by lentiviral vectors. Binding specificity and fusion of lentiviral 
vectors must be provided by envelope glycoprotein domains. The Sindbis virus 
envelope can pseudotype lentiviral particles and display exogenous protein domains. 
Previous results from this lab demonstrated that Sindbis envelope can accommodate 
anti-receptor single-chain antibodies (scFv) and target via cell-specific viral infection. 
In addition, Dr Irvin Chen laboratory has shown that Protein A-chimeric Sindbis 
envelope can specifically target cells immunolabelled with anti-receptor IgG via Fc
recognition. However, these strategies might present some problems for in vivo
applications, since there may be non-specific reactions with plasma antibodies and the 
need for cloning a receptor specific antibody each time a new molecule needs to be 
targeted. To overcome these problems we developed a new lentiviral vector capable of 
transducing several cell types in a specific manner without the above constraints, that 
consists of a chimeric scFv-Sindbis virus envelope that binds fluorescein 
isothiocyanate (FITC) with high affinity and consequently recognize FITC-conjugated 
proteins. Therefore, a target cell expressing on its surface a receptor targeted by FITC-
conjugated IgG can be infected by this scFv-Sindbis envelope pseudotyped lentiviral 
vector. Anti-FITC scFv was successfully incorporated at the surface of Sindbis-
pseudotyped lentiviruses and could bind to FITC-labelled cells. Using this targeting 
strategy, we were able, in vitro, to target efficiently and specifically Jurkat cells 
labelled by a CD7 FITC-conjugated antibody. Moreover, we could specifically kill 
those transduced cells using an HSV-TK/GCV suicide gene strategy. The in vivo
efficiency of this gene therapy proposal was tested in a mouse model of T-cell acute 
lymphoblastic leukaemia (T-ALL), which allowed targeting 15.2% of the tumour cells.  
This provides an alternative strategy to deliver molecular therapeutics using a modular 
specific targeting with lentiviruses. Moreover, it will overcome the need for new scFv 
cloning each time a new cell receptor must be targeted and it will avoid the 
competition by serum antibodies when applied in vivo, since the chimeric envelope 
will only recognize an organic molecule not present in the serum. Although the 
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strategy herein proposed was applied to a leukaemia model it has the potential to be 
applied to a broad range of diseases.
Keywords: gene therapy, lentiviral vectors, recombinant antibodies, leukaemia
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Resumo 
Um factor crucial para realizar uma terapia génica com sucesso é a transferência
específica e eficaz de genes, o que normalmente é conseguido através do uso de 
vectores lentivirais. A especificidade de reconhecimento do alvo e o processo de fusão 
dos vectores lentivirais deve ser realizado pelas glicoproteínas do invólucro viral. A
glicoproteína do invólucro do vírus Sindbis pode pseudotipar lentivírus e apresentar na 
sua estrutura domínios exógenos de proteínas. Resultados anteriores deste laboratório
demonstraram que o invólucro do Sindbis pode acomodar na sua estrutura um 
fragmento de anticorpo (scFv) que reconhece receptores presentes na superfície celular 
infectando especificamente esse tipo de células através de um mecanismo alvo-
específico. Para além disso, o laboratório do Doutor Irvin Chen mostrou que a 
glicoproteína quimérica Sindbis-Proteína A pode reconhecer especificamente as 
células marcadas previamente com IgG, através de um reconhecimento da região Fc da
imunoglobulina. No entanto, essas estratégias podem apresentar alguns problemas
quando aplicadas in vivo, pois pode haver competição inespecífica por parte de 
anticorpos em circulação, para além da necessidade de se clonar um novo scFV 
receptor-específico cada vez que se queira fazer o reconhecimento de uma nova 
molécula. Para ultrapassar estes problemas, desenvolveu-se um novo vector lentiviral 
capaz de transduzir vários tipos de células de uma maneira específica e sem as 
restrições acima mencionadas, que consiste na incorporação no invólucro do vírus 
Sindbis de um scFv que reconhece com elevada afinidade a fluoresceína (FITC) e, 
consequentemente, é capaz de reconhecer proteínas conjugadas com FITC. Assim, 
qualquer molécula da superfície de uma célula alvo que seja marcada com um 
anticorpo conjugado com FITC, será identificada e especificamente infectada por este
vector lentiviral. Este anti-FITC scFv foi incorporado com sucesso à superfície de 
lentivírus pseudotipados com o envelope do Sindbis e foi capaz de reconhecer células
marcadas com FITC. Usando esta estratégia in vitro, foi possível fazer o 
direccionamento, de uma forma eficiente e específica, de células Jurkat marcadas por 
um anticorpo CD7 conjugado com FITC. Além disso, conseguiu matar-se
especificamente as células transduzidas usando como estratégia o sistema HSV-TK / 
GCV. A eficiência in vivo desta proposta de terapia genética foi testada num modelo 
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de ratinho de leucemia linfoblástica aguda das células T, o que permitiu “atingir”
15.2% das células tumorais. Esta proposta de investigação vai fornecer os meios para 
uma entrega eficiente de bioterapias alvo-específicas utilizando uma estratégia 
modular de reconhecimento. Além disso, com este sistema deixa de ser necessário 
realizar novas clonagem de scFv para cada vez que se pretenda fazer o 
direccionamento para um receptor celular diferente e também evita a competição com
anticorpos existentes no soro, quando aplicado in vivo, uma vez que o envelope 
quimérico só irá reconhecer uma molécula orgânica que não está presente no soro. 
Apesar da estratégia aqui proposta ter sido aplicada a um modelo de leucemia ela tem 
potencial para ser aplicada a uma vasta gama de doenças.
Palavras-chave: terapia génica, vector lentiviral, anticorpos recombinantes, leucemia
Table of contents
ix
Table of contents
PREFACE ....................................................................................................................... I
ACKNOWLEDGMENTS.............................................................................................III
ABSTRACT...................................................................................................................V
RESUMO .................................................................................................................... VII
TABLE OF CONTENTS..............................................................................................IX
LIST OF TABLES ........................................................................................................XI
LIST OF FIGURES....................................................................................................XIII
ABBREVIATIONS..................................................................................................... XV
OBJECTIVES .......................................................................................................... XVII
1. INTRODUCTION...................................................................................................1
1.1 GENE THERAPY: AN OVERVIEW .................................................................................................... 3
1.2 GENE DELIVERY VECTORS ............................................................................................................ 6
1.2.1 Non-viral vectors..................................................................................................................... 6
1.2.2 Viral vectors ............................................................................................................................ 6
1.2.3 Lentiviral vectors................................................................................................................... 10
1.3 IMMUNE RESPONSES TO VIRAL VECTORS AND TRANSGENES ....................................................... 14
1.4 TARGETING STRATEGIES ............................................................................................................ 18
1.4.1 Pseudotyping lentiviral vectors ............................................................................................. 19
1.4.2 Sindbis pseudotyped lentiviral vectors .................................................................................. 24
1.4.3 Single-chain antibodies (scFv) as a targeting vehicle in gene therapy ................................. 27
1.5 SUICIDE GENE THERAPY ............................................................................................................. 31
1.6 APPLICATIONS OF GENE THERAPY IN DISEASES AND IN CLINICAL TRIALS ................................... 34
1.7 HUMAN T-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA (T-ALL): THE MODEL FOR OUR DELIVERY
AND TARGETING STRATEGY ................................................................................................................. 37
1.7.1 Overview of the disease ......................................................................................................... 37
1.7.2 Treatment and new therapies ................................................................................................ 38
2. MATERIALS AND METHODS..........................................................................41
2.1 CELL LINES................................................................................................................................. 43
2.2 PLASMID CONSTRUCTION AND SINDBIS VIRAL ENVELOPE MUTATION......................................... 43
2.3 LUCIFERASE ASSAY .................................................................................................................... 45
2.4 ALAMARBLUE® CELL VIABILITY ASSAY .................................................................................... 45
2.5 DSRED FLUORESCENCE ANALYSIS.............................................................................................. 46
2.6 VIRAL VECTOR PRODUCTION ...................................................................................................... 46
2.7 WESTERN BLOT AND ANTIBODIES............................................................................................... 47
2.8 IN VITRO BINDING OF SINDBIS/ANTI-FITC ENVELOPE EXPRESSED IN 293T CELLS ...................... 48
Lentiviral target-specific strategy for molecular therapy 
x
2.9 IN VITRO BINDING OF LENTIVIRAL VECTORS............................................................................... 49
2.10 IMMUNOFLUORESCENCE STAINING........................................................................................ 49
2.11 TARGETED IN VITRO TRANSDUCTION..................................................................................... 49
2.12 COMPETITION ASSAY............................................................................................................. 50
2.13 HSV-TK/GCV SUICIDE GENE ASSAY .................................................................................... 50
2.14 MICE ..................................................................................................................................... 50
2.15 IN VIVO TARGETED CELL TRANSDUCTION.............................................................................. 51
2.16 REAL-TIME PCR.................................................................................................................... 51
3. RESULTS AND DISCUSSION........................................................................... 53
3.1 IN VITRO GENE THERAPY............................................................................................................ 55
3.1.1 Generation of mutations on the Sindbis glycoproteins and expression of anti-FITC scFv at 
the surface of Sindbis-pseudotyped lentiviral vector...................................................................... 55
3.1.2 Expression of the Sindbis envelope at the surface of 293T cells ........................................... 59
3.1.3 Binding of the Sindbis/anti-FITC M123 envelope to the anti-CD7-FITC tested in 293T cells
....................................................................................................................................................... 61
3.1.4 In-vitro binding of Sindbis/anti-FITC pseudotyped lentiviruses to Jurkat/CD7-FITC cells . 62
3.1.5 Production of lentiviral vectors: optimization to reach the highest levels of transduction... 65
3.1.6 In-vitro targeting of Jurkat cells ........................................................................................... 77
3.1.7 Competition of an anti-FITC antibody with the anti-FITC scFv displayed by Sindbis-
pseudotyped lentiviruses ................................................................................................................ 83
3.1.8 Suicide gene therapy ............................................................................................................. 84
3.1.8.1 The DT-A approach........................................................................................................................84
3.1.8.2 The HSV-TK approach ...................................................................................................................89
3.2 IN VIVO GENE THERAPY.............................................................................................................. 95
3.2.1 The choice of gene reporter (transgene) for detection of transduced cells ........................... 95
3.2.2 Establishment and validation of the animal model for cell engraftment............................... 98
3.2.3 In vivo targeting of leukemic cells....................................................................................... 106
3.2.4 In vivo killing of leukemic cells ........................................................................................... 115
4. CONCLUSIONS AND PERSPECTIVES.......................................................... 121
REFERENCES ........................................................................................................... 129
APPENDICES ............................................................................................................ 143
List of tables
xi
List of Tables
Table I. Viral vectors used in gene therapy.....................................................................8
Table II. Transduction efficiency of Jurkat and Molt-4 cells infected with the VSV-G-
pseudotyped lentiviral vectors expressing GFP or RFP........................................69
Table III. Transduction efficiency of Jurkat cells infected with the VSV-G-
pseudotyped lentiviral vectors expressing GFP or RFP, produced in the presence 
or absence of serum and using different ratios of plasmids. .................................70
Table IV. Transduction efficiency of Jurkat cells infected with the VSV-G-
pseudotyped lentiviral vectors expressing GFP produced ....................................72
Table V. Transduction efficiency of Jurkat cells infected with the VSV-G-pseudotyped 
lentiviral vectors expressing GFP (FUGW) produced ..........................................73
Table VI. Comparison of transduction efficiency between Jurkat and Molt-4 cells 
infected with the VSV-G-pseudotyped lentiviral vectors expressing GFP (FUGW) 
or RFP (FUW/RFP) produced...............................................................................74
Table VII. Transduction efficiency of Jurkat cells infected either with Sindbis/anti-
FITC-pseudotyped lentiviruses expressing RFP or with VSV-pseudotyped 
lentiviral vectors expressing GFP or RFP. ............................................................74
Table VIII. Transduction efficiency of Jurkat cells infected with Sindbis/anti-FITC- or 
VSV-G-pseudotyped lentiviral vectors, both expressing DsRed. .........................75
Table IX. Copy numbers of lentiviral vectors expressing DsRedIRESRenilla or 
RenillaIRESTK ...................................................................................................120
Table X. List of the primers used for sequencing. ......................................................145
Table XI. List of the primers used for Sindbis envelope mutagenesis........................145
Table XII. List of the primers used for cloning...........................................................146
Table XII. (Continued) ................................................................................................147
Table XIII. Primers used for real-time PCR. ..............................................................147
Lentiviral target-specific strategy for molecular therapy
xii
List of figures
xiii
List of Figures
Figure 1. Retrovirus structure........................................................................................10
Figure 2. Schematic of HIV provirus, typical HIV-1-derived transfer vectors (left) and 
packaging constructs (right). .................................................................................12
Figure 3. Principle of re-targeting of lentiviral vectors.................................................19
Figure 4. Detection of Sindbis/anti-FITC envelope on pseudotyped virions................55
Figure 5. Schematic of Sindbis/anti-FITC construct with the several mutations 
depicted by an arrow. ............................................................................................57
Figure 6. Sindbis/anti-FITC M123 expression at the surface of 293T cells. ................59
Figure 7. Sindbis/anti-FITC M1234 expression at the surface of 293T cells. ..............60
Figure 8. Binding of Sindbis/anti-FITC M123 to the CD7-FITC antibody tested in 
293T cells. .............................................................................................................61
Figure 9. In vitro binding assay in Jurkat cells assessed by flow cytometry. ...............63
Figure 10. In vitro binding assay in Jurkat cells assessed by microscopy. ...................64
Figure 11. Schematic diagram of the lentiviral transfer vectors FUGW and #318/GFP-
Fluc........................................................................................................................66
Figure 12. Titration of the plasmid ratio used to produce VSV-G-pseudotyped 
lentiviruses encoding the transgenes GFP or RFP. ...............................................67
Figure 13. Titration of the plasmid ratio used to produce VSV-G-pseudotyped 
lentiviruses encoding RFP.....................................................................................68
Figure 14. Titers of the VSV-G-pseudotyped lentiviruses encoding GFP or RFP. ......68
Figure 15. Titers of the VSV-G-pseudotyped lentiviruses encoding GFP or RFP, 
produced in the presence or absence of serum......................................................70
Figure 16. Titers of the VSV-G-pseudotyped lentiviruses expressing GFP (FUGW), 
produced either by CaPO4 or by lipofectamine transfection.................................71
Figure 17. Titers of the VSV-G-pseudotyped lentiviruses expressing GFP (FUGW), 
produced either by Lipofectamine or by Fugene 6 transfection............................73
Figure 18. Transduction of Jurkat cells with the pseudotyped Sindbis/anti-FITC 
lentiviruses. ...........................................................................................................78
Figure 19. Transduction of Jurkat cells with the pseudotyped Sindbis/anti-FITC 
lentiviruses. ...........................................................................................................80
Figure 19. Continued.....................................................................................................81
Figure 20. Competition between an anti-FITC antibody and the anti-FITC scFv 
displayed by Sindbis-pseudotyped lentiviruses for binding to FITC-labelled 
Jurkat cells.............................................................................................................83
Figure 21. Inhibition of protein synthesis by FUW-DTA in 293T (A) and HeLa (B) 
cells........................................................................................................................85
Figure 22. Inhibition of protein synthesis by FUW-DTA in 293DTR cells. ................86
Figure 23. Inhibition of protein synthesis by FUW-DTA in 293T and 293DTR cells. 86
Figure 24. Fluorescence intensity of the DsRed and TK constructs. ............................89
Figure 25. GCV sensitivity of 293T cells expressing DsRedIRESTK assessed by 
Alamarblue assay. .................................................................................................90
Figure 26. GCV titration in 293T cells expressing DsRedIRESTK by flow cytometry.
...............................................................................................................................91
Figure 27. GCV titration in Jurkat cells expressing DsRedIRESTK. ...........................92
Figure 28. Ganciclovir treatment can kill transduced Jurkat cells expressing DsRed. .93
Lentiviral target-specific strategy for molecular therapy
xiv
Figure 29. Imaging of fluorescence of Jurkat/DsRed cells in a cell culture plate. ....... 96
Figure 30. Imaging of fluorescence of Jurkat/DsRed cells in a Balb/c mouse. ............ 96
Figure 31. Firefly luciferase imaging in NOD/SCID mice, one week after injection 
with Molt-4 cells. .................................................................................................. 99
Figure 32. Luciferase imaging in NOD/SCID mouse three weeks after injection with 
Molt-4 cells. ........................................................................................................ 100
Figure 33. Renilla luciferase imaging in a Balb/c mouse. .......................................... 101
Figure 34. Percentage of human cells in Rag2 -/- IL2Rc -/- mice injected with Jurkat.
............................................................................................................................. 102
Figure 35. Imaging Jurkat/GFP-Fluc cells fluorescence in a culture plate................. 103
Figure 36. Firefly luciferase imaging of tumour cells distribution in NOD/SCID mice.
............................................................................................................................. 103
Figure 37. Firefly luciferase imaging in NOD-Rag1
-/-
IL2r
-/-
mice one week after 
injection with Molt-4 cells. ................................................................................. 105
Figure 38. Sindbis/anti-FITC M1234 pseudotyped lentiviral vector can target specific 
leukemic cells after systemic delivery in mice. .................................................. 109
Figure 39. Sindbis/anti-FITC M1234 pseudotyped lentiviral vector can target specific 
leukemic cells after systemic delivery in mice. .................................................. 110
Figure 40. Efficiency of in vivo transduction of leukemic T cells with Sindbis/anti-
FITC M1234 pseudotyped lentiviral vector........................................................ 111
Figure 41. Sindbis/anti-FITC M1234 lentiviral vector can target specific leukemic cells 
after systemic delivery in mice. .......................................................................... 112
Figure 42. Efficiency of in vivo transduction of leukemic T cells with Sindbis/anti-
FITC M1234 pseudotyped lentiviral vector........................................................ 113
Figure 43. Sindbis/anti-FITC M1234 lentiviral vector expressing RenillaIRESTK was 
not able to target specific leukemic cells upon systemic delivery in mice. ........ 116
Figure 43. Continued (2
nd
group of mice). .................................................................. 117
Figure 44. Comparison of the efficiency of in vivo targeting between Sindbis/anti-
FITC pseudotyped lentiviral vectors expressing DsRedIRESRenilla or 
RenillaIRESTK. .................................................................................................. 119
Figure 45. Comparison of the renilla luminescence from Jurkat cells expressing 
DsRedIRESRenilla or RenillaIRESTK............................................................... 120
Figure 46. Optimization of in vitro viral transduction using Sindbis/ZZ pseudotyped 
lentiviral vectors expressing DsRed.................................................................... 149
Figure 46. Continued. ................................................................................................. 150
Figure 47. Comparison between transduction efficiency mediated by virus 
concentrated by ultracentrifugation or by Lenti-X concentrator. ....................... 151
Figure 48. Comparison between transduction efficiency of Molt-4 and Jurkat mediated 
by Sindbis/anti-FITC Wt pseudotyped lentiviruses. ........................................... 153
Figure 49. Analysis of the reporter gene expression of several 
FUW/DsRedIRESRenilla clones in vitro in 293T cells...................................... 155
Figure 50. Analysis of the reporter gene expression of several RenillaIRESTK clones 
in vitro in 293T cells. .......................................................................................... 156
Figure 51. GCV has no effect on the untransduced cell population. .......................... 157
Abbreviations
xv
Abbreviations
AAV Adeno-associated virus 
ADA Adenosine deaminase 
AIDS Acquired immunodeficiency syndrome
ATCC American type culture collection
CCD Charged-coupled device 
CGD Chronic granulomatous disease
CLL Chronic lymphocytic leukaemia
CMV Cytomegalovirus
CNS Central nervous system 
CTL Cytotoxic T lymphocyte 
DT-A Diphtheria toxin-subunit A
EF-2 Elongation factor-2
EGFR Epidermal growth factor receptor
ELISA Enzyme-linked immunosorbent assay
ETA Pseudomonas aeruginosa-exotoxin A
FACS Fluorescence-activated cell sorting
FasL Factor-related apoptosis ligand
FBP Folate binding protein
FCS Foetal calf serum
FITC Fluorescein isothiocyanate
GCV Ganciclovir
GFP Green fluorescent protein
GSI Gamma secretase inhibitor
GvHD Graft versus host disease
HA Hemaglutinin protein (from Influenza virus)
HBV Human hepatitis B virus
HCL Hairy cell leukaemia
HIV Human immunodeficiency virus
HRP Horseradish peroxidise
HSCT Hematopoietic stem cell transplantation
HSV Herpes simplex virus
IRES Internal ribosome entry site
LTR Long terminal repeat
MLV Murine leukaemia virus
MOI Multiplicity of infection
MoMLV Moloney murine leukaemia virus 
NOD Non obese diabetic
pIX Adenovirus minor capsid protein
PSA Prostate specific antigen
RD114 Feline leukaemia virus
RCR Replication-competent retroviruses
RCL Replication-competent lentiviruses
RFP Red fluorescent protein 
scFv Single-chain variable fragment 
Lentiviral target-specific strategy for molecular therapy
xvi
SCID Severe combined immunodeficiency
SIN Self-inactivating
siRNA small interfering RNA
SIV Simian immunodeficiency virus
T-ALL T-cell acute lymphoblastic leukaemia
TCR T cell receptor
TK Thymidine kinase gene from HSV
TRAIL Tumour necrosis factor-related apoptosis-inducing ligand
TU Transducing units
VSV-G Vesicular stomatitis virus-glycoprotein
PBS Phosphate Buffered Saline
PCR Polymerase Chain Reaction
SDS-PAGE Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis
Objectives
xvii
Objectives
Gene therapy has been developed for the treatment of various inherited disorders, as 
well as acquired diseases, such as cancer and human immunodeficiency virus (HIV)
infection. An essential tool for this gene therapy is the delivery vector, which can be 
viral or non-viral. The remarkable advances in the development of delivery vectors and 
the knowledge of the molecular mechanisms of disease have contributed for the 
progress of human gene therapy. An important feature for successful gene therapy is 
the efficient target to specific cells or tissues. An approach that is used to “solve” the 
problem of specificity that occurs, for instance with lentiviral vectors, is to change the 
tropism of its envelope by using a cell-specific ligand or scFv that recognizes and 
binds to specific cell receptors. Nevertheless, despite some level of specificity, there 
are problems concerning the low fusion activity and low viral titer. In an attempt to 
develop better delivering and targeting strategies, it has been used alphavirus 
envelopes like the one from Sindbis virus, to pseudotype lentiviral vectors, since this 
virus can be produced at very high titres, can achieve high levels of expression and can 
fuse with cells independently of the receptor binding protein. Nevertheless, even 
though effective in vitro, Sindbis virus has a nonspecific cell tropism in vivo because 
its receptors have wide distribution and are highly conserved. The insertion of a scFv 
and the generation of mutations in the Sindbis envelope glycoprotein would eliminate 
the problem of its non-specificity and has been shown, in fact, to augment the targeting 
strategies. However, these strategies might present some problems for in vivo
applications, since there might occur non-specific reactions with plasma antibodies. 
Moreover, it needs cloning of a receptor specific antibody each time a new molecule 
needs to be targeted. To overcome these limitations it was developed a Sindbis 
pseudotyped lentiviral vector displaying a FITC scFv at the surface to target 
specifically any cell labelled with FITC-conjugated antibody. This new FITC scFv 
chimeric virus may have a wide therapeutic application, since any receptors or surface 
antigens can be targeted by this system. As a proof of concept of this strategy it was 
employed a model of T-cell leukaemia. 
Therefore, the specific aims of this work were:
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1) Expression of competent anti-FITC scFv at the surface of Sindbis envelope 
pseudotyped lentiviral vector;
2) In vitro specific targeting and killing of T-cells previously labelled with FITC-
conjugated IgG;
3) Validation of this strategy in vivo in a leukaemia mouse model.
Introduction
1
1. Introduction
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Introduction
3
1.1 Gene therapy: an overview
Gene therapy refers to the insertion of genes into an individual’s cells or tissues to treat 
a disease, in which a defective gene (responsible for the disease) is replaced by a 
functional one, or is supplemented in the case it is absent. The main idea behind gene 
therapy has been the treatment of both inherited and acquired diseases but particular 
importance has been placed in targeting molecular processes associated with 
carcinogenesis and on improving gene transfer efficiency of current vector systems.
A large number of gene transfer protocols has involved ex vivo approaches, where cells 
are explanted from the patient, infected with a viral vector and implanted back into the 
patient. However, the long term goal is the development of in vivo delivery, i.e., to 
inject the patient with a vector capable of specifically delivering the therapeutic gene 
to a target tissue or cells. 
Successful gene therapy depends on an efficient delivery and targeting of the 
therapeutic gene to specific cells or tissues in a safe way (without harming non-target 
cells) and with stable transgene expression. This would avoid problems with toxicity 
and unwanted healthy cells to be affected. An important factor to be considered is the 
virus native tropism. Often this should be diminished or ablated in order to avoid toxic 
side effects due to targeting to undesired sites. Vectors are usually engineered to target 
cells that they do not infect naturally but, for instance, in the case of herpesviruses its 
tropism can match its utility and can be therefore used for neuronal gene delivery 
30
.
Innate immune responses triggered by systemic vector administration can be a 
limitation of the use of gene therapy vectors. It is essential to overcome these vector-
mediated innate immune responses, such as production of inflammatory cytokines, the 
maturation of antigen-presenting cells and tissue damage, because the induction of 
these responses not only shortens the period of gene expression but also leads to 
serious side effects.
When using viral vectors, the deletion of unnecessary viral genes considerably reduces 
cytotoxicity and immunogenicity and prevents the generation of replication-competent
virus particles and subsequent spread of virus infection. Moreover, the transgene itself 
Lentiviral target-specific strategy for molecular therapy
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can be highly immunogenic or even toxic to the host. Host immune response can be 
more problematic in the case of adenoviral vectors as they can elicit potent cytotoxic T 
cell responses against viral proteins that can eliminate the transduced cells. Moreover, 
because they do not integrate and are lost by cell division, they need repeated infection 
and the raised neutralizing antibodies will preclude repeated administration of the 
vector. In one of the early gene therapy trials in 1999, massive immune responses to an 
adenoviral vector used to correct a mutation led to the death of Jesse Gelsinger, a 18-
year-old volunteer 
200
. For instance, the main safety concern of using onco-retroviral 
vectors is related to the risk of malignant transformation following oncogene activation 
due to random onco-retroviral genomic integration. There is an apparent low risk of 
malignancy that is predominately associated with the occurrence of chronic 
retroviremia resulting from replication-competent retroviruses (RCR), particularly in 
immunosuppressed recipient hosts
225
. On the other hand, the strict dependency of 
onco-retroviral gene transfer on cell division is an important safety advantage that 
significantly limits the risks of horizontal transmission.
Successful clinical trials have been reported for hematopoietic diseases, such as X-
chromosome-linked severe combined immunodeficiency (X-SCID)
33
and adenosine 
deaminase-deficient (ADA)-SCID. However, treatment of X-SCID with retroviral 
vectors has raised some safety concerns about its use in clinical gene therapy since the 
treated patients developed leukaemia
95
, that seemed to be linked to the activation of a 
known oncogene adjacent to the vector insertion sites. To avoid or to repair this risk in 
the mean time, chromatin insulators can be used to reduce chances for retrovirus-
mediated oncogenesis by inhibiting non-specific activation of close cellular proto-
oncogenes
64
. Co-transduction of a suicidal gene under the control of an inducible 
promoter could also be one of the important safety measures, since destruction of 
transduced cells can be triggered if abnormal growth is observed. Additionally, 
conditional expression of the transgene only in appropriate target cells via the 
combination of targeted transduction, cell type-specific expression, and targeted local 
administration will increase the overall safety of the retroviral systems. Finally, 
splitting of the viral genome, use of self-inactivating (SIN) retroviral vectors, or 
complete removal of the coding sequences for gag, pol, and env genes is desirable to 
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virtually eliminate the possibility of generation of RCR
225
. Therefore, positioned 
genome integration and reduced cytotoxicity and immunogenicity are very important 
factors to take into consideration when choosing a gene therapy vector. 
Ex-vivo transduction is better for introducing therapeutic genes into haematopoietic 
cells. For instance, in the case of congenital haematopoietic diseases, ex. X-SCID and 
ADA-SCID, delivery of therapeutic genes is achieved by isolating haematopoietic 
cells from patients, transducing it in-vitro and then re-infusing the cells back into the 
patients. In the case of cells of solid organs, it is difficult to isolate and replace these 
types of cells without causing the loss of their physiological functions and preservation 
of basic organ structure. One possibility for this would be to inject the gene therapy 
vector into the body, for example intratumoral administration, which result in 
transduction only in the injection surrounding area. Vector administration to the 
bloodstream would be a good mean to get to the target organs however, non-specific 
transduction may occur. Therefore, it is important to develop specific targeting 
strategies for an effective gene therapy approach. 
Lentiviral target-specific strategy for molecular therapy
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1.2 Gene delivery vectors
An efficient delivery is crucial for the success of any gene therapy approach. Various 
viral and non-viral vectors have been engineered for improved gene and drug delivery.
1.2.1 Non-viral vectors
Although viral vectors have been widely used for years, it has been mainly the
concerns about the safety and immunogenicity of the viral vectors that has driven 
investigators to develop non-viral vectors with targeting capacities for selective gene 
delivery. Non-viral vectors have low transfection efficiencies and lack of sustained 
gene expression and hence are little effective however, they have been improved to 
overcome these limitations and increasing attention has been given them because of
advantages such as lack of immunogenicity, ease of preparation, and relative safety
that, at the same time, make them suitable for repeated administration. Among these 
types of vectors are liposomes, cationic polymers, nanoparticles, naked DNA, 
antibodies and complexes of liposome with small-interfering RNAs (siRNAs)
172
or 
with single-chain variable fragments (scFv)
237
that can overcome the problem of non-
specificity. Certain peptides, such as arginine peptides, containing high percentage of 
cationic amino acids can efficiently translocate through the cell membrane
99
. For 
instance, a nonamer arginine peptide (9R) conjugated to a anti-CD7 scFv was used for 
targeted delivery of siRNA into T cells enabling inhibition of HIV infection in a 
humanized mouse model
109
.
Additionally, vectors that can replicate autonomously as an episome can be used as a 
delivery vehicle. For example, an Epstein-Barr virus (EBV) replicon non-viral vector 
(carrying mini-oriP) containing the diphtheria toxin subunit A (DT-A) was able to
suppress tumour growth in a mouse mammary cancer model after electrogene transfer 
for in vivo transduction
196
.  
1.2.2 Viral vectors
Viral vectors have been the most used and the most efficient mean of gene transfer. 
Some viral properties, such as efficient delivery of nucleic acid to specific cell types 
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while avoiding immunosurveillance by the infected host, make them attractive gene 
delivery vehicles. The usage of a viral vector in gene therapy depends on factors such 
as packaging capacity, host range, cell-or tissue-specific targeting, replication 
competency, genome integration and duration of transgene expression 
130
(Table I). 
Therefore, its choice will depend on its ultimate application. For instance, in the case 
of cancer gene therapy, only high-level transient expression is required, while with 
genetic diseases it is required long-term therapeutic transgene expression.
The main groups of viral vectors used in gene therapy and their principal advantages or 
disadvantages are indicated in table I, to which should be added the alphaviruses. Viral 
vectors can be divided into two general categories: integrating and non-integrating. 
Integrating vectors include adeno-associated viruses (AAV), lentiviruses and 
retroviruses that allow long-term expression. Herpes simplex viruses (HSV) also allow 
for long-term expression since they cause a latent infection in the host. On the other 
hand, adenoviruses and alphaviruses give just transient expression levels. HSV have a 
strong tropism for neurons and large packaging capacity while the AAV do not allow 
the insertion of a large transgene. However, AAV are not inflammatory unlike 
adenoviruses that induce strong inflammatory responses, but are the most efficient in 
transducing the majority of tissues. The choice of the proper vector to apply in gene 
therapy should take into consideration the various features of each vector and the type 
of disease to be treated, as there is no ideal viral vector system available 
130
.
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Although efficient in vitro, in cell lines, viral vectors have not demonstrated the same 
efficiency in vivo. Innate and adaptive immune responses to vector particles and 
components are some of the limitations of gene therapy vectors that may restrict the 
efficiency of gene transfer and the persistent expression of the transgene. This can 
occur more often when using adenovirus based gene transfer systems. Nevertheless, 
vectors based on human adenovirus remain the most used gene delivery vehicles in 
clinic trials as they display in vivo stability and provide very efficient gene transfer to 
numerous dividing and non-dividing cell targets, without integration into the host 
genome, and are rarely linked to any severe disease in immunocompetent patients.
In addition, a number of vectors are derived from parent viruses that humans encounter 
through natural infection, resulting in pre-existing antibodies and possibly in memory 
responses against vector antigens. Similarly, an immune response can also be mediated 
against the transgene that has been delivered which may actually limit its sustained 
expression. 
Other potential problems associated with viral vectors include the risk of insertional 
mutagenesis, difficulty in large-scale production, and size restrictions for exogenous
DNA. These limitations of viral vector systems can significantly restrict their clinical 
application.
In comparison with non-viral vectors, the high packaging capacity of viral vectors is of 
great advantage when delivering large gene sequences. Moreover, the inclusion of an 
appropriate promoter/enhancer allows for specific regulation and increase in the levels 
of transgene expression. Viral vectors have also been developed to include a 
bidirectional promoter
5
, or several promoters, making possible the simultaneous 
expression of multiple genes in the same cell. This feature allows, besides the 
inclusion of the therapeutic gene, the inclusion of a suicide gene, that can activate a 
pro-drug in case something goes wrong, or a reporter gene, which allow the
monitoring of the efficiency of the gene therapy application. 
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Due to their capacity to stably integrate into the target cell genome, retroviruses have 
been quite used for gene therapy applications. However, its clinical use is currently 
limited by their poor efficiency in transducing non-dividing cells and the potential 
genotoxic consequences of their uncontrolled insertion into the human genome
12, 137
.
1.2.3 Lentiviral vectors 
Lentiviral vectors are derived from viruses belonging to the family of retroviruses 
(Retroviridae) and the lentiviruses genus. A typical structure of a retrovirus with its 
Gag, Pol and Env proteins is represented in Figure 1. Lentiviral vectors are usually 
generated by co-transfection of packaging cells with a transfer construct, a plasmid 
containing the vector genome, and the packaging construct encoding the viral proteins, 
that contains the trans-acting sequences, essential for assembly and function.
Figure 1. Retrovirus structure. Adapted from
193
.
Lentiviral vectors have been widely used for gene delivery purposes. They can 
efficiently transduce non-dividing cells. The viral genome integrates into host 
chromosomes and the inserted gene can be maintained in the cells permanently. This
capacity to maintain stable, long-term transgene expression, added to the considerable
versatility in the design of the expression cassettes leading to improvements in term of 
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biosafety and efficacy, contribute to their increasing use, particularly in pre-clinical 
applications.
Because of the previous adverse events in clinical trials due to insertional mutagenesis 
using retroviral vectors as mentioned above, this is still an important point in vector 
safety. Nevertheless, lentiviruses, unlike gamma-retroviruses, are not associated with 
tumour development. Moreover, lentiviral vectors prefer to integrate in regions where 
expressed genes are concentrated
144, 192, 44
, opposite to transcription start sites for 
retroviruses
234, 67
. To overcome this problem, integration-deficient lentiviral vectors
have been developed232. Additionally, the integration of the transgene can be 
controlled using zinc-finger nucleases 
32
and insulators
63
. As well, microRNA 
regulation can be applied to restrict transgene expression to a specific cell type by
eliminating off-target expression in undesirable cells
28, 26
. 
Development of replication-competent lentiviruses (RCL) represents another safety 
concern as recombination between vectors and endogenous retroviral sequences could 
theoretically generate new human pathogens although, in this situation, non-human 
lentiviruses-based vectors could circumvent the problem as lentiviral infection is 
species-specific but, when a broad tropism envelope protein, like vesicular stomatitis 
virus-glycoprotein G (VSV-G), is used, this could be a major issue. Lentiviral vectors 
can be engineered to be safer and minimize the chances of generating RCL during 
vector production (Figure 2). The first generation of lentiviral vectors had the HIV 
envelope replaced by a heterologous envelope, such as VSV-G, in a different 
construct, which avoids formation of wild-type HIV (Figure 2D). Deletion of 
unnecessary viral genes from the packaging construct reduces cytotoxicity and 
immunogenicity and prevents the generation of replication-competent virus and spread 
of virus infection. This is characteristic of the second generation vector (Figure 2E).
Removal of the transcriptional transactivator tat gene further improved safety and the 
additional separation of the gag/pol and rev gene expression into two non-overlapping
expression constructs generates the third generation packaging plasmids (Figure 2F).
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SIN lentiviral vectors are the ultimate generation of these vectors, in which the 
absence of long terminal repeat (LTR)-derived viral enhancers (in the 3’ U3 region)
and the reduced propensity to integrate a short distance from gene promoters gives it a 
better safety profile, as it reduces the risk of insertional oncogenesis, vector 
recombination and mobilization (Figure 2 B).  The improved SIN includes sequences 
that allows efficient gene transduction of many cell types and enhances the levels of 
transgene expression (Figure 2C). 
Figure 2. Schematic of HIV provirus, typical HIV-1-derived transfer vectors (left) and packaging 
constructs (right). (A) Wild type, (B) Self-inactivating (SIN), (C) improved SIN, (D) first, (E) second 
and (F) third generation packaging constructs. The envelope construct is unrelated to HIV-1 and is used 
to pseudotype the vector (E). LTR, long terminal repeats; SD, splice donor; GA, portion of the HIV-1 
gag gene with a closed reading frame; CMV, cytomegalovirus strong promoter; prom., internal 
promoter; polyA, polyadenylation signal; RSV, rous sarcoma virus promoter; SA, splice acceptor; , 
packaging signal; RRE, Rev responsive element; VSV-G, vesicular stomatitis virus G protein; WPRE, 
post-transcriptional regulatory element of the woodchuck hepatitis virus; cPPT, central polypurine tract. 
Adapted from 
163
.
Although there is still some concerns regarding the safety of lentiviral vectors because 
few sequences are derived from HIV (~25%), they have been proven to be safe and 
there is no evidence suggesting that lentiviral vectors are capable of self-replication 
after infection. Indeed, HIV-1 derived lentiviral vectors are among the most efficient 
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and safest systems currently available for stable genetic modification of cells in 
culture. They actually have been the choice for researchers in the field of gene therapy. 
In addition to HIV-1, lentiviruses vectors have been engineered mostly with Simian 
Immunodeficiency Virus (SIV), Feline Immunodeficiency Virus (FIV) or Equine 
infectious anaemia virus (EIV)
181, 224
.
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1.3 Immune responses to viral vectors and transgenes
The responses produced by the immune system can be not only against the vector but 
also against the transgene and these can have an impact on the therapeutic efficacy by 
restricting the effectiveness of gene transfer and the persistence of transgene 
expression. A gene therapy strategy for Duchene’s muscular dystrophy employing a 
naked DNA gene transfer of the human dystrophy gene into mdx mice caused both a 
dystrophin-specific humoral and a cytotoxic T-cell response,  even though human and 
mouse dystrophin proteins are more than 90% identical (some epitopes are different 
enough to trigger an immune response)
69
. There is a probability of occurring an 
immune response even if the difference between therapeutic and host protein is only a 
single amino acid 
70
. When using allogeneic hematopoietic stem cell transplantation 
(HSCT) to treat hematologic malignancies there is a risk of occurring a graft-versus-
host disease (GvHD) which is usually controlled by HSV-thymidine kinase (HSV-TK)
suicide gene therapy that will induce a graft-versus-leukaemia immune response. In a 
clinical study, involving donor lymphocyte infusion with lymphocytes transduced to 
express HSV-TK, 7 out of the 23 patients treated developed a strong cytolytic T-
lymphocytes (CTL) immune response against the HSV-TK protein, although in this 
case the immune response did not affect the efficacy of the therapy
217
. The transgene 
expression level could also be a determining factor. There were reports mentioning 
transgene-driven autoimmunity with AAV gene transfer of the erythropoietin gene
39, 
79
.
Tissue specificity can also influence the triggering of an immune response. That was 
the case when Follenzi and colleagues used lentiviral vectors for gene therapy of 
haemophilia B
71
. The expression of factor IX cDNA driven by a ubiquitously promoter 
(human cytomegalovirus, hCMV) triggered a specific cellular and humoral immune 
response which lead to clearance of the transduced cells and the transgene product but 
when the gene was expressed under the control of a liver-specific promoter that did not 
occur
71
. However, a recent study by Feng and colleagues
68
has shown that this does not 
always happen, as there is a large number of parameters that might interfere with the 
results.
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Besides aspects related with the transgene, the vector used may also affect the host’s 
immune responses. Innate and/or adaptive immune responses to transfer vectors can 
inhibit transgene expression (or eliminate transduced cells)
37, 229
. Viral vectors can 
stimulate the release of inflammatory mediators, cytokines, and chemokines 
37
. This
inflammatory response depends on the vector components (viral capsid, transgenes, 
marker genes), viral vector dose, site of injection, tissue injected, and cells 
transduced
122, 128
. Different vectors encoding a similar transgene, but injected into 
different tissues, can stimulate very different types of immune responses 
90
. These
responses are related, in part, with the viral tropism. For instance, the immunogenicity,
and dissemination of adenoviral vectors to other cells or organs, limits the effective 
period of adenovirus-based gene therapy
186, 54
. However, these aspects will be 
overcome with improvements in vector design.
So far, there have been basically no reports on the potential of lentiviral vectors to 
induce inflammatory cytokine storm upon delivery into different tissues. However,
there was a study showing that intravenous administration of late-generation lentiviral 
vectors in mice induced a rapid and transient interferon β response27. This inhibited
transduction efficiency, specifically within the liver, and contributed to immune-
mediated clearance of transduced cells. In a recent report, a doxycycline inducible 
lentiviral vector used to regulate the expression of erythropoietin led to an immune 
response against the tet-dependent transactivator (rtTA)
134
. However, that was not 
induced by the lentiviral vector as the same type of response was previously reported 
using a helper-dependent adenoviral vector harbouring the same type of transactivator 
to control long-term erythropoietin gene expression
114
. In a study characterizing the 
use of lentiviral vectors for central nervous system (CNS) gene therapy no measurable 
inflammatory responses were shown after vector injection. Subsequent systemic 
immunization with a lentiviral vector carrying the same transgene as the vector 
injected into the CNS resulted in a decrease in transgene expression and inflammation
that were caused by the immune responses against the transgene, since with a lentiviral 
vector carrying a different transgene no immune responses were observed. This 
demonstrated the low immunogenicity of lentiviruses and prolonged transgene 
expression even in the presence of pre-existing lentiviral immunity
1
. Nevertheless, 
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although lentiviral vectors are less immunogenic than other viral vectors, they can 
elicit certain immune responses in vivo, limiting their clinical application in gene
delivery. They have been shown to elicit strong CTL responses against the transgene-
encoded proteins what make them excellent vectors for anti-tumour immunotherapy
61, 
21
. 
VSV-G is largely used in lentiviral vector preparations but there are some aspects that 
need to be taken into consideration. A few studies showed that VSV-G-pseudotyped 
LVs are inactivated by human serum complement
53
, although the incorporation of 
complement regulatory proteins have shown to provide complement resistance187, and 
the in vivo use of unaltered VSV-G-pseudotyped vectors in human patients would be 
problematic because of complement inactivation. In addition, VSV-G-pseudotyped 
lentiviral vectors can form tubulovesicular structures in transfected cells that carry 
residual amounts of the plasmid DNA used for transfection, which can be co-purified 
with viral particles during viral concentration, and therefore act as strong activators of 
plasmacytoid dendritic cells that induces the secretion of high levels of IFN-170.
Serum complement inactivation is also one of the major obstacles in the use of 
baculovirus vectors for in vivo gene transfer. By displaying complement regulatory 
proteins on its surface, such as decay-accelerating factor (DAF), it was possible to 
protect the vector against complement inactivation and reduce inflammatory 
responses
94
.
The amount of viral vector and its quality can also be an issue. Suboptimal vector 
manufacturing or excessive dose increase may trigger toxic and inflammatory 
nonspecific responses after intravenous administration. Therefore, vector production 
and purification can be optimized using new protocols that can avoid or minimize 
unexpected immune reactions, toxicity or inflammation due to contaminants. For 
instance, purification by sucrose gradient ultracentrifugation was reported to abolish 
the immune response, however vector titers also decreased considerably
10
. On the 
other hand, lentiviral vector production in the absence of serum in the cell culture 
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medium reduced immunogenicity in the same way but without affecting transduction 
efficiency
10
.
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1.4 Targeting strategies
The development of efficient, safe and cost-effective clinical applications will depend 
on a better ability of delivery vectors to target specifically the cells of interest. 
Currently, three types of strategies can be applied for targeting lentiviral vectors. These 
consist in: 1) targeting at the level of vector-cell entry through lentiviral vector surface 
modifications; 2) targeting at the level of transgene transcription by insertion of tissue-
specific promoters into lentiviral vectors; 3) a novel microRNA technology that rather 
than targeting the 'right' cells will 'detarget' transgene expression from non-target cells,
while achieving high expression in the target-cell 
75
.
Viral vector tropism can restrict the application of gene therapy, as vectors are directed 
towards specific receptors on the cell surface. A mean to overcome this is to substitute 
the endogenous envelope glycoprotein for another one that will broaden that tropism.
Specific tissue tropism can be achieved by altering the envelope protein, which can be 
done by (Figure 3): i) engineering onto the envelope a ligand for a receptor expressed 
on the target tissue, ii) engineering onto the envelope an antibody binding site that 
recognizes a cell-specific antigen on the target tissue and iii) pseudotyping.
The advantage of an antibody over a ligand is that it acts as an antagonist for a given 
receptor, whereas its ligand will inevitably elicit a biological response upon binding 
(triggering a signalling pathway). 
Regarding transcriptional targeting, the existence of tissue-specific (or cell-specific) 
and tumour-specific enhancer/promoter sequences that can drive the expression of 
therapeutic genes can be a benefit to targeting
242
. Nevertheless, this kind of promoters 
are not as stronger as viral promoters (such as CMV), or other ubiquitous promoters 
(such as UbiC), and as a result, gene expression and consequently transduction 
efficiency are reduced.  
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Figure 3. Principle of re-targeting of lentiviral vectors. Adapted from 
29
.
1.4.1 Pseudotyping lentiviral vectors
Usually, the host-cell tropism of a virus can be changed by replacing the virus 
attachment protein with that of a related virus, a method called pseudotyping. 
Pseudotyping was first described when investigators noted that host cells infected with 
two enveloped viruses generated progeny, with both the native envelope and the co-
infected viral envelope
40
.
Although pseudotyping can be used for non-enveloped vectors like AAV and 
adenoviruses, it has been used most extensively to modify the tropism of retroviral 
(and lentiviral) vectors because they are highly permissive for incorporation of 
heterologous attachment glycoproteins 
49
.  For this incorporation to occur, it is 
important a high cell-surface expression level in the packaging cell at the site of virus 
budding
184
. Additionally, some modifications in the cytoplasmic tail of the 
pseudotyping glycoprotein might also be necessary
41, 140
, as interactions between them 
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and the components of the virion core dictate assembly of viral particles for some 
incorporation models. 
Viral entry of enveloped viruses occurs in a two-step process. First, the viral surface 
protein binds to receptors on the plasma membrane of the host cell. After that, 
membrane fusion takes place between the lipid bilayer of the viral envelope and host 
cell membranes. This fusion reaction can occur either at the plasma membrane (direct 
entry, pH-independent) or in acidic endosomes following receptor-mediated 
endocytosis (indirect entry, pH-dependent). In pH-independent cell entry, the fusion 
between the viral envelope and the cellular membrane occurs directly at the cell 
surface. During direct entry at the cell surface, the membrane fusion process is 
triggered by receptor contact that induces conformational changes in the glycoprotein.
During the endocytic process, the low pH environment induces structural 
rearrangements in the glycoprotein that leads to membrane fusion. In either case, the 
membrane fusion reaction delivers the viral nucleocapsid into the host cytoplasm. The 
envelope glycoproteins of VSV
210
, human foamy virus
168
, Ross River virus (RRV) and 
other alphaviruses
98
are some of the examples involved in pH-dependent cell entry. On 
the other hand, viruses such as HIV-1
204
, the feline retrovirus RD114
136
and measles 
virus
199
use a direct viral entry. 
Lentiviruses are membrane-bound virions that acquire their membrane immediately 
prior to being released from the host cell. Therefore, pseudotyping is facilitated since 
the envelope glycoprotein, that is important in determining tissue tropism, is not 
required for budding, as the viral core particle can form and bud in the absence of any 
glycoprotein
171
. Any transmembrane proteins that are present at the site of budding 
become incorporated into the lentiviral vector particle and are displayed on its surface 
36
, although some envelope glycoproteins assemble with lentiviral core at late 
endosomes
184
. 
There is a long list of foreign envelope glycoproteins that have been incorporated into 
lentiviral vectors (see the paper by Bischof and Cornetta
18
for a list of glycoproteins 
successfully used for pseudotyping). A major contribution to the advances in lentiviral
Introduction
21
vector application for gene delivery was the efficient use of VSV-G to pseudotype 
HIV-1 virions
153
that, together with fact that it allows infection of a broad range of cell 
types in many species, made it the most used glycoprotein for pseudotyping.
Nevertheless, this broad tropism of VSV-G can be problematic when tissue specificity 
or cell targeting is required. VSV-G has other disadvantages including cytotoxicity
178
, 
potential for priming of immune responses against transgene products through efficient 
transduction of antigen-presenting cells (APCs)
101
, such has dendritic cells, and 
sensitivity to inactivation by human complement 
53
. For these reasons, other envelopes 
have been used as an alternative to VSV-G to pseudotype lentiviral vectors.
Although many viral envelopes have been used to pseudotype HIV-1-derived lentiviral 
vectors
18
, the infectious titres are usually low when compared with VSV-G 
pseudotyped lentiviruses. On the other hand, SIV-derived vectors pseudotyped with 
amphotropic or modified feline endogenous retrovirus envelope (RD114/TR) 
transduced more efficiently human and macaque primary blood lymphocytes and 
CD34
+
cells than the vector pseudotyped with VSV-G
183
. Additionally, RD114/TR-
pseudotyped vectors may be concentrated by ultracentrifugation and are resistant to 
complement inactivation
183
. Moreover, a study comparing VSV-G-pseudotyped 
vectors with RD114/TR-pseudotyped particles showed that the chimeric envelope was 
able to transduce hematopoietic stem/progenitor cells at a lower multiplicity of 
infection (MOI), with less toxicity and pseudo-transduction at comparable vector copy 
number per genome
56
. 
Ross River virus-pseudotyped HIV-1-derived lentiviral vectors were able to transduce 
epithelial and fibroblast-derived cell lines from various tissues at levels comparable to 
VSV-G
92
, while in another study by the same research group, transduction of 
hematopoietic cells was significantly impaired
93
, which at the same time can be an 
advantage in clinical applications when targeting of hematopoietic tissue should be 
avoided. 
The choice of the envelope glycoprotein for pseudotyping depends on the tropism that 
needs to be achieved, i.e., a broad or a more restricted one. There is a limited 
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availability of viral envelopes with a natural restricted tropism, and for that reason, 
most of the envelope glycoproteins used for pseudotyping are the ones with a broad 
tropism. Nevertheless, there have been some reports describing the use of the former
ones. For instance, the Mokola virus envelope protein was used for astrocytes 
transduction
45
, the glycoprotein from lymphochoriomenigitis virus was used for 
glioma cells targeting
143
, the glycoproteins from measles virus wild-type strain for 
activated human lymphocytes 
78
and also the glycoproteins from HIV that targets 
specifically CD4-expressing cells
191, 124, 215
. This means that a certain envelope from a 
virus with a tropism for a specific cell-type or tissue might be used for the treatment of 
a disease in which those cells or tissues are affected. For instance, the use of envelope 
glycoproteins from virus infecting the lungs via the airway epithelia can be useful for
vector pseudotyping in gene therapy for diseases of the respiratory tract
103
. Also, 
Murine leukemia virus (MLV) pseudotyped with human hepatitis B virus (HBV) large 
(L) and small (S) surface antigens (HBsAg) exhibits strict tropism for primary human 
hepatocytes, similar to the natural target cell specificity of HBV, thus offering a 
potential liver-specific targeting system for gene therapy
209
.
However, vector pseudotypes may not always retain the same tropism as the parental 
virus from which the glycoproteins were derived, as occurred for instance with 
neurotropic Mokola virus glycoprotein pseudotyped HIV-1 based vector
55
. 
Sometimes it might be required to truncate the cytoplasmic domains of the 
glycoproteins used to pseudotype the viral vector in order to get proper envelope 
function. For instance, RD114/TR contains the RD114 cytoplasmic tail of its 
glycoprotein replaced for that of MLV-A
183, 56
. This chimeric glycoprotein preserve the 
host range of the original RD114 and have increased titres compared to SIV vectors 
pseudotyped with the wt glycoprotein
183
. Others have also substituted with success the 
cytoplasmic tail of the parental envelope glycoprotein by that of MLV
206, 41
.
The engineered glycoproteins must fold correctly, be stably incorporated on virions 
and allow efficient retargeted virion binding to the expected cell-surface molecules. 
Although the majority of the exploited ligand-displaying envelope glycoproteins can
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bind specifically and efficiently to the targeted cells, the infectivity of the viral 
particles is usually low. Indeed, infectivity of the recombinant viruses can be inhibited 
at a post-binding step, as occasionally the chimeric glycoprotein incorporated on viral 
particles maintains the fusogenic potential but the interaction of the displayed ligand 
with its target cell-surface molecule is generally not able to activate the fusion 
functions of the chimeras
243
. Besides this inability to induce membrane fusion 
(inability of the targeted receptors to activate envelope fusogenicity), the sequestration 
of the targeted receptor-bound retroviral particles to cell compartments by some types 
of cell-surface molecules might also abolish infection
48
. When aiming at retargeting a 
specific surface receptor molecule, the receptor attachment function in an envelope 
protein has to be altered, whereas the membrane fusion function has to be kept 
completely active. Thus, to circumvent the above-mentioned constraints, these two 
functions have been recently separated in two proteins
120
. This has been successfully 
used for instance for Sindbis envelope glycoprotein
239, 76, 113, 111
.
Other envelopes that have been widely used lately are those from Sindbis virus and 
Measles virus because of their ability to incorporate a ligand, an antibody or a scFv for 
efficient targeting. Funke and colleagues have obtained specificity and high 
transduction efficiency by altering the measles virus envelope to preferentially infect 
CD20
+
cells to target lymphoid tissue
77
. Moreover, in a different study by the same 
group, they targeted different cell surface molecules on different cell types taking 
advantage of scFv antibodies for those molecules and where natural receptor usage 
was prevented by mutation of the relevant residues in the hemagglutinin protein 
receptor recognition domain
6
. Recently, measles virus hemagglutinin (H) and fusion 
(F) envelope glycoproteins were used to pseudotype replication defective VSV and 
redirect entry and infection specifically to tumor-associated receptors, through the 
display of scFv antibodies specific for epidermal growth factor receptor (EGFR), folate 
receptor (FR) or prostate membrane specific antigen (PSMA)
8
.
Special attention will be given to Sindbis virus envelope in the next section. 
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1.4.2 Sindbis pseudotyped lentiviral vectors
Sindbis virus is an enveloped virus with single-stranded positive sense RNA genome. 
It is the prototype of the alphavirus genus in the Togaviridae family 
208
. The Sindbis 
genome codifies for non-structural and structural proteins but only the structural 
proteins, namely capsid (C), E3 peptide, envelope protein 2 (E2), 6K peptide and 
envelope protein 1 (E1), are present in the Sindbis pseudotyped lentiviral vectors. E2 
protein mediates interactions with the target cell receptors, laminin receptor and 
heparin sulphate
230, 31, 102
, and E1 mediates low pH-dependent fusion. Unlike 
retroviruses, the Sindbis virus fusogenic E1 protein can fuse to cells independently of 
the receptor binding E2 protein. Modified retroviral envelope proteins, despite having 
specific binding activities, have low fusion activity resulting in inefficient entry into 
cells 
243
. The Sindbis envelope proteins mediate binding to host cell receptors, leading 
to the endocytosis of the virion. When the endocytic vesicle is acidified, the envelope 
proteins undergo conformational changes that result in the fusion of the lipid bilayer of 
the virion and that of the vesicle. The nucleocapsid, a complex of the capsid protein 
and the genomic RNA, is then deposited into the cytoplasm of the host cell
91, 117
.
Sindbis virus has a wide host-range because its host-cell receptors, laminin and heparin 
sulphate are widely distributed and are highly conserved 
208
, resulting therefore, in an 
in vivo non-specific infection. But apart from this, it gives a high level of gene 
expression, it can infect non-dividing cells and can be purified to high titers
236, 208
, 
which makes this virus an efficient vector system for delivery and expression of 
fusogenic membrane glycoproteins. 
Sindbis virus is an oncolytic virus that selectively targets tumours through the laminin 
receptor, which is overexpressed in these cells
220, 83
. In fact, downregulation of this 
receptor reduced Sindbis vector infectivity, further confirming its role in mediating the 
tumour-targeting ability of Sindbis
219
. In a study by Scheiman and colleagues
188
,
Sindbis-pseudotyped lentiviruses expressing a short-hairpin RNA (shRNA) specific 
for the 37/67-kDa laminin receptor (LAMR) could target and inhibit tumour growth 
via binding and downregulation of that receptor showing once more its importance for 
cancer gene therapy. Besides this, the non-structural proteins of Sindbis are potent 
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inducers of apoptosis and thus, it naturally induces cell death in tumour cells. In 
addition, the blood-borne nature of Sindbis enables Sindbis vectors to reach tumour 
cells throughout the body. For all these reasons, it has been used mainly in cancer gene 
therapy. In a report, Tseng and colleagues demonstrated that a single intraperitoneal 
treatment allowed a Sindbis vector to target systemically and eradicate tumour cells 
throughout the body without adverse effects 
221
. Another study by the same group,
showed that Sindbis vectors containing a HSV-TK gene could successfully deliver this
suicide gene to tumour cells that in combination with the pro-drug ganciclovir (GCV)
exposure provided subsequent GCV activation and tumour killing 
222
. Therefore, these 
studies indicate that the incorporation of reporter genes in Sindbis vectors provides a 
mean of tumour detection and subsequent suppression. 
Vectors based on the Sindbis virus RNA genome were constructed where the E2 
envelope protein was modified by insertion of an Fc-binding portion (ZZ domain) of 
Staphylococcus aureus protein A
159
and demonstrated to be able to target efficiently 
human cell lines when used in conjunction with monoclonal antibodies. But being a 
lytic RNA virus, Sindbis virus is not suitable for applications requiring stable 
transduction
87
. Therefore, Morizono and colleagues used instead HIV-1- and murine 
leukaemia virus-based retroviral vectors pseudotyped with a modified Sindbis virus 
envelope containing the Fc-binding domain of protein A to target specific cells in vitro
147
. However, there is non-specific gene transduction to the liver and spleen with this 
pseudotyped virus. This problem was overcome with the generation of a modified 
Sindbis envelope containing mutations in specific domains of E2 and E3 glycoproteins 
152
. These strategies based on the incorporation of the ZZ domain into the envelope 
glycoproteins have been widely used
16, 152, 4, 105
. However, it might cause problems
after systemic administration due to competition for binding between the antibodies 
present in the serum and the targeting antibody. Additionally, other limitation of this 
ZZ system that might also affect the targeting efficiency is the non-covalent linkage to 
the antibody.  
Lentiviral pseudotyping with Sindbis virus envelope has been widely used and is a 
great promise for gene delivery systems. Sindbis envelope protein pseudotyped 
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lentiviral vector displaying anti-CCR5 scFv lead to specific targeting to CCR5-
expressing cells and primary lymphocytes in vitro
2
. P-glycoproteins on metastatic 
melanoma cells in lung tissue were also successfully targeted by modified lentivirus 
pseudotyped with a chimeric Sindbis envelope (termed m168 and lacking nonspecific 
infectivity) and a surface displayed anti-P-glycoprotein antibody, through intravenous 
injection
152
. Additionally, by incorporation of an antibody conferring target specificity 
and a modified influenza hemagglutinin mutant mediating pH-dependent membrane 
fusion, the pseudotyped lentiviral vector was successfully used to target CD20 in
human B cells in vitro and in animals 
240
. The incorporation of biotin-adaptor peptides 
or integrin-targeting peptides into the envelope of Sindbis-pseudotyped lentiviruses 
were also successfully employed for redirecting vectors to the specific receptors via 
conjugation with a targeting molecule or antibody
149, 151
. 
More recently, this method of lentiviral pseudotyping with engineered Sindbis 
envelope was reported for immunization against cancer, where dendritic cells were 
targeted specifically in vivo through its cell surface molecule DC-SIGN thereby 
inducing strong antigen-specific immune responses 
241
. 
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1.4.3 Single-chain antibodies (scFv) as a targeting vehicle in gene therapy
As already mentioned, viral envelope glycoproteins mediate the binding and fusion 
between virus and target cell, allowing the control of target cell recognition and host 
range of the viral vectors used for gene delivery. Then, when one wants to target a 
specific surface receptor molecule for cell entry, the way is to engineer the envelope 
glycoproteins (re-targeting) and usually it is the domain of the envelope protein 
responsible for receptor binding that is modified. Therefore, inserting a ligand, scFv or 
antibody bridge into this structure allow their display at the virus surface and therefore 
the specific targeting of cells. 
Single-chain antibodies are intracellular antibodies (intrabodies) that consist of the 
variable domains of the heavy (VH) and the light (VL) chain of an antibody connected 
by a linker peptide. They have the advantage of being highly specific and possess a 
high affinity for the target and for that reason, they have increasingly been used in the 
field of gene therapy to target intracellular molecules with potential therapeutic 
applications. For example, this was done some time ago by the group of Dr. Roger 
Pomerantz in which they inhibited the early stages of HIV-1 life cycle by intracellular 
expression of scFvs against integrase and reverse transcriptase in order to control HIV-
1 infection
115, 195
. Other important characteristics and usages of intrabodies that can be 
very advantageous to gene therapy applications include redirecting target antigen to a 
particular subcellular location through an appropriate trafficking signal peptide fused 
with it and the unique ability to specifically disrupt a specific function of a 
multifunction protein
11, 47
. ScFvs have been used also to target infected cells. For 
instance, scFvs against the laminin receptor were used in an in vivo gene delivery 
system, based on AAV vectors, to reduce prions propagation
246
.
The use of scFv in gene therapy has gained increased interest in the last several years. 
One of the first studies to describe the use of scFvs to target retroviral vectors 
specifically to human cells was the work by Somia and colleagues
201
. They fused a 
scFv directed against the low density lipoprotein receptor to the envelope of Moloney 
murine leukaemia virus (MoMLV) and infected specifically the cells through the 
recognition of that receptor. In particular, scFv have been most used in the cancer 
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research field to target molecular processes closely associated with carcinogenesis, 
being the oncogenes the more frequent molecular targets for scFv. Recently it was 
demonstrated the inhibition of LMO2-dependent leukaemia in a mouse T-cell 
tumourigenesis transplantation assay with retroviral-mediated expression of anti-
LMO2 scFv
154
. LMO2 is an oncogene whose insertional activation was associated with 
the development of leukaemia in patients involved in an X-SCID gene therapy clinical 
trial. The oncogene c-erbB-2 was also efficiently targeted by an adenovirus engineered 
to express an adapter protein containing a scFv against c-erbB-2
96
. The authors
demonstrated that the adaptor protein efficiently blocked adenovirus native tropism 
while simultaneously mediating virus infection, and thus enhanced gene transfer 
efficiency to cancer cell lines overexpressing c-erbB-2
96
. Additionally, amphotropic 
retroviruses with modified envelope displaying scFv directed against the c-Met 
receptor were generated and found to efficiently and selectively deliver genes into 
hepatocarcinoma cells
156
. 
This strategy of targeting through scFv display has been previously used in Dr. João 
Gonçalves lab to successfully target cells expressing the CCR5 chemokine receptor, as 
already mentioned above
2
.
Alternatively, in the case of viral vectors without envelope, like adenovirus, the scFv 
can be fused to a capsid protein. Efficient and functional incorporation of a fusion 
between hyper-stable scFv (directed against beta-galactosidase) and adenovirus minor 
capsid protein IX (pIX) into the adenovirus capsid was reported by Vellinga and 
colleagues as a possible strategy for retargeting
226
, thus demonstrating that pIX can 
also be used as a platform for the presentation of scFv antibodies.
Still, the inclusion of a scFv is not always favourable. The insertion of a scFv targeted 
to folate-binding protein (FBP) into the N-terminus of MoMLV Env resulted in the 
reduction of the infectivity and the kinetics of entry of the MoMLV vectors. The scFv 
targeted to FBP increased the threshold for fusion and might have re-routed the entry 
of the targeted MoMLV-FBP vector towards an endocytic, non-productive pathway
227
.
In addition, despite scFv could be displayed on the capsid of adenovirus through 
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genetic fusion to native pIX, these molecules failed to retarget the virus, due to 
improper folding of the scFv. This could be overcome with single-domain antibodies
(sdAb)
173
.
As mentioned earlier, previous studies based on the addition of ligand motifs that 
binds to specific molecules associated with the cell membrane allowed binding to the 
new receptors and internalization, but the infection titres were low. Inefficient 
transduction was mostly due to diminished fusion activity of the engineered 
glycoprotein, most likely because this chimeric protein cannot undergo the appropriate 
conformational change that is thought to be triggered by receptor binding and that lead 
to viral entry
13, 243
. An attempt to redirect cell transduction was also performed for the 
widely used VSV-G. A large ligand binding domain, a scFv against major 
histocompatibility complex I (MHC-I), was attached directly to the N-terminal of the 
glycoprotein
58
, a site previously shown to be permissive for insertion of short peptides 
189
. Although this provided a new binding specificity, cells were transduced very 
inefficiently, again probably due to inefficient fusion activity. More recently, this 
fusion inability has been overcome by inclusion of a fusogenic protein in the 
engineered chimeric envelope. The laboratory of Dr. Pin Wang has developed a 
method to incorporate a membrane-bound antibody (anti-CD20) and a fusogenic 
molecule derived from Sindbis virus glycoprotein to provide binding and fusion 
functions respectively, into gamma-retroviral vectors for targeted gene delivery
239
.
Gene constructs expressing scFv may also be incorporated into non-viral vector 
systems. For example, by linking nucleic acid-binding human protamine to the C-
terminus of an anti-erbB2 scFv antibody
118
, exogenous DNA could be selectively 
delivered into erbB-2 positive cells. Alternatively, a liposome, which can hold within 
its lipid bilayer nucleic acids or proteins, has been coupled with antibodies 
(immunoliposome) to facilitate targeting and endocytosis to specific cells
157
.
ScFv have also been used in siRNA delivery. An ErbB2 single-chain antibody fused 
with protamine delivered siRNAs specifically into ErbB2-expressing cancer cells and 
the same report describe the use of a protamine-HIV-1 envelope antibody fusion to 
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deliver siRNA only to cells expressing the HIV-1 envelope
202
. In a work by Kim and 
colleagues, two antibody-based strategies were developed for systemic delivery of 
siRNA for anti-HIV-1 therapy, either specifically to T cells via the CD7 receptor or to 
multiple immune cell types via LFA-1, present on all leukocytes, using a cationic-
peptide based delivery or a liposome-based delivery, respectively
100
. 
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1.5 Suicide gene therapy
In suicide gene therapy, the gene encoding an enzyme is delivered to target cells, 
followed by administration of a prodrug, which is converted locally to a cytotoxin by 
the enzyme. Consequently, the target cells, as well as surrounding bystanders, are 
killed. Investigation in suicide gene therapy has been mostly applied for the targeting 
of cancer cells and essentially as a safety control of the therapeutic procedure. When 
replication-competent viral vectors (or oncolytic virus) are used, one safety measure
employed to reduce the risk of toxicity associated with possible vector propagation to 
normal tissue cells is to include a suicide gene into one of the non-structural genes 
assuring in that way its co-expression. This was done in a study by Tseng and 
colleagues
218
using a simple replication-competent (RC) Sindbis viral vector where 
they show a considerable increase in in vivo tumour targeting and killing capability of 
that viral vector/suicide gene system comparing with the conventional replication-
deficient vectors. Another widely used application of suicide gene therapy is in gene 
therapy for allogeneic hematopoietic stem cell transplantation, a therapeutic modality 
for patients affected by haematological diseases. A major complication in these
disorders is the incidence of graft-versus-host disease where alloreactive donor T cells 
recognize host antigens presented by recipient cells. The suicide gene therapy is 
employed in these situations to exploit the alloreactivity against malignant cells
131
.
Importantly, the activation of the suicide gene does not interfere with the process of 
reconstitution of the immune cells by the graft
42
.
Some of the most common suicide gene therapy systems used include the already 
mentioned HSV-TK/GCV, the Escherichia coli cytosine deaminase/5-fluorocytosine 
(CD/5-FC), and the suicide genes inducers of cell death, tumour necrosis factor-related 
apoptosis-inducing ligand (TRAIL or Apo2L) and factor-related apoptosis ligand 
(FasL or CD95L). The CD/5-FC suicide strategy was shown to be associated with the 
triggering of cellular and molecular events leading to an efficient antitumor immune 
response involving both innate and acquired immunity, in a rat liver metastasis 
model
17
. An scFvC45: sTRAIL antigen has been used to target specifically EGP2 
antigen on the surface of tumour cells and induce apoptosis
22, 23
. TRAIL has also 
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potential for application in allogeneic hematopoietic-cell transplantation for an 
enhanced graft-versus-tumour effect
190
. The apoptosis-inducing activity of scFvCD7: 
sTRAIL was even stronger than that of the immunotoxin scFvCD7: ETA
24
. The same 
group of investigators have developed a fusion protein, designated scFvCD7: sFasL
that consists of soluble FasL genetically linked to a high-affinity scFv antibody 
specific for the T-cell leukaemia-associated CD7 antigen. Soluble homotrimeric 
scFvCD7: sFasL is inactive and acquires tumoricidal activity only after specific 
binding to tumour cell-surface-expressed CD7
25
.
Nevertheless, HSV-TK is the prototype of suicide gene therapy. This enzyme can 
phosphorylate the nucleoside analogue GCV, which can inhibit cellular DNA 
replication by substitution for normal nucleosides in the DNA chain leading to 
premature interruption of replication and cell death. Although this system is efficient 
and safe in the selective control of GvHD, it has some disadvantages. The first relates 
to the presence of an active cryptic splicing site in the TK gene, resulting in a non-
functional TK
80
. Therefore, some mutant variants were developed to overcome the 
problem with alternative splicing
34
that is important to ensure high GCV sensitivity to 
transduced target cells. Fehse group constructed a fully codon optimized mutant HSV-
TK suicide gene that combines better killing performance with reduced unspecific 
toxicity
175, 174
. The second limitation is concerned to immunogenicity of viral TK in 
humans leading to the unwanted elimination of gene-modified cells 
180
. This is, in fact, 
a problem in immune reconstituted patients15 but not in the immunodeficient ones
217, 
139
. 
Other suicide genes currently used provide an alternative to HSV-TK, as they are not 
immunogenic in humans or have a low immunogenicity. CD20, a cell surface 
molecule, is the first human suicide gene developed where anti-CD20 monoclonal 
antibodies are used to kill CD20
+
cells. It has also the advantage of being used as a 
selection marker
88
. CD20 has also been applied as a novel suicide gene system 
particularly for the treatment of GvHD. In a study by Serafini and colleagues, 
exogenous CD20 protein was used both to mediate selection of transduced human T 
lymphocytes (using a Moloney-derived retroviral vector) and subsequent killing with 
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rituximab, a commercial available antibody against CD20
194
. Additionally, Griffioen 
and co-workers
81
also reported a successful application of this suicide gene strategy in 
adoptive T-cell therapy of cancer. 
A novel suicide system that can also overcome the immunogenicity of the use of HSV-
TK is the chimeric inducible caspase 9 (iCasp9) that is based on the fusion of truncated 
human caspase 9 to a modified human FK-binding protein, allowing conditional 
dimerization.  When exposed to a synthetic dimerizing drug, Casp9 becomes activated
leading to the rapid death of the cells in which it is expressed. This strategy has been 
used as a safety switch in adoptive cell therapies214, 52, 57. 
Other genes that have been used in suicide gene therapy are those from bacterial 
toxins, such as Pseudomonas aeruginosa exotoxin A (ETA) and DT-A. Both toxins 
are very potent inhibitors of protein synthesis and catalyze ADP ribosylation of human 
elongation factor 2 (EF-2), which triggers cell death by apoptosis. It has been 
estimated that a single molecule of DT is sufficient to kill a cell
238
. DT (and ETA) has 
two subunits, the B subunit which is responsible for binding to the cell and the A 
subunit which contains the catalytic domain of its enzymatic activity. In particular, 
numerous human clinical trials have been conducted using DT-fusion proteins for 
cancer therapy, for instance in patients with previously treated chronic lymphocytic 
leukaemia (CLL), i.e., with recurrent or refractory CLL
73, 74
.
Indeed, treatment of tumours with cytotoxic agents coupled to antibodies or ligands 
directed to tumour cell-specific structures is truly promising as demonstrated by 
numerous clinical studies and approved drugs such as Ontak, a fusion between peptide 
sequences of diphtheria toxin and human IL2
62
. The immunotoxins, molecules that 
contain a protein toxin and a ligand, have been applied in the treatment of cancer, 
particularly in chemoresistant hematologic malignancies
107
. A malignancy where 
recombinant immunotoxins are most successfully applied is hairy cell leukaemia
(HCL). A good example is the fusion of a truncated form of Pseudomonas exotoxin A 
(termed PE38) with the variable domain (Fv) of anti-CD22 antibody
108, 107
that has 
been further improved to reduce immunogenicity
160
.
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1.6 Applications of gene therapy in diseases and in clinical trials
The field of gene therapy has made important advances in the last decades that has 
made possible to move from the laboratory research to the clinical trials on a diversity 
of diseases. 
It is possible to find a wide variety of gene therapy applications that are currently in 
clinical trials or that have already terminated, within both the US and other countries,
through the website ClinicalTrials.gov. Remarkably, almost all of the registered trials 
involving viral vectors employ AAV or Adenoviruses. Accounting for that, in addition 
to the previously mentioned advantages, are the well established production 
parameters for clinical grade Adenoviruses and AAV vectors.
Currently ongoing are several human gene therapy clinical trials to evaluate the use of 
lentiviral vectors for treatment of human diseases such as Parkinson's disease, β-
thalassemia, X-linked adrenoleukodystrophy (X-ALD), and acquired 
immunodeficiency syndrome (AIDS). The improvements in lentiviral vectors design
already mentioned, mainly those regarding safety, have important implications for its 
adoption as the vector of choice for clinical trials. Indeed, the first lentiviral vector on 
phase I clinical trial was a HIV-1-based vector carrying an antisense sequence against 
the HIV-1 envelope gene. Transduction of CD4
+
T lymphocytes with this vector
(VRX496) resulted in expression of the therapeutic antisense sequence and subsequent 
inhibition of productive HIV-1 replication. The main objective of the study was to 
determine the safety and tolerability of treatment with autologous CD4
+
T cells 
modified (transduced) ex vivo with the vector VRX496 when administered to HIV-
infected patients
132
. This vector is already in a phase II, open-label, multicenter study 
to evaluate the safety, tolerability, and biological activity of single and repeated doses 
of autologous T cells transduced with the vector in HIV-positive individuals (Clinical 
trials identifier number NCT00131560).
Some of the most important advancements in gene therapy for diseases include genetic 
disorders such as ADA-SCID; chronic granulomatous disease (CGD) and haemophilia, 
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to which exciting treatment results have been obtained in appropriate animal models of 
the disease. In ADA-SCID, affected children are born without an effective immune 
system and will succumb to infections without bone marrow transplantation from 
matched donors. Ex vivo gene therapy with retroviral-transduced CD34
+
bone marrow 
cells was applied to deliver the therapeutic ADA gene to the patients. The immune 
system was reconstituted in all treated patients without noticeable side effects, and 
without need for further treatment
3
(ClinicalTrials.gov NCT00598481 and 
NCT00599781). CGD is a genetic disease affecting the immune system that leads to 
the patients' inability to fight off recurrent bacterial and fungal infections, leading to 
the formation of chronic granulomas that can be life threatening. Two patients with 
this disease were treated in a gene therapy trial. However, after initial resolution of the 
infection, the delivery vector caused insertional activation of a gene and, 27 months 
after gene therapy, one subject died from sepsis while the other has undergone
successful allogeneic HSC transplantation
205
. Haemophilia is an inherited bleeding 
disorder caused by a deficiency of functional clotting factors VIII or IX in the blood 
plasma that can be life threatening. Several strategies have been considered for the 
development of haemophilia gene therapy, which have resulted in stable correction of 
the bleeding problem, both in murine and canine models (reviewed in
167
). 
Other genetic disorders where gene therapy has been fairly applied with significant 
advances include congenital blindness and muscular dystrophy, among others. For 
instance, recombinant AAV vectors carrying the human RPE65 gene have been shown 
to restore vision in animal models that resemble RPE65-associated retinal disease
called Leber congenital amaurosis, an incurable retinal degeneration, which causes 
severe vision loss. A clinical trial to assess the safety of rAAV2-hRPE65 in subjects 
with the disease reported increased visual sensitivity without vector-related serious 
adverse events detected or systemic toxicity
82
. The safety and efficacy of this gene 
transfer was extended to at least 1-year post treatment
43
and phase III clinical trials are 
ongoing. 
Gene therapy for acquired diseases such as cancer, neurodegenerative diseases 
(example Parkinson's Disease, Huntington's Disease) and other acquired diseases such 
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as viral infections (e.g. influenza, HIV, hepatitis), heart disease and diabetes have also 
been performed and advanced to clinical studies.
A large part of all clinical trials are gene therapy trials for cancer and many of these 
are entering the advanced stage, including a phase III trial of Ad.p53 for head and neck 
cancer (reviewed in
155
) and phase III gene vaccine trials for prostate cancer
133
. Among 
the various gene therapy strategies that have been employed to treat many types of 
cancer are suicide gene therapy, oncolytic virotherapy, anti-angiogenesis and 
therapeutic gene vaccines. For instance, a phase II study of the efficacy, safety and 
immunogenicity of OncoVEXGM-CSF, a replication-competent HSV-1 vector, in 
patients with different stages of malignant melanoma is underway (ClinicalTrials.gov
NCT00289016). There is a phase I study for the treatment of recurrent ovarian cancer 
(ClinicalTrials.gov NCT00964756) based on a preclinical suicide gene therapy safety 
study using a tropism modified bicistronic adenovirus (Ad5.SSTR/TK.RGD) with 
capability for non-invasive imaging of gene transfer in patients
135
. 
Searching the clinical trials database mentioned above, one can find many clinical 
studies for HIV infection treatment, consisting mainly in the evaluation of the safety 
and immune responses to a possible vaccine. For example, one of the most recent 
phase I clinical trial was a study of MVA-CMDR, a candidate HIV-1 vaccine based on 
a recombinant modified vaccinia Ankara viral vector expressing HIV-1 genes 
env/gag/pol. This study demonstrated that vector administration was safe, well-
tolerated and elicited durable cell-mediated and humoral immune responses
50
.
ClinicalTrials.gov identifier number NCT00376090.
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1.7 Human T-cell acute lymphoblastic leukaemia (T-ALL): the model
for our delivery and targeting strategy
ALL is the most common type of leukaemia and is a rapidly progressing disease. In 
this study, to investigate the ability of the Sindbis/anti-FITC pseudotyped lentiviral 
vector to mediate targeted cell transduction and gene delivery in vivo it was used a T-
ALL mouse model, in which leukaemia is induced by transplantation of the T-ALL 
cells.
1.7.1 Overview of the disease
ALL most likely originates from various genetic lesions in blood-progenitor cells that 
are committed to differentiate in the T-cell or B-cell pathway, including mutations that 
give the capacity for unlimited self-renewal and those that lead to precise stage-
specific developmental arrest 
176
. Leukaemia cells in ALL have clonal rearrangements 
in their immunoglobulin or T-cell receptor genes and express anti-receptor molecules 
and other differentiation-linked cell-surface glycoproteins that basically run through 
those of immature lymphoid progenitor cells within the early stages of normal T and B 
lymphocytes development
176
. T -cell acute lymphoblastic leukaemia is a neoplastic 
disease of the T-lymphocytes that is linked with a poor prognosis. It represents 15% of 
childhood and 25% of adult ALL
176
. Compared with the more common B-cell-lineage 
ALL, T-ALL is defined by distinct clinical and biological characteristics and is 
generally associated with more unfavourable clinical features, such as a high 
whiteblood-cell count, bulky adenopathy and involvement of the central nervous 
system
223
. However, despite these features, the outcome for patients with T-ALL has 
improved markedly in recent years owing to the application of intensive chemotherapy 
regimens but even though, significant short-term and potentially long-term side effects
occurs.
Although current treatment protocols have improved the overall outcome for patients 
with T-ALL, a significant number of patients remain at a high risk of relapse with 
severe complications resulting from the intensive regimens, and few individuals 
survive when the disease recurs.
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T-ALL is considered to result from the malignant transformation of normal developing 
T cells in the thymus, the thymocytes. Signalling pathways that control T-cell 
development in the thymus or are involved in T-cell activation are important in its
development. Therefore, deregulated signalling is considered a major contributing 
factor in leukemogenesis of T-ALL.
Additionally, oncogenic transcription factors are expressed aberrantly in leukaemia 
cells. Just to give an example, MYB oncogene is frequently duplicated in human T cell 
acute lymphoblastic leukaemia (T-ALL)
110
. Cytogenic analyses in lymphoblasts reveal 
that there are a good percentage with chromosomal translocations that activate a small 
number of oncogenes and deletions that lead to losses of tumour suppressor genes. 
Indeed, chromosomal translocations are a hallmark of ALL; however they must act in 
concert with several other genetic lesions to induce an evident leukaemia. In T-ALL at 
least five multi-step mutational pathways leading to leukaemia have been identified, 
and in some cases these pathways involve several genetic lesions
51
. 
Four major classes of mutations are involved in the molecular pathogenesis of T-ALL:
cell cycle defects (96% attributed to mutations in CDKN2A/2B); differentiation 
impairment (with the highest percentage given to mutations in TAL1 plus LMO1/2 
genes); most mutations implicated in proliferation and survival are still to be 
identified, but ABL1-fusions can account for 8%; and finally, more than fifty percent 
of mutations concerning self-renewal capacity comprise NOTCH-1, with the 
remaining still unknown
51
. NOTCH-1 is a gene codifying for a transmembrane 
receptor that regulates normal T-cell development. The exact mechanisms by which 
alterations in NOTCH-1 signalling cause T-ALL are still unclear but probably is 
related to constitutive expression of oncogenes such as MYC and cooperation with 
other signalling pathways
177
. 
1.7.2 Treatment and new therapies
Current treatment is based on conventional chemotherapy and HSCT that has 
developed to act in conjunction with the former or as replacement with the aim of 
improving survival and quality of life.
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Targeting many of the molecules involved in the pathogenesis of T-ALL can be used 
as a therapeutic strategy for the treatment of the disease. Since NOTCH-1 activation is 
known to play a crucial role in T-ALL pathogenesis
233
, pharmacologic inhibition of 
NOTCH-1 by gamma secretase inhibitors (GSI) is a therapeutic strategy in T-ALL
116, 
212
. However, only a few T-ALL cell lines show sensitivity in terms of the growth 
inhibitory effect. In a subsequent study, small-molecule inhibitors, including heat-
shock protein 90, histone deacetylase, PI3K/AKT, and proteasome inhibitors, could 
reverse the gene expression changes induced by NOTCH1. Furthermore, most of the
inhibitors synergized with GSI in vitro in suppressing T-ALL cell growth in GSI-
sensitive cells182.
More recently, therapeutic antibodies were generated to target specifically each of the 
NOTCH receptors alone with the advantage of reducing the toxicity associated with 
inhibition of both NOTCH 1 and 2 by those gamma secretase inhibitors
235
.
Additionally, the immunotoxin HA22 (containing an Fv fragment anti-CD22 fused to 
truncated Pseudomonas exotoxin), which is an improved version of the mentioned 
above BL22 with higher affinity to CD22, is undergoing clinical testing in HCL, CLL, 
non-Hodgkin's lymphoma, and also paediatric ALL (reviewed by
107
).
The progress in understanding the biology of the disease and the underlying molecular 
mechanisms will contribute to the design of new alternative or complementary 
therapies.
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2.1 Cell lines
HeLa cells, 293T cells and 293DTR cells
119
(kindly provided by Dr. Ronald
Rodriguez) were grown in Dulbecco's modified Eagle medium (DMEM - Lonza) 
supplemented with 10% foetal bovine serum (FBS), 2 mM glutamine and 100 U/ml 
penicillin, streptomycin and amphotericin (Lonza). Jurkat (E6-1 clone, ATCC) and 
Molt-4 (ATCC) cells were cultured in RPMI medium (Lonza) supplemented as 
mentioned above. Cells were maintained up to a month in culture in a humidified 
incubator at 37ºC and 5% CO2. Jurkat/GFP-Fluc were obtained by fluorescence 
activated cell sorting (FACS) of VSV-G/GFP-Fluc transduced cells. Jurkat/DsRed and 
Jurkat/DsRedIRESRenilla were obtained by transduction of Jurkat cells with VSV-
G/DsRed and VSV-G/DsRedIRESRenilla, respectively, followed only by Ficoll 
density centrifugation to remove dead cells. 
2.2 Plasmid construction and Sindbis viral envelope mutation
A recombinant anti-FITC specific single-chain antibody fragment was kindly provided 
by Dr. K. Dane Wittrup (MIT, Boston, USA)
141
. The 4M5.3 anti-FITC scFv contains 
14 mutations from the wild-type scFv and has a 1800-fold increase in fluorescein-
binding affinity. A DNA fragment encoding the 4M5.3 scFv modified at 5’ and 3’ ends
with primers to introduce the BstEII cloning sites was generated by polymerase chain 
reaction (PCR) amplification. The resulting PCR fragment was gel-purified, digested 
with the restriction endonuclease BstEII, and cloned into the BstEII restriction sites of 
the Sindbis envelope expression vector pIntron Sindbis-ST6LL
2
generating the 
plasmid pIntron Sindbis/anti-FITC
1
. This plasmid has an HA tag in fusion with the 
scFv. Mutations in the Sindbis envelope, which were already described
152, 162
, were 
generated by the  QuikChange II XL site-directed mutagenesis kit from Stratagene 
using the primers listed in table XI, Appendix A. These mutants were designated as 
M1, M2, M3 and M4 for simplicity and correspond to: M1: deletion of E3 aa 61-64, 
M2: E2 SLKQ68-71AAAA, M3: E2 KE159-160AA, M4: E1 AK226-227SG. 
Therefore, through combination of these mutations it was produced the final plasmids 
pIntron Sindbis-FITC M123and pIntron Sindbis/anti-FITC M1234. The mutations
1
This construct was generated by Frederico Aires da Silva.
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were confirmed by DNA sequencing and the expression of scFv on the Sindbis 
envelope was confirmed by western blot with anti-HA HRP antibody (Roche).
The DsRed-Vpr fusion plasmid was constructed by PCR amplification of the DsRed 
from pIRES2 DsRed-Express2 vector (Clontech) and the Vpr from pEGFP-Vpr (NIH 
AIDS Research & Reference Reagent program) followed by overlapping. This fusion 
was then cloned into a vector using the pcDNA™3.1/V5-His TOPO
®
TA Expression 
Kit (Invitrogen). 
FUW lentiviral vector was obtained by removing the GFP reporter gene from the 
vector FUGW
127
(http://www.addgene.org/14883/) using the restriction enzymes 
BamHI/EcoRI and blunted by T4 DNA polymerase (Fermentas) and re-ligated by T4 
DNA ligase (New England Biolabs).
FUW/DsRed was constructed by PCR amplification of the DsRed from the pIRES2 
DsRed-Express2 vector (Clontech), digested with BamHI/EcoRI and cloning into
FUGW, previously cut with the same enzymes. FUW/DsRedIRESTK,
FUW/DsRedIRESRenilla and FUW/RenillaIRESTK were constructed by overlap PCR
using the primers and template indicated in Table XII, Appendix A, and subsequent 
cloning into FUW. Renilla was amplified from the vector pGL4.70 [hRLuc]
(Promega). The original plasmids containing DTA (PSA-DTA)
166
and HSV-TK
(TK.007)
175
were a kind gift of Dr. Janet Sawicki and Dr. Boris Fehse, respectively.
DTA was cloned into FUW by digesting the PSA-DTA plasmid with AgeI and SalI to 
generate a 1.3 Kb fragment containing the DT-A sequence and blunt ligated to the 
vector. FUW-Luc was constructed by PCR amplification of the firefly luciferase gene 
from the pGL3-Basic vector (Promega), digested with BamHI/EcoRI and cloning into 
FUGW, previously cut with the same enzymes.
Dr. Luigi Naldini provided the #318/GFP-FLuc lentiviral plasmid. #318/RFP was 
generated by AgeI/SalI digestion of an RFP plasmid, to excise the insert, and 
#318/GFP-Fluc, to excise the vector, and ligated by T4 DNA ligase. This RFP was 
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further cloned into FUW (FUW/RFP) using the primers listed in Table XII, Appendix
A. 
The 3
rd
generation lentiviral vector packaging plasmids pMDL (containing Gag/pol) 
and pRSV/Rev were described before
60
. The VSV-G envelope plasmid, pMD2.G
(http://www.addgene.org/12259/), and the 2
nd
generation packaging construct 
pCMV8.9, which carries gag, pol, tat and rev genes, are available from Addgene. 
For all cloning procedures, ligations and transformations were performed using T4 
DNA ligase (New England Biolabs) and E. coli XL10-Gold competent cells
(Stratagene), respectively, according to suppliers’ instructions. Plasmids were prepared 
using the Genomed midi-prep procedure (Genomed) or using the maxi-prep kit 
(Roche) in the case of the in vivo work. Verification of reporter gene expression for 
each construct was done after transfection of 293T cells and performing the adequate
assays. For each transfection approximately 1105 cells were seeded per well of a 24-
well plate. Transfections were performed using the TransIT
®
LT1 transfection reagent 
(Mirus Bio), according to the manufacturer’s instructions, with a ratio of DNA:reagent
of 1:3. Assays were performed 48 or 65 h post-transfection.
2.3 Luciferase assay
Cells were seeded in a 24-well plate at a confluence of 1×10
5
cells per well and 
transfected the following day with the TransIT-LT1 reagent. The total amount of DNA 
(0.9 µg) was kept constant by addition of an empty plasmid. Approximately 65 hrs 
later, cells were washed once in phosphate buffered saline (PBS) and lysed in 125 µl 
potassium phosphate buffer (0.1M potassium phosphate pH 7.8, 1%Triton X-100, 1 
mM DTT, 2 mM EDTA) and 20 µl of lysate was incubated with 100 µl of the 
substrates, according to the Dual-Luciferase® Reporter Assay System from Promega. 
Luminescence was measured in the Infinite 200 reader (TECAN). 
2.4 AlamarBlue® cell viability assay
For the alamarblue assay, 10 µl of the reagent (Invitrogen) was added to 100 µl of cells 
harvested from a 24-well confluent plate and incubated at 37ºC for 1 or 2 hrs. 
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Fluorescence was read on the Infinite 200 reader in a white 96-well plate and at 
550/600 nm.
2.5 DsRed fluorescence analysis
For red fluorescence quantification, cells were washed once in PBS and 100 µl of 
PBS-ressuspended cells were applied in a white 96-well plate for fluorescence reading 
at 554/591 nm on the Infinite 200 reader. 
2.6 Viral vector production
When performing the optimization of viral vector production, it was used 
Lipofectamine reagent (Invitrogen) and Fugene 6 reagent (Roche) at a ratio 
(DNA:reagent) of 1:2 and 1:3, respectively and according to the manufacturer’s 
instructions. For the calcium phosphate protocol, the following solutions were used:
2.5 M CaCl2, 2×HBS (50 mM HEPES, 280 mM NaCl, 1.5 mM Na2HPO4) pH 7.05 and 
1/10 TE pH 7.6. Total amount of DNA was 5 µg for 6-well plates or 2 µg for 24-well 
plates. Medium was replaced 2 hrs before transfection and the 2×HBS solution plus 
the CaCl2/DNA mixture (mixed while vortexing) were incubated for 30-40 minutes 
before drop-wise addiction to the medium. 
The following protocol was the one adopted after the optimization mentioned in the 
results. For the in vitro transduction assays, 293T cells were seeded in 6-well plates at 
the density of 5105 cells /well (~ 60% confluent), 24 hrs before transfection. Cells 
were co-transfected with the packaging plasmids Gag/pol (1 µg) and Rev (0.32 µg), 
the lentiviral vector (1.4 µg) and the envelope plasmid Sindbis/anti-FITC (0.7 µg) or 
the VSV-G (0.12 µg) using the TransIT transfection reagent mentioned above (ratio 
DNA:reagent of 1:4). Approximately 65 hrs post-transfection viral supernatants were 
harvested, filtered through a 0.45-µm filter and concentrated by ultracentrifugation at 
50 000 rpm in a TLA-100.3 rotor (Beckman). Each pellet was resuspended in 75 µL 
cold PBS. Only the Sindbis/anti-FITC pseudotyped lentiviruses were concentrated. 
AMICON ultra 100K centrifugal filter devices (Millipore) were also tested for viral 
concentration. 
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DsRed-Vpr-labelled lentiviral vectors were produced by co-transfection with the 
plasmid DsRed-Vpr (0.9 µg) in addition to the plasmids used to produce the 
lentiviruses. The lentiviral transfer vector used was FUW, which does not contain any 
reporter. 
To produce lentiviral vectors expressing the DT-A toxin, 293DTR cells were used 
instead of 293T. 
For the initial in vivo assays, cells were seeded in 100 mm plates and transfected with 
6 more plasmids as mentioned above and using TransIT transfection reagent. For 
most of the in vivo transduction assays, 293T cells were seeded in 150 mm plates at the 
density of 9106 cells /plate (~ 75% confluent), 24 hrs before transfection. Medium 
was changed 2 hrs before transfection. Cells were co-transfected with the packaging 
plasmids Gag/pol (12.5 µg) and Rev (6.25 µg), the lentiviral vector (25 µg) and the 
envelope plasmid Sindbis/anti-FITC (9 µg) using the calcium phosphate method by Dr 
Luigi Naldini’s lab. The solutions used were as follows: 2.5 M CaCl2, 2×HBS (100 
mM HEPES, 281 mM NaCl, 1.5 mM Na2HPO4) pH 7.12 and 1/10 TE pH 8. The 
2×HBS solution was added drop wise to the DNA-TE-CaCl2 mixture while vortexing 
at full speed and the precipitate was added to 293T cells immediately. Between 14-16 
hours after transfection, medium was replaced. Forty-eight hours post-transfection, 
viral supernatant was harvested and filtered through a 0.45-µm filter. The lentiviral 
vectors were concentrated overnight using a Lenti-X concentrator (Clontech) 
according to the manufacturer’s instructions, followed by an ultracentrifugation using 
the same conditions as above. Viruses were titrated by measuring the p24 levels with 
an enzyme-linked immunosorbent assay (ELISA) HIV p24 kit, using either the
Innotest HIV antigen mab (Innogenetics) or the HIV-1 p24 antigen capture assay kit 
(AIDS & Cancer Virus Program, National Cancer Institute at Frederick).
2.7 Western blot and antibodies
Concentrated viral supernatants were subjected to protein denaturation at 100ºC for 5 
minutes in 2×SDS-gel loading buffer (2% SDS, 30 mM Tris.HCl pH 6.8, 10% 
glycerol, 5% -mercaptoethanol, 0.05% bromophenol blue). Samples were loaded on a 
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10 % sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and
transferred to a nitrocellulose membrane (Scheiller & Schuller). After staining with 
Ponceau S (Sigma) to verify the uniformity of protein load and transfer, the membrane 
was incubated for 1 h at room temperature in blocking buffer (Tris buffered saline pH 
7.4 containing 0.05% Tween-20 (TBST) and 5% skim milk) and immunoblotted with 
the respective antibodies. Membranes were washed 6  10 minutes in TBST after 
incubation at room temperature with the primary (1 hr
1
) and secondary (30 min.) 
antibodies. Antibodies were diluted in the blocking solution. Anti-HA horseradish 
peroxidase (HRP)-conjugated mouse monoclonal antibody (Roche) was diluted 
1:1000. Human anti-p24 antibody (NIH AIDS Research & Reference Reagent 
Program) was used at a dilution of 1:5000. Rabbit polyclonal Sindbis antiserum 
(diluted 1:2500) was a kind gift of Dr. Peter Bredenbeek. HRP-conjugated secondary 
antibodies (Bio-Rad) were used at 1:10000 dilution. Proteins were detected by 
enhanced chemiluminescence SuperSignal (PIERCE).
2.8 In vitro binding of Sindbis/anti-FITC envelope expressed in 293T
cells
Cells were plated on 24-well plates (1105 per well) and transfected the following day 
with Sindbis/anti-FITC M123 plasmid using the TransIT transfection reagent. Two 
days later, cells were washed twice with PBS and increasing concentrations of anti-
CD7-FITC (BD Biosciences) were added for 30 minutes on ice. After another washing 
step, cells were ressuspended in PBS and analysed by flow cytometry (BD 
FACSCalibur) for FITC
+
cells. 
To check anti-FITC scFv expression at the cells surface, transfected cells were 
incubated with rat anti-HA HRP (1:1000) for 30 minutes on ice, washed with PBS/1% 
BSA and incubated with secondary anti-mouse Cy5 (Jackson ImmunoResearch) at 
1:2500 dilution for another 30 minutes on ice. Cells were washed one more and 
analysed by flow cytometry for Cy5
+
cells.
1
2 hrs in the case of Sindbis antiserum.
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2.9 In vitro binding of lentiviral vectors
Five µg/mL of anti-CD7-FITC antibody was incubated with 150 ng of Sindbis/anti-
FITC M1234 pseudotyped lentiviruses (total volume of 150 µL in PBS) at 4ºC for 1:30 
hrs to allow binding. Jurkat cells (5105, seeded the day before) were added and 
incubated for another 1:30 hrs at 4ºC. Cells were spun down at 450 ×g for 5 minutes at 
4ºC and washed twice with PBS and then fixed with 4% paraformaldehyde, for 20 
minutes at room temperature (RT). Cells were washed and ressuspended in 500 L 
PBS for analysis either by flow cytometry or by immunofluorescence for binding 
(DsRed
+
) and labelling (FITC
+
).
2.10 Immunofluorescence staining
For the immunofluorescence, 293T cells were seeded at a confluence of 4105 cells per
well in a 6-well plate containing 13 mm  coverslips previously coated with poly-D-
lysine (Sigma) and transfected as described before with pIntron Sindbis/anti-FITC. 
Forty-eight hours after transfection, cells were washed for 5 minutes in phosphate 
buffered saline (PBS) and fixed with 4% paraformaldehyde, for 20 minutes at RT. For 
Jurkat cells, after fixation, they were cytospun at 800 rpm for 5 minutes. Cells were 
washed twice in PBS and permeabilized with 0.1% Triton X-100 in PBS, for 20 
minutes at RT. After washing with 0.05% Tween 20 in PBS, cells were blocked in this 
washing solution plus 5% normal goat serum for 1 hr at RT. Cells were incubated for 1 
hr at RT with rabbit anti-Sindbis serum diluted 1:500 and goat anti-rabbit IgG (H+L) 
rhodamine secondary antibody (PIERCE), at 1:500 dilution, for 45 min at RT and in 
the dark. Cells were always washed 3 times after each incubation with antibody. A 
drop of DAPI (at a concentration of 50 ng/ml) was used to stain the nucleus. 
Coverslips were mounted in Fluoromount-G medium (Beckman Coulter) and cells 
were visualized using an Olympus IX-50 inverted microscope. 
2.11 Targeted in vitro transduction
Lentiviral vectors expressing DsRed (~200 ng HIV p24) were added to retronectin
(Takara Bio)-coated 24-well plates (40-60 µg/mL per well) and centrifuged at 2000xg 
for two hrs at 32ºC. Jurkat cells (8104, seeded 24 hrs before), FITC-conjugated 
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antibodies (5 g/mL) and polybrene (8 g/mL) were added to the plates with the 
lentiviruses (800 µl total volume per well) and spinoculated for 1:30 hrs at 930×g and
32ºC. Cells were incubated overnight at 37ºC and 5% CO2. The next morning, medium 
was removed and cells were treated with a low-pH buffer (0.131 M citric acid, 0.066 
M Na2HPO4, pH 5), for approximately 1 min at RT. The buffer was replaced with 
culture medium and the cells were incubated for two more days. Jurkat cells were
acquired for DsRed (transduction efficiency) and for FITC (cell labelling) by flow 
cytometry. Data analysis was performed using the FlowJo software. The anti-CD7-
FITC and anti-CD19-FITC antibodies were purchased from BD Biosciences and the 
FITC anti-HLA class I (clone W6/32) was purchased from Sigma.
2.12 Competition assay
For in vivo competition assays, the procedure was the same as for the in vitro
transduction assays but with the addition of increasing concentrations of mouse IgG1 
anti-FITC (clone FIT-22, Biolegends) or isotype control antibody (Biolegends) to the 
mixture of cells, anti-CD7-FITC and virus, before the spinoculation. 
2.13 HSV-TK/GCV suicide gene assay
For GCV titration, DsRedIRESTK transfected 293T cells or VSV/DsRedIRESTK 
transduced Jurkat cells were treated with several concentrations of GCV for a period of 
5 days, starting on the day following transfection or transduction, respectively. Jurkat 
cells were transduced with Sindbis/anti-FITC M1234 lentiviruses expressing 
DsRedIRESTK as mentioned before and after acidic buffer treatment on the next day, 
a new medium was added containing 1 µg/mL of GCV. Cells were removed at several 
time points for flow cytometry analysis (DsRed
+
cells) and to the remaining cells it 
was added more GCV supplemented medium. 
2.14 Mice
Non-obese diabetic/severe combined immunodeficiency (NOD/SCID) mice were 
obtained from Charles River Laboratories, Rag2-/-c-/- were obtained from IMM, 
Balb/c were from IMM and NOD.Cg-Rag1IL2rg (abbreviated as NOD-Rag1
-/-
IL2r-/-) 
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were obtained from The Jackson Laboratory. Mice were housed at IMM animal 
facility in pathogen-free conditions. At the first indication of morbidity (weight loss, 
lethargy, ruffled fur), or no more than 5 weeks following cell inoculation, mice were 
killed by cervical dislocation.  
2.15 In vivo targeted cell transduction
Twenty million Jurkat/GFP-Fluc cells were injected through the tail vein of female 
NOD-Rag1
null
Il2rnull mice, which were irradiated the day before using a 137Cs 
source (Gammacell ELAN 3000 irradiator) at a dose of 550 cGy 
164
to induce 
leukaemia. D-luciferin (3 mg /mice in DPBS – Caliper Life Sciences) was 
administered intraperitonially
1
1 week after cell injection to check for engraftment
under a CCD (charged-coupled device) camera (IVIS Lumina - Xenogen). Mice were 
anesthetized before imaging with an i.p. injection of ketamine/xylazine. The following 
day (or 3 days later), Sindbis/anti-FITC pseudotyped lentiviruses expressing 
RenillaIRESDsRed (or RenillaIRESTK) (~3µg of HIV p24) were injected through the 
tail vein and its biodistribution was analysed 4 days later by intravenous administration
(retro-orbital injection) of 100µg of coelenterazine
2
(benzyl-coelenterazine (h-CTZ) in 
sterile injection vials, NanoLight Technology) per mice. Acquisition time for both 
luciferases was 3 min, bin large, f/stop 1. At the 3
rd
or 4
th
week after cell injection, 
mice were killed and the femurs and spleens were removed. Bone marrow and spleen 
cells, collected in PBS, and blood cells (lysed with an eBioscience lysis buffer) were 
subjected to flow cytometry analysis to evaluate the percentage of engraftment (GFP
+
) 
and transduction (GFP
+
DsRed
+
). The CD45-FITC antibody used to stain human 
engrafted cell was from eBioscience. Coelenterazine stock solution was prepared at 5
µg/µl in provided diluent. Working solution was diluted in PBS, containing only 5 mM 
NaCl, pH 7.2
213
. Each mouse received 150 µl of this coelenterazine solution.
2.16 Real-time PCR
Real-time PCR was performed to quantify the vector copy number in the genomic 
DNA isolated from mice. Bone marrow was collected by flushing the femurs with PBS 
1
Acquisition was started 10 minutes after injection.
2
Acquisition was started 1 minute after injection.
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and genomic DNA was isolated using the innuPREP DNA Mini Kit (Analytic Jena 
Life Science), according to the supplier’s instructions. Quantification of vector copy 
number and cell number was performed by using SYBR Green (Fermentas) and an 
ABI PRISM 7300 sequence detector (Applied Biosystems). All reactions were 
performed with 0.5 ng of DNA, 12.5µl of SYBR Green PCR master mix and 7.5 pmol 
forward and reverse primers in a final reaction volume of 25 µl. The primers for 
analysis of vector copy number (Renilla luciferase) are indicated in Table XIII, 
Appendix A. The standard for quantification of vector copy number was 
FUWDsRedIRESRenilla. Quantification of the cell number was performed using 
primers for human β-actin (Table XIII, Appendix A) and the standard was made using 
genomic DNA isolated from known numbers of Jurkat cells. 
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3. Results and discussion
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3.1 In vitro gene therapy
3.1.1 Generation of mutations on the Sindbis glycoproteins and expression of anti-
FITC scFv at the surface of Sindbis-pseudotyped lentiviral vector 
A recombinant anti-FITC specific scFv was cloned between amino acids 71 and 74 of 
the E2 Sindbis glycoprotein by substitution for ST6 scFv in the envelope expression 
vector pIntron Sindbis-ST6LL
2
. The chimeric Sindbis envelope encode the 4M5.3 
scFv in which the N-terminal VL region is linked with the VH region through the 18-
aa peptide linker
141
. This chimeric Sindbis/anti-FITC envelope has also an HA tag at 
the C-terminus of the scFv to facilitate its detection. To evaluate the successful 
incorporation into the lentiviral vector and the expression of the anti-FITC at the 
surface, viral particles were produced by transfection of 293T cells and the virus-
containing supernatant was collected approximately 68 hours post-transfection, 
concentrated by ultracentrifugation and ressuspended in 2×SDS loading buffer. 
Expression of the anti-FITC at the surface of the virus was confirmed by Western Blot
using both an anti-Sindbis serum and an anti-HA HRP antibody (Figure 4), which 
detected a band of approximately 80 KDa, corresponding to the chimeric Sindbis 
envelope. 
72 KDa
WB -HIV p24
Gag/Pol: +       -
72 KDa
95 KDa
55 KDa
WB -HA
WB -Sindbis
Figure 4. Detection of Sindbis/anti-FITC envelope on pseudotyped virions. Viral supernatant
harvested from transfected 293T cells was concentrated by ultracentrifugation and the pellet was 
ressuspended in 30 µl 2×SDS-loading buffer and applied on a 10% SDS-PAGE. Western blot with an 
anti-HA HRP antibody reveals a band of approximately 80 KDa corresponding to the Sindbis envelope. 
The same band is detected with an anti-Sindbis virus serum. Supernatant harvested from cells where 
gag/pol plasmid was absent was included as a negative control. 
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Clinically effective gene therapy protocols for various diseases would ideally use 
procedures for efficient and specific targeting of therapeutic genes to the affected cells
while maintaining stable transduction and long-term expression. This can be 
accomplished by direct injection into the bloodstream followed by homing of the 
vector to the desired target cells or organs. For the success of this strategy with 
chimeric Sindbis/anti-FITC envelope, the background non-specific infection of wild 
type Sindbis envelope has to be reduced. Sindbis virus envelope is able to pseudotype 
oncoretroviruses and lentiviruses and it has an entry mechanism via low-pH mediated 
endocytosis. It is commonly used due to its high levels of expression and production of 
high-titer infectious particles. Even though effective in vitro, it has a nonspecific cell 
tropism in vivo as intravenous injection of Sindbis envelope pseudotypes into mice 
results in higher levels of infectivity in liver and spleen cells. This occurs because its 
receptors, the high-affinity laminin and heparin sulphate, have wide distribution and 
are highly conserved
148
. It has been shown that the display of exogenous protein 
domains or scFv can target lentiviral vectors to specific cells
147, 2, 152
and with the 
further addition of mutations in the envelope glycoprotein it would eliminate the 
problem of its non-specificity. Moreover, the insertion of the scFv at that position (E2 
aa 71) will also eliminate Sindbis original tropism. Sindbis virus has three envelope 
glycoproteins: E1, E2 and E3. E2 binds to the host cell receptor, E1 mediates 
membrane fusion in a low pH-dependent fashion and E3 works as a signal sequence 
peptide for E2 protein. Therefore, some domains of the these Sindbis envelope proteins 
were mutated using the Quickchange II XL Site Directed mutagenesis kit to reduce 
inherent non-specific infection. The list of oligonucleotides used for each mutation can 
be found in table XI, Appendix A. These mutations have been previously described
152
and will be defined here as M1, M2 and M3, which corresponds to (Figure 5): M1: 
deletion of E3 aa 61-64, resulting in higher selectivity, but decreased virus titer; M2: 
E2 SLKQ68-71AAAA that enhances titer without altering specificity; M3: E2 KE159-
160AA, which enhances selectivity. 
The final chimeric Sindbis envelope will have a combination of these mutations.
Nevertheless, Pariente and colleagues have additionally modified the Sindbis virus 
envelope containing the three mutations described above (M123) by introducing the 
AK226-227SG mutation in the E1 glycoprotein 
162
. These mutations have been 
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described to mediate fusion in the absence of cholesterol in the target membrane
129
, 
increasing the tropism and the infectivity of Sindbis pseudotyped vectors
150
. Therefore, 
it was created a modified Sindbis envelope with these four mutations combined to use 
in the in vivo studies in order to reduce endogenous Sindbis virus tropism. These 
mutations were confirmed by sequencing and the expression of the anti-FITC at the 
surface of the virus, called Sindbis M1234 for simplification, was confirmed by 
Western Blot with an anti-HA HRP antibody.
Figure 5. Schematic of Sindbis/anti-FITC construct with the several mutations depicted by an 
arrow.
One disadvantage of the noncovalent conjugation of vectors with antibodies reported 
by Morizono and colleagues
147, 152
is that in immunocompetent animals, serum 
immunoglobulin will compete with conjugated antibodies for biding to the ZZ domain 
of the envelope protein. In the strategy herein proposed this problem does not arise 
since FITC is a small organic molecule not present in the serum and therefore, it 
avoids competition between scFv anti-FITC and the immunoglobulins present in the 
serum. Another favourable feature of this scFv is the fact that it is an improved version
with enhanced fluorescence and increased binding and therefore, the titers of the 
pseudotyped vector (and consequently the transduction efficiency) will be also 
improved as that is dependent on the affinity and specificity of the inserted scFv.
With the insertion of the scFv on the Sindbis envelope and the created mutations, the 
binding of the pseudotyped lentiviral vector will depend only on the affinity of the 
scFv for the FITC on the surface of labelled cells.  
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Probably multiple insertions of the scFv into the envelope proteins would increase the 
avidity of the pseudotyped vector for target cells and consequently the viral titer, but 
one could not predict the effect it would have on the folding and assembly of the entire 
envelope and consequently, on its fusion ability.
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3.1.2 Expression of the Sindbis envelope at the surface of 293T cells  
In order to check the display of the FITC scFv in the virus producing cells and evaluate 
the amount of the Sindbis envelope plasmid that should be used for transfection to 
allow the highest expression possible at the surface of 293T cells, the cells were 
transfected with three different amounts of Sindbis/anti-FITC M123 envelope. Forty-
eight hours later, cells were stained with an anti-HA HRP as primary antibody and 
with anti-mouse Cy5 as secondary and analysed by flow cytometry (Figure 6). The 
percentage of Cy5 positive cells indicates the amount of the envelope protein displayed 
at the surface of 293T cells. This result indicates that the best display is achieved using
0.5 g of the plasmid envelope. 
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Figure 6. Sindbis/anti-FITC M123 expression at the surface of 293T cells. Cells were transfected 
with the indicated amounts of Sindbis/anti-FITC M123 envelope. Forty-eight hours later, cells were 
collected, stained with an anti-HA HRP antibody followed by an anti-mouse Cy5 and analysed by flow 
cytometry. Cy5 positive cells indicate the amount of envelope displayed at the surface of 293T cells.
This is a representative of two independent assays.
To further demonstrate the surface expression of Sindbis/anti-FITC on 293T cells, it 
was used an indirect immunofluorescence assay with rabbit anti-Sindbis polyclonal 
serum as primary antibody and anti-rabbit rhodamine as the secondary antibody. In
Figure 7, despite not including a nuclear staining, one can easily observe the cell 
membrane stained in red, clearly showing the expression of Sindbis envelope at the 
surface of 293T cells transfected with the plasmid Sindbis/anti-FITC M1234.
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Figure 7. Sindbis/anti-FITC M1234 expression at the surface of 293T cells. The cells were 
transfected with Sindbis/anti-FITC plasmid and 48 hours later an immunofluorescence assay was 
performed using anti-Sindbis polyclonal serum as primary antibody and an anti-rabbit rhodamine as 
secondary antibody, both at 1:500 dilution, and slides were visualized under the microscope.
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3.1.3 Binding of the Sindbis/anti-FITC M123 envelope to the anti-CD7-FITC tested 
in 293T cells
The antibody chosen for T-cell labelling in our system was the FITC-conjugated CD7 
antibody because CD7 is a surface antigen abundantly present on the majority of T 
cells and is rapidly internalized after antibody binding. The capacity of Sindbis/anti-
FITC M123 envelope for binding to the anti-CD7-FITC was tested in 293T cells. 
Therefore, increasing amounts of the antibody were incubated with cells expressing the 
three different quantities of envelope tested above, 0.05, 0.5 and 1 g (Figure 8). 
Analysis of the FITC expression by flow cytometry indicated the percentage of 
binding.  One can notice that the augment in binding, which is exclusively mediated by 
the scFv as CD7 receptor is T cell-specific and is not present in 293T, is proportional 
to the amount of CD7-FITC antibody and somewhat stabilizes from 10 g/mL, most 
likely because all binding sites were already occupied. Consequently, this assay 
allowed us to determine that the concentration of FITC-conjugated antibody from 
which we can obtain a good cell labelling is 2.5 g/mL and confirmed as well that the 
amount of envelope for the best display of anti-FITC is 0.5 g.
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Figure 8. Binding of Sindbis/anti-FITC M123 to the CD7-FITC antibody tested in 293T cells.
Titration of the anti-CD7-FITC antibody for binding to the different amounts of Sindbis/anti-FITC 
M123 envelope tested, in two separate assays. Cells were transfected with 0.05, 0.5 or 1 g of envelope 
plasmid and 48 hrs later incubated at 4ºC with increased concentrations of the anti-CD7-FITC antibody. 
After washing, cells were analysed for binding (FITC positive) by flow cytometry. This is a 
representative of two independent assays. 
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3.1.4 In-vitro binding of Sindbis/anti-FITC pseudotyped lentiviruses to Jurkat/CD7-
FITC cells
Prior to starting the transducing of the target cells, it was important to demonstrate 
binding of the Sindbis-pseudotyped lentiviruses to the cell membrane. Given that the 
anti-mouse Cy5 secondary antibody previously used in the staining of the Sindbis/anti-
FITC envelope at the surface of 293T cells will also recognize the mouse anti-human 
CD7-FITC besides the rat anti-HA HRP (used as primary for staining the Sindbis/anti-
FITC envelope), it was necessary to use another method for detecting virus binding at 
the cell surface. It was shown that GFP-vpr can be incorporated into the virion when 
the GFP-vpr plasmid is supplied in trans during viral preparation
138
. The resulting 
virus is labelled by GFP and could be detected by green fluorescence. Because the 
antibody used for labelling is FITC-conjugated (CD7-FITC), the lentivirus would have
to be labelled with a different colour. Therefore, it was constructed a plasmid that 
expresses DsRed fused to the N-terminus of HIV-1 vpr (designated DsRed-vpr).
However, the expression of the DsRed from this plasmid in 293T cells is much more 
reduced as compared to the lentiviral plasmid FUW/DsRed (14% versus 62%, 
respectively, as analysed by flow cytometry). Nevertheless, viruses were produced 
with the backbone plasmid FUW that lacks the transgene and co-transfection of the 
plasmid expressing DsRed-Vpr. Different amounts of lentiviruses were incubated with 
Jurkat cells plus anti-CD7-FITC at 4ºC, to avoid fusion. Binding was analysed by flow 
cytometry but no red fluorescence was detected, despite the good cell surface labelling 
with CD7-FITC antibody (Figure 9). 
Several studies by Pin Wang’s group have used the GFP-vpr labelling scheme
89, 245, 113, 
211
either to demonstrate the presence of the Sindbis envelope at the surface of vector 
particles by co-localization of the vector core and the stained envelope, by imaging 
only the lentiviral vectors, or to demonstrate lentiviral vector binding to cells. 
Curiously, they employ the GFP-vpr labelling scheme only with confocal microscopy. 
When using a flow cytometry approach to detect binding, they only perform the 
staining of the fusogenic molecule derived from the Sindbis virus glycoprotein via 
indirect immunofluorescence.
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Figure 9. In vitro binding assay in Jurkat cells assessed by flow cytometry. Different viral 
concentrations: (1) 312 ng; (2) 156 ng; (3) 78 ng and (4) 39 ng (HIV p24) of Sindbis/anti-FITC M1234 
lentiviruses labelled with DsRed were incubated with anti-CD7-FITC (5g/mL) for 1:30 hrs on ice.
Then, 5105 Jurkat cells were added and incubated for another 1:30 hrs. For viral production 0,3 g 
DsRed-Vpr was used in transfection. Cells were analysed by flow cytometry for FITC (surface-labelled 
cells) and DsRed (cell-binding viruses) fluorescence.
Therefore, we have opted for another technique to demonstrate the binding of the virus 
to the cell.  For that, an indirect immunofluorescence assay was employed, which used 
a rabbit anti-Sindbis polyclonal serum to stain the viral envelope and anti-rabbit 
rhodamine as a secondary antibody, given that we were able to show the display of the 
Sindbis/anti-FITC envelope at the surface of 293T cells before using this approach. 
The binding procedure was the same as the one mentioned above and the 
immunofluorescence performed exactly as described for Sindbis/anti-FITC detection 
on 293T cells. Binding of the virus (in red) to the cell membrane (in green) (Figure 10) 
is only detected when anti-CD7-FITC is present at the cell surface, while no detectable 
virus is observed on the surface of Jurkat cells alone.
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Figure 10. In vitro binding assay in Jurkat cells assessed by microscopy. Sindbis M1234/anti-FITC 
pseudotyped lentiviruses (bearing no reporter gene) were incubated with or without anti-CD7-FITC (5 
µg/mL) for 1 hour at 4ºC and after that, cells were added and incubated for another hour. An 
immunofluorescence assay was performed as mentioned in the Figure 7. Lentiviruses are stained in red, 
the CD7-FITC antibody in green and the nucleus in blue. 
Thus, so far, it was demonstrated that the anti-FITC scFv is exposed on the virion and 
accessible to the receptors expressed on target cells. The binding specificity of the
Sindbis-pseudotyped lentiviral vector is determined by the specificity of the anti-FITC 
scFv. As mentioned before, the 4M5.3 scFv (anti-FITC) was improved to have a 
higher fluorescein-binding affinity. It seems that (or we may say that) the fusion of the 
anti-FITC scFv with the Sindbis envelope proteins did not change its structure what 
could lead otherwise to loss of their function. Moreover, if the scFv was inserted into 
the regions of envelope proteins which are difficult to access, the chimeric proteins 
(scFv plus envelope) would not be able to bind the targeted molecules on the cells.
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3.1.5 Production of lentiviral vectors: optimization to reach the highest levels of 
transduction
For an efficient gene therapy, it is crucial to use a delivery vector that allows high 
levels of cell transduction and transgene expression. HIV-1-derived lentiviral vectors 
were the choice for this kind of gene therapy, mainly because of its capacity to stably 
integrate into the genome of a wide range of cells, both dividing and non-dividing, 
allowing long-term transgene expression and due to its safety. Several factors may 
influence lentiviral titer and consequently transduction efficiency. These can be the 
amount of plasmid transfected into the packaging cells, the type of transfer vector and 
its internal promoter, the transgene, viral vector collection time and concentration (e.g. 
ultracentrifugation), the presence of serum in the medium (during vector production 
and during transduction) and even the type of envelope used to pseudotype the 
lentiviral vector
125
. Viral infectivity (and titer) is also dependent on the type of 
transfection reagent used for virus production and the type of cells used for targeting. 
Therefore, it is very important that all these variables be optimized in order to achieve 
the best viral titers, as that is critical for an efficient gene delivery. 
Available in the lab were the lentiviral packaging plasmids from the 2
nd
generation,
CMV8.9, and the 3rd generation, pMDL (containing Gag/pol) and pRSV/Rev. For 
pseudotyping, VSV-G was the choice for this initial optimization steps because of its 
wide tropism and ability to pseudotype a vast range of viral vectors, its stability and
high titers of viral production. The lentiviral transfer plasmids used initially in the 
experiments were the #318/GFP-Fluc and the RFP, but later on these were replaced by 
FUGW and FUWDsRed (Figure 11). However, to evaluate the transduction efficiency
in our Sindbis/anti-FITC system, one would have to use a red fluorescent plasmid as 
reporter gene due to the overlap between the GFP and the FITC emission spectra.
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Luc hCMV hPGK GFP WPRE U3RSV U5 U5RR #318/GFP-FLuc
Figure 11. Schematic diagram of the lentiviral transfer vectors FUGW and #318/GFP-Fluc.
FUGW and #318/GFP-Fluc have the CMV enhancer and the RCV enhancer/promoter, respectively, 
substituted for the U3 region of the 5’LTR. U3 denotes a deletion in the U3 region of the 3’LTR that 
renders the 5’LTR of the integrated provirus transcriptionally inactive. GFP expression is driven by the 
human ubiquitin promoter (Ubi) in the FUGW plasmid and by the human phosphoglycerate kinase 
(hPGK) promoter in the #318/GFP-Fluc plasmid. The latter has the human CMV promoter to drive the 
expression of firefly luciferase (Luc). Both vectors have the Woodchuck hepatitis virus post-
transciptional element (WPRE) and the central polypurine tract (cPPT) (this one is not depicted). 
An ELISA assay was employed to determine the levels of the HIV capsid protein p24, 
which gives an estimate of the titer based on the amount of physical particles (pp).
Previous reports indicated that 1 pg of p24 Gag protein is equivalent to 1-10 infectious 
viral particles (TU)
242
, thus a vector stock with a 100 ng/ml p24 count contains 
approximately 10
6
/ml infectious viral particles or fewer. That same titer would 
correspond to 10
9
pp based on the estimation that 1 pg of p24 capsid protein represents 
around 10
4
pp
65
.
As a starting point, different ratios of the plasmids required for viral production were 
tested to see which one gave the highest value of the HIV capsid protein, p24 (Figure 
12). 293T cells were transfected by the calcium phosphate method and viruses were 
harvested 48 hours later for quantification of HIV p24. The ratio of plasmids that gave 
the best viral titer was 2:1:1:1 (Gag/pol:VSV:transfer vector:Rev) using the vector 
expressing GFP, whereas the one expressing RFP was always slightly lower, probably 
because of its toxicity to the cells.
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Figure 12. Titration of the plasmid ratio used to produce VSV-G-pseudotyped lentiviruses 
encoding the transgenes GFP or RFP. 293T cells (5× 10
5
per well of a 6-well plate) were transfected 
by CaPO4 precipitation with different ratios of plasmids and each viral supernatant was harvested 48 hrs 
later for HIV p24 quantification. Depicted in the x axis are the ratios of the Gag/pol:VSV:transfer 
vector: Rev plasmids.
Sodium butyrate (NaB) is commonly used to increase viral production. It has an effect 
on transcriptional activity, presumably through up-regulation of viral promoters, 
enhancing protein production capability
19
. Nevertheless, its addition to the cell culture
medium during transfection did not increase much the viral production (Figure 13), 
although the titers obtained in this experiment were higher than in the previous one. 
Using the packaging construct CMV8.9, the virus production was lower than using 
the third generation Gag/pol and Rev constructs with the ratios of 1:2:1:1 and 1:3:1:1 
(RFP: Gag/pol: Rev:VSV). 
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Figure 13. Titration of the plasmid ratio used to produce VSV-G-pseudotyped lentiviruses 
encoding RFP. 293T cells (5× 10
5
per well of a 6-well plate) were transfected by CaPO4 precipitation 
with different ratios of plasmids (in µg) and in the presence or absence of NaB (4 mM for 22 h). Each
viral supernatant was harvested 48 hrs later for HIV p24 quantification. Depicted in the x axis are the 
ratios of the RFP:Gag/pol:Rev:VSV plasmids. 
Next, new viruses were produced either with GFP and RFP vectors, using the ratio of 
1:3:1:1 (transfer vector:Gag/pol:Rev:VSV) for cell transfection by calcium phosphate 
precipitation. The generated lentiviruses were at a concentration of HIV p24 near 7000 
pg/ml for GFP and 6000 pg/ml for RFP (Figure 14). 
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Figure 14. Titers of the VSV-G-pseudotyped lentiviruses encoding GFP or RFP. 293T cells (5× 10
5
per well of a 6-well plate) were transfected by CaPO4 precipitation with the plasmid ratios of 1:3:1:1 
(Transfer vector:Gag/pol:Rev:VSV). Each viral supernatant was harvested 48 hrs later for HIV p24 
quantification. 
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Both Jurkat and Molt-4 cells were then transduced by spinoculation in 6-well plates for 
1 hour at 1200 rpm and 20ºC. The best transduction efficiency was 4% obtained for 
Jurkat cells infected with the GFP lentiviruses, whereas for Molt-4 the transduction 
efficiency was only 1.5% (Table II). 
Table II. Transduction efficiency of Jurkat and Molt-4 cells infected with the VSV-G-pseudotyped 
lentiviral vectors expressing GFP or RFP. Cells (8×10
5
per well of a 6-well plate) were infected with 
all the volume of the lentiviruses by spinoculation for 1 hour at 1200 rpm and 20ºC. Three days later, 
the percentage of transgene expression was analysed by flow cytometry.
Another viral production experiment was set up using two different ratios of plasmids
for transfection, either a GFP or a RFP transfer plasmid, and including or not serum in 
the cell culture medium. Virus were harvested 48 hours post-transfection and 
concentrated by ultracentrifugation. As it can be observed on Figure 15, the presence
of serum in the medium improved viral titers. The results confirms the previous 
experiments showing that the best ratio of plasmids for transfection is 1:3:1:1 (Transfer 
vector:Gag/pol:Rev:VSV) but, on the other hand, this time the RFP lentiviral had the 
highest titer. Nevertheless, this titer was ten times lower than that of the positive 
control lentivirus included in the ELISA, which was produced using the FUGW
lentiviral transfer vector that has the GFP under the control of the UbiC promoter 
(Figure 11). All the amount of lentiviruses was used to transduce Jurkat cells through 
spinoculation for 1 hour at 2000 rpm and 32ºC. One can observe that despite the higher 
titer (and thus slightly higher MOI) of the RFP lentiviruses it did not allowed any cell 
transduction, opposite to GFP lentiviruses where transduction efficiency was 7.86% 
(Table III). In fact, only GFP expressing lentiviruses were able to transduce the Jurkat 
cells and that was proportional to the viral amount used. The lentiviruses produced 
using the FUGW plasmid gave a transduction efficiency of 99.6%. Again, this 
confirmed that using 3 times more of Gag/pol is better for viral production and that is 
better to maintain the serum in the cell culture medium during viral production. The 
results also indicated that RFP might be toxic to the target cells and that the FUGW 
CELLS % FLUORESCENCE
Cells only GFP vector RFP vector
Jurkat 0.02 4.00 0.11
Molt-4 0.03 1.48 0.00
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lentiviral transfer vector might be a better option for viral production. Therefore, the
FUGW plasmid was chosen for the subsequent experiments. 
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Figure 15. Titers of the VSV-G-pseudotyped lentiviruses encoding GFP or RFP, produced in the 
presence or absence of serum. 293T cells (5× 10
5
per well of a 6-well plate) were transfected by 
CaPO4 precipitation with the plasmid ratios of either 1:3:1:1 (Transfer vector:Gag/pol:Rev:VSV) or 
4:2:1:1,2 and in the presence or absence of serum in the medium. Each viral supernatant was harvested 
48 hrs later and concentrated by ultracentrifugation before HIV p24 quantification. A viral sample 
obtained from other lab and produced with FUGW lentiviral transfer plasmid was used as a positive 
control and the concentration indicated corresponds to a dilution of 1:10 of that sample. 
Table III. Transduction efficiency of Jurkat cells infected with the VSV-G-pseudotyped lentiviral 
vectors expressing GFP or RFP, produced in the presence or absence of serum and using different 
ratios of plasmids. Cells (4×10
4
per well of a 48-well plate) were infected with all the volume of 
lentiviruses through spinoculation for 1 hour at 2000 rpm and 32ºC. Three days later the percentage of 
reporter gene positive cells was analysed by flow cytometry.
The influence of the transfection method in viral production was also assessed. The 
lipofectamine reagent and the CaPO4 precipitation were used in parallel in the
transfection using either the CMV8.9 or the Gag/pol and Rev plasmids for 
comparison. In addition, other ratios of the plasmids were used in the experiment in 
which all the amounts of plasmids were increased, except the amount of the envelope 
RATIO % FLUORESCENT CELLS 
GFP + serum GFP RFP + serum RFP FUGW
1:3:1:1 7.86 2.57 0.00 0.00
99.6
4:2:1:1,2 4.42 2.09 0.16 0.11
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plasmid. According to Figure 16, higher viral titers were achieved by the CaPO4
method when using the 3
rd
generation packaging constructs (Gag/pol and Rev in 
separate plasmids). Transduction of Jurkat cells was performed with spinoculation for 
1:30 hours at 2200 rpm and 32ºC. Despite allowing a viral production two times lower
than that achieved with lentiviruses generated by CaPO4 transfection, the lentiviruses
resulting from transfection with lipofectamine transduced Jurkat more efficiently
(Table IV). This occurs probably because the CaPO4 method produces more toxicity in 
the cells (cell detachment and death), releasing cell components that become co-
concentrated with viral particles, thereby introducing toxic components to viral 
preparations. These results indicate that lentiviruses produced using lipofectamine 
allow superior transduction efficiency and further confirms that the 3
rd
generation 
lentiviral packaging vectors are better for producing high amounts of lentiviruses.
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Figure 16. Titers of the VSV-G-pseudotyped lentiviruses expressing GFP (FUGW), produced 
either by CaPO4 or by lipofectamine transfection. 293T cells (1×10
5
per well of a 24-well plate) were 
transfected either by CaPO4 precipitation (with the plasmid ratios of 5:10:5:1 (Transfer 
vector:Gag/pol:Rev:VSV) or 10:10:1 (Transfer vector:CMV8.9:VSV) or by lipofectamine (ratios of 
3,2:10:3,2:1 or 10:10:1, for the four and three plasmid approach, respectively). Each viral supernatant
was harvested 48 hrs later and subjected to HIV p24 quantification. 
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Table IV. Transduction efficiency of Jurkat cells infected with the VSV-G-pseudotyped lentiviral 
vectors expressing GFP produced either by CaPO4 or lipofectamine transfection. Cells (8×10
4
per 
well of a 24-well plate) were infected with all the volume of produced lentiviruses through 
spinoculation for 1:30 hrs at 2200 rpm and 32ºC. Three days later the percentage of GFP positive cells
was analysed by flow cytometry.
The use of a liposome-based reagent for transfection seems to greatly influence the 
transduction efficiency. Therefore, the Lipofectamine reagent was compared with 
Fugene 6, again using the tree-plasmid or the four-plasmid approach. Conditions for 
transfection and for transduction were maintained, except that this time new plasmid 
DNA was prepared and viruses were harvested 65 hours post-transfection. As it can be 
observed in Figure 17 and in Table V, virus collection at late time points after the 
initiation of vector production led to an increase in viral titer, and therefore, an 
increase in the transduction efficiency, compared with the previous result obtained by
transfection with lipofectamine in which the viruses were harvested 48 hours post-
transfection (Figure 16 and Table IV). For all the conditions tested, the transduction 
efficiency was proportional to the viral titer and was higher for the lentiviruses 
generated by Fugene 6 transfection, reaching 96.48% GFP positive cells. 
% GFP
CaPO4 Lipofectamine
CMV8.9 Gag/pol CMV8.9 Gag/pol
3.00 5.93 4.81 17.35
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Figure 17. Titers of the VSV-G-pseudotyped lentiviruses expressing GFP (FUGW), produced 
either by Lipofectamine or by Fugene 6 transfection. 293T cells were transfected as mentioned on 
the previous assay and lentiviruses were harvested 65 hrs later for HIV p24 quantification. As the 
absorbance values for Gag/pol lentiviruses were too high (left graph) and outside the range of the 
calibration curve it was not possible to determine its concentration (right).  
Table V. Transduction efficiency of Jurkat cells infected with the VSV-G-pseudotyped lentiviral 
vectors expressing GFP (FUGW) produced either by Lipofectamine or by Fugene 6 transfection.
Cells (8×10
4
per well of a 24-well plate) were infected with all the volume of lentiviruses through 
spinoculation for 1:30 hrs at 2200 rpm and 32ºC. Three days later the percentage of GFP positive cells 
was analysed by flow cytometry.
Being determined the optimal conditions for viral production that allowed the highest 
transduction efficiency in Jurkat cells it was necessary to: 1) replace the GFP reporter 
gene in the FUGW lentiviral vector by a red fluorescent protein; 2) test again the 
transduction efficiency in Molt-4 cells and 3) use the Sindbis/anti-FITC envelope 
instead of the VSV-G. In Table VI are indicated the percentages of both Jurkat and 
Molt-4 transduction with VSV-G-pseudotyped lentiviruses expressing either GFP or 
RFP. The efficiency of Molt-4 transduction is clearly lower than that of Jurkat cells 
being more evident when the red fluorescent expressing lentiviruses were used. Taking 
into account this result, Jurkat cells were chosen to proceed with the further 
experiments for this project.
% GFP 
Lipofectamine Fugene 6
CMV8.9 Gag/pol CMV8.9 Gag/pol
23.36 84.35 60.88 96.48
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Table VI. Comparison of transduction efficiency between Jurkat and Molt-4 cells infected with 
the VSV-G-pseudotyped lentiviral vectors expressing GFP (FUGW) or RFP (FUW/RFP)
produced using Fugene HD for transfection. Cells (8×10
4
per well of a 24-well plate) were infected 
with approximately 50 ng of lentiviruses through spinoculation for 1:30 hrs at 2200 rpm and 32ºC. 
Three days later the percentage of GFP or RFP positive cells was analysed by flow cytometry.
Finally, the Sindbis/anti-FITC chimeric envelope was tested in another experiment, 
which included the VSV-G as positive control. Lentiviruses were prepared as 
previously mentioned and all the supernatant was used for infection after concentration 
by an AMICON filtration device. Table VII summarizes the results obtained for 
transduction. VSV-G/GFP lentiviruses gave a higher cell transduction (twice much) 
than VSV-G/RFP (92.2% versus 43.49%). Sindbis/anti-FITC/RFP, on the other hand, 
allowed only 7.66% Jurkat transduction. Therefore, it was still necessary to improve 
the efficiency of transduction.
Table VII. Transduction efficiency of Jurkat cells infected either with Sindbis/anti-FITC-
pseudotyped lentiviruses expressing RFP or with VSV-pseudotyped lentiviral vectors expressing 
GFP or RFP. Cells (8×10
4
per well of a 24-well plate) were infected with approximately 500 ng of 
Sindbis/anti-FITC lentiviruses (concentrated by AMICON centrifugation) plus 1.5 µg/ml anti-CD7-
FITC or with 40 ng of VSV-G lentiviruses through spinoculation for 1:30 hrs at 2200 rpm and 32ºC. 
Three days later the percentages of GFP or RFP positive cells were analysed by flow cytometry.
There is a noticeable difference between the transduction efficiency mediated by
lentiviruses expressing GFP and lentiviruses expressing RFP. Since the variation 
between the two lentiviruses resides only in the transgene, that may indicate that the
RFP protein might cause some toxicity to the cells. A new variant of red fluorescent 
protein, called DsRed-Express2 but that will be here simplified as DsRed, had just 
CELLS % GFP % RFP
Jurkat 99.38 76.89
Molt-4 24.15 1.51
% GFP % RFP 
Cells only 0.03 0.09
VSV-G/GFP 92.2 -
VSV-G/RFP - 43.49
CD7-FITC 22.54 -
Sindbis/anti-FITC+CD7-FITC 42.11 7.66
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been engineered at the time and showed minimal cytotoxicity
207
. This new red 
fluorescent gene was cloned into the FUW transfer plasmid for the subsequent 
experiments. Transgene-related toxicity was also reported for a VSV-G-pseudotyped 
SIV expressing GFP
59
. When VSV-G-pseudotyped lentiviruses are used to transduce 
Jurkat cells at more than 200 ng of HIV p24 it become toxic to the cells and around 
40/50% cell death can be observed, even using the less toxic DsRed gene. 
Thus, another experiment was performed to produce lentiviral vectors pseudotyped 
with Sindbis/anti-FITC or VSV-G and expressing this time the new red fluorescent 
protein. Viruses were harvested 65 h later, concentrated by ultracentrifugation and 
used to transduce Jurkat cells. There was an improvement in Jurkat transduction with
VSV/DsRed lentiviruses, which could now transduce 80% of the cells, even using an
amount of viruses lower than the previously used for VSV/RFP (Table VIII). With the 
Sindbis/anti-FITC/DsRed lentiviruses the transduction efficiency was only 7.5%, 
despite the higher amount of virus used. As it will be shown in the next section, the in 
vitro transduction, some modifications were added which allowed us to overcome this 
difficulty in the transduction with Sindbis chimeric envelope.
Table VIII. Transduction efficiency of Jurkat cells infected with Sindbis/anti-FITC- or VSV-G-
pseudotyped lentiviral vectors, both expressing DsRed. Cells (8×10
4
per well of a 24-well plate)
were infected as described before with approximately 2.5 µg of Sindbis/anti-FITC lentiviruses 
(concentrated by ultracentrifugation) plus 5 µg/ml anti-CD7-FITC or with 25 ng of VSV-G lentiviruses. 
Three days later the percentage of GFP or RFP positive cells was analysed by flow cytometry.
Therefore, from this set of experiments we can conclude that the ratio of the plasmids 
used to produce lentiviral vectors by transient transfection does influence viral titer. 
The four-plasmid approach using the 3rd generation packaging construct was more 
efficient for virus production than the 2
nd
generation. The amount of the Gag/pol
plasmid should be higher than the other plasmids and the amount of the envelope 
% FITC % DsRed
Cells only 0.09 0.14
VSV-G/DsRed - 80
CD7-FITC 68.2 0.15
Sindbis/anti-FITC+CD7-FITC 89.0 7.5
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plasmid should be ten times lower than that one. This is in agreement with others that 
reported very small amounts of the envelope plasmid
9
and low ratio of envelope to 
transfer vector plasmid
38
for optimal infection and transduction efficiency. As will be 
seen early in the next point, a high amount of the lentiviral transfer plasmid is crucial.
It is usually used more than twice the amount of the other plasmids
72
. The type of 
lentiviral transfer vector and its promoter-driven transgene expression can also 
influence the viral infectivity and the expression of the transgene. The FUGW 
construct has a better performance than the #318GFP-Fluc. The former contains the 
human ubiquitin-C promoter that proved to be stronger than the hPGK.
The presence of serum in the cell culture medium also favoured lentiviral production,
and consequently infectivity, contrary to a study by Logan and colleagues
125
that 
observed superior vector production and a slightly elevated infectivity of vector 
produced in serum-free medium. Others have reported that lentiviral vector production 
in the absence of serum, while reducing immunogenicity, did not affected transduction 
efficiency
10
.
The choice of the transfection reagent proved to be a determinant factor. A low
toxicity liposome-based approach, like the Fugene or TransIT- LT1 (cheaper than 
Fugene but with the same transfection performance), is definitely the best to reach the 
highest viral titers and transduction efficiencies. The viral concentration method used 
is also important. We found that ultracentrifugation worked better than the AMICONs 
filter devices or the lenti-X concentrator (see Appendix C) as it allows a higher vector 
recovery. 
Finally, the efficiency of targeting will obviously depend on the type of cells used. We 
found a significant difference between the levels of transduction of the Jurkat versus
the Molt-4 leukemic cell lines using the same viral construct that is not due to 
differences in the levels of cell-surface labelling, as those assays were performed with 
VSV-G that does not need a targeting antibody as happens for Sindbis/anti-FITC.
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3.1.6 In-vitro targeting of Jurkat cells
The effectiveness of the in vitro targeting of Jurkat cells can be assessed by producing 
Sindbis/anti-FITC pseudotyped lentivirus and transducing the cells with this virus. 
Transduced cells will express DsRed protein that can be detected by measuring the 
percentage of fluorescent cells through flow cytometry. Nevertheless, our transduction 
protocol needed further optimization. To do that it was used the Sindbis/ZZ envelope 
(that contains the Fc binding domain of protein A), whose transduction efficiency was 
already demonstrated
147
, and two different groups of plasmid ratios for 293T cells 
transfection in order to produce virus. Moreover, transduction (with equal amounts of 
both groups of viruses) was carried out in plates coated or not with retronectin and 
with or without an acidic pH treatment that was performed approximately 18 hours 
later (Appendix B). It was previously demonstrated that the reduction of the pH in the 
culture medium following incubation of Sindbis virus with liposomes at 4ºC triggered 
fusion
198
and that cell lines resistant to transduction by a Sindbis ZZ mutant 
pseudotyped lentiviral vector showed an enhancement in infectivity of 20 to 25 fold 
with low pH treatment
150
. According to figure 46 (Appendix B), the lentivirus 
produced to higher titers, denominated “Black” (121 ng/ml versus 91 ng/ml of HIV 
p24 for the “Blue”), was not the one with the best efficiency of transduction, which 
benefited from retronectin and low pH treatment. These modifications to the protocol 
allowed us to obtain 85% transduction efficiency and thus, these were the conditions 
used to address the efficiency of the Sindbis/anti-FITC targeting system. Morizono and 
colleagues reported an efficiency of 77.85% in Jurkat transduction using a Sindbis ZZ 
envelope with mutations corresponding to our M3 and M4, and with similar conditions 
(low pH treatment, retronectin-coated plates, anti-HLA targeting antibody and 200 ng 
HIV p24 of lentivirus)
150
. 
A transduction assay was then performed using the anti-HLA-FITC antibody for cell 
labelling and using the Sindbis/anti-FITC Wt (without mutations in the envelope 
glycoproteins) and two Sindbis/anti-FITC envelope mutants M123 and M1234. These 
mutants showed less non-specific transduction when virus was added alone comparing 
with the Wt (Figure 18). In the presence of the HLA antibody, M123 showed the 
highest infectivity, although M1234 had less non-specific infection. 
Lentiviral target-specific strategy for molecular therapy
78
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
0 0.1
23.276.7
cells + HLA-FITC
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
0.03 0
0.0399.9
cells
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
14.5 15.6
22.247.8
Wt + HLA-FITC
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
9.46 28.7
31.630.2
M123 + HLA-FITC
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
6.94 16.2
36.740.2
M1234 + HLA-FITC
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
2.33 0.016
0.02697.6
Wt w/o antibody
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
0.092 0.036
0.06199.8
M123 w/o antibody
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
0.097 0.026
0.04199.8
M1234 w/o antibody
D
s
R
e
d
FITC
Figure 18. Transduction of Jurkat cells with the pseudotyped Sindbis/anti-FITC lentiviruses. Wt 
viruses and the mutants M123 and M1234 (~250 ng HIV p24) were spinoculated in a retronectin (60 
µg/mL) coated 24-well plate and then cells and anti-HLA-FITC antibody (5 g/mL) were added to the 
wells and spinoculated again. The next day cells were treated with a low pH buffer and medium was 
replaced. Fourty-eight hours later cells were analysed by flow cytometry for DsRed fluorescence.
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In Figure 19A, it is shown a good efficiency of Jurkat transduction with Sindbis/anti-
FITC Wt, which is higher when using the anti-CD7-FITC antibody for labelling the 
cells than when the anti-HLA-FITC is used (82.8% versus 55.8%, respectively). 
Moreover, with a lentivirus displaying a non-specific scFv (ST6 that binds to the 
CCR5 receptor
2
) at the surface of the wt Sindbis envelope there was no targeting to 
Jurkat cells, which indicates that the binding is mediated through specific binding of 
the FITC scFv to the FITC at the cell surface. However, using an antibody specific for 
B cells for cell labelling (anti-CD19-FITC) there was some non-specific targeting that 
was also observed when using the virus alone, meaning that the virus was able to enter 
the cells in a non-specific way. Compared with the results in Figure 18, one can say 
that the increase in transduction efficiency was accompanied by an increase in non-
specific entry, and particularly when the virus is added alone rather than in the 
presence of the cell-coating antibody. In Figure 19B, it was investigated whether the
mutants of the Sindbis envelope were able to reduce the non-specific transduction, this 
time using the anti-CD7-FITC antibody, and, in fact, that is observed with both the 
M123 and the M1234 Sindbis envelopes, but the effect is more visible with the 
lentivirus Sindbis/anti-FITC M1234 where the background is almost completely 
removed. Nevertheless, the infectivity is lower than the Wt lentiviruses (35.9% versus
64.8%). Results from both panels indicate that the inclusion of the receptor-specific 
FITC-conjugated antibody to which the scFv FITC can bind augments specific 
transduction while reducing non-specific one, thus reinforcing the fact that the 
presence of a targeting moiety can re-direct binding to specific cells. This further 
highlights the fact that insertion of the scFv did not block the folding of the entire 
envelope proteins or abrogated their fusion activity. Moreover, the results are in 
accordance with the ones obtained by Morizono and colleagues
152
for Sindbis/ZZ 
given that in the absence of antibody the background level of infectivity is reduced for 
the mutant viruses, particularly the Sindbis/anti-FITC M1234 (panel B), compared 
with the non-mutated envelope (Wt, panel A).  
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Figure 19. Transduction of Jurkat cells with the pseudotyped Sindbis/anti-FITC lentiviruses.
Viruses were spinoculated in a retronectin coated 24-well plate and then cells and a FITC-conjugated 
antibody (5 g/mL) were added to the wells and spinoculated again. The next day cells were treated 
with a low pH buffer and medium was replaced. Fourty-eight hours later cells were analysed by flow 
cytometry. In panel A are the results obtained with the non-mutated Sindbis envelope virus expressing 
the scFv anti-FITC (Wt) and another expressing the scFv anti-CCR5 (ST6), both using three different 
antibodies: anti-HLA-FITC, anti-CD7-FITC and anti-CD19-FITC. In panel B are shown the results for 
the Sindbis/anti-FITC Wt and mutants M123 and M1234 (same volume of virus) using the antibodies 
anti-CD7-FITC, anti-CD19-FITC and without antibody. In panel A, it was used 40 µg/mL of retronectin 
and in panel B, it was used 50 µg/mL.
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Figure 19. Continued.
In summary, the difference in infectivity among the different Sindbis/anti-FITC 
mutants and Wt are due to differences in titer, as it was used the same volume of virus 
and not the same concentration, except for Figure 18. In figure 19B, where the viruses 
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were not normalized for HIV p24 concentration, one can see that the Wt allowed a 
higher transduction due to the production of higher titers than the other mutants did. 
Besides that, the variation observed for Wt within the three panels of experiments is 
also related with different amounts of retronectin used for coating the 24-well plates.
The binding of the anti-FITC scFv to the FITC labelled cells mediated the viral entry, 
but when the ligand is not present, the virus (Sindbis/anti-FITC Wt) can enter via its 
natural receptors heparin sulphate and laminin, therefore it showed that levels of 
background transduction. Although viral vectors are extremely efficient in gene 
transfer, the alteration in target specificity of the virus can result in a decrease in 
infectivity of the recombinant virus and this explains the lower titer and infectivity of 
the Sindbis envelope mutants.
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3.1.7 Competition of an anti-FITC antibody with the anti-FITC scFv displayed by 
Sindbis-pseudotyped lentiviruses
To demonstrate that the targeting is mediated by the anti-FITC scFv display we 
performed a competition assay where transduction was done in the presence of 
increased amounts of an anti-FITC antibody that would compete for binding to the 
FITC present on labelled cells. Targeted transduction decreased as the concentration of 
this soluble antibody increased, reducing transduction efficiency by 50%, whereas the 
isotype control antibody had no effect (Figure 20). This shows that the viral infectivity 
blockade is mediated by the antibody-specific inhibitory effects. Therefore, the 
specific targeting of FITC-labelled cells by chimeric scFv-Sindbis pseudotyped 
lentiviral vectors is triggered by the recognition and binding of the anti-FITC scFv to 
the FITC.
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Figure 20. Competition between an anti-FITC antibody and the anti-FITC scFv displayed by 
Sindbis-pseudotyped lentiviruses for binding to FITC-labelled Jurkat cells. Effect of the addition of 
a soluble anti-FITC antibody on the efficiency of targeted transduction. Increasing concentrations of 
anti-FITC or isotype control antibody were added to the wells during transduction, which was 
performed as described before. On the following day, medium was replaced with a new one after a low 
pH treatment and DsRed expression (transduced cells) analysed 2 days post-transduction by flow 
cytometry. Values are presented as the percentage of transduced cells relative to the control without 
soluble anti-FITC antibody. This figure is a representative of two independent assays. 
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3.1.8 Suicide gene therapy
From the wide range of suicide genes employed in gene therapy, DT-A and HSV/TK
are among the most successfully used and for this reason both strategies were chosen 
to be tested.
3.1.8.1 The DT-A approach 
A single molecule of diphtheria toxin is sufficient to kill a cell
238
, what makes it a 
highly potent strategy. Therefore, the initial approach adopted to kill the leukemic cells 
was the DT-A. DT has two subunits: the A subunit that contains the catalytic activity 
and the B subunit that binds to receptors present at the cells surface
46
. DT-A inhibits 
protein synthesis by catalysing the ADP-ribosylation of diphtamine, a post-
translationally modified histidine residue, in elongation factor-2 (EF-2)
46
, and triggers 
apoptosis and detachment of cells
35
. The DT-A gene was cloned in the lentiviral vector 
FUW and DT-A toxicity from this construct was tested by measuring its ability to 
inhibit protein synthesis (Figure 21), which was compared to other plasmids available 
in the lab that were used as controls, PSA-DTA, containing a prostate-specific antigen 
(PSA) promoter, and ROSA-DTA, allowing expression in a ubiquitous manner. Two 
different cells lines, 293T and HeLa, were used because of the possible differences that 
might be observed from cell to cell using different promoters. Cells were co-
transfected with the DT-A plasmids and a control plasmid with the firefly luciferase 
gene under the UbiC promoter. Cells were harvested 65 h post-transfection and 
luciferase activity was measured in the protein extracts. Reduction in luciferase 
activity was used as a measure of the inhibition of protein synthesis. The FUW-DTA 
construct revealed to be as efficient as the other ubiquitous expressed construct in 
inhibiting luciferase expression (Figure 21). On the other hand, DT-A expression from 
the tissue-specific promoter plasmid was able to reduce the luciferase expression in the 
HeLa cancer cell line but did not cause changes to luciferase expression in 293T cells.
These results demonstrated that this construct was completely functional.  
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Figure 21. Inhibition of protein synthesis by FUW-DTA in 293T (A) and HeLa (B) cells. Cells were 
transfected with a plasmid expressing firefly luciferase (FUW-Luc) either alone (control, 0.8 µg) or co-
transfected with other plasmids expressing DTA (0.1 µg). The total amount of plasmid was maintained 
constant by addiction of an empty plasmid. Sixty-five hours post-transfection cells were harvested and 
subjected to a luciferase assay. PSA-DTA and ROSA-DTA were used as positive controls for DTA 
inhibition. Y-axis indicates absolute luciferase values. Error bars show standard deviation.
Because the toxin is extremely toxic, its expression in the virus-producer cells will
inhibit protein synthesis and, consequently, viral production (for the generation of 
viruses containing DT-A) will be negatively affected. For that reason, a DT-A-resistant 
cell line was employed to try to overcome this difficulty in generating lentiviral 
vectors (non-tissue specific) containing the DT-A toxin gene in 293T cells. 293DTR 
cells
119
are resistant to apoptosis mediated by the toxin because it has a mutation in 
EF-2 that blocks ADP-ribosylation by the DT-A toxin 
104
(in these cells, the toxin is 
incapable of EF-2 inactivation and can support the growth of viruses expressing the 
toxin). To confirm the reduced DT-A inhibition of protein synthesis in the new cells it 
was performed again a luciferase assay (Figure 22). Only a slightly decrease was 
observed in the luciferase expression levels.
The efficacy of the DT-A toxin was further tested by observing a reduction in DsRed 
fluorescence (Figure 23). In comparison to 293T cells, in which the expression of DT-
A has a dramatic reduction in the fluorescence levels, in 293DTR cells the toxin 
basically has no effect. Moreover, these results also confirm that these DTA-resistant 
cells do not allow a high level of gene expression. 
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Figure 22. Inhibition of protein synthesis by FUW-DTA in 293DTR cells. Cells were transfected 
with a plasmid expressing firefly luciferase (FUW-Luc) either alone (control, 0.8 µg) or co-transfected 
with FUW-DTA (0.1 µg). The total amount of plasmid was maintained constant by addiction of an 
empty plasmid. Sixty-five hours post-transfection, cells were harvested and subjected to luciferase 
assay. Y-axis indicates absolute luciferase values. Error bars show standard deviation.
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Figure 23. Inhibition of protein synthesis by FUW-DTA in 293T and 293DTR cells. Cells were 
transfected with a plasmid expressing DsRed (FUW-DsRed) either alone (DsRed, 0.8 µg) or co-
transfected with FUW-DTA (0.1 µg). The total amount of plasmid was maintained constant by addiction 
of an empty plasmid. Sixty-five hours post-transfection, cells were harvested and red fluorescence was 
quantified. A reduction in DsRed expression was observed in the presence of DT-A but only in the 
sensitive 293T cells. In 293DTR it had almost no effect. This is a representative of two independent 
assays.
Thus, the 293DTR cells were transfected with the vectors needed for viral production, 
but still, the viral titer of the supernatant harvested from the cells was very low (3.2 
ng/ml) compared with the one usually obtained for virus produced in 293T cells (	50 
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ng/ml), indicating that possibly no viral particles were being generated. The amount of 
plasmid used for transfection (1.4 µg) was still toxic to the 293DTR cells. This could 
indicate that the cells were only resistant to low amounts of the toxin (partially 
resistant to the toxin). However, in the study first describing this cells, they tested the 
sensitivity to DT holoenzyme at concentrations ranging from 10
-11
M to 10
-7
M (this 
maximum corresponds to ~ 6-7 µg/mL) and 293DTR cells were resistant to 10
-7
M. 
One possible explanation for the DT-A sensitivity of the cells in our hands would be 
that the EF-2 mutation had reverted to wild type. 
Therefore, it was adopted another strategy to overcome the problem with virus 
production, which consisted in the addition of nicotinamide during viral production 
that at high doses reverses the ADP-ribosylation of EF-2
146
. For that, 293T cells were
co-transfected with the plasmids needed for lentiviral production of VSV/DT-A and 4 
hours later different amounts of nicotinamide were added (0, 1, 4 and 8 mM). The 
supernatant was harvested and titrated but, again without success in virus production. 
In parallel, cells were transfected to produce VSV/DsRed generating a good viral titer.
Thus, all these strategies to produce lentiviral vectors expressing the DT-A were 
unsuccessful. Possibly, a better approach to overcome the toxicity of DT-A would be 
to control its expression during the phase of viral production. That can be done at the 
transcriptional level using promoters (for example, tissue-specific promoters) that 
would be turned off in the virus-producer cells but that could be activated in target 
cells. That has been achieved for instance using the PSA promoter to target DT-A 
gene expression to prostate cancer cells
242, 244, 119
although, in some cases, the toxicity 
was not completely eliminated even when using attenuated versions of the toxin
97
. In 
addition, a synthetic beta-catenin-dependent promoter (CTP4) that allowed the 
generation of adenovirus vectors expressing DT-A showed promise for gene therapies 
of tumours deregulated for beta-catenin
121
. This strategy could have been applied to 
our lentiviral delivery system if T-cell specific promoters were available. Another 
approach would be to use a regulatable or inducible promoter in the vector system.
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Nanoparticles can be an alternative to viral vectors to deliver DT-A and avoid the 
problems associated with its toxicity in virus-producing cells. For instance, the lab of 
Dr Janet Sawicki, who gently provided the original DT-A plasmid, has been using
polymeric nanoparticles to deliver DT-A combined with transcriptional regulation to 
target gene expression to prostate and ovarian tumours
166, 86
. Nevertheless, more 
recently, Wang and colleagues created a DT-A-resistant 293T cell line that allowed a 
non-integrating Rev-dependent lentiviral vector carrying DT-A and human TRAF6 to 
target HIV-positive cells
231
.
The advantage of DT-A gene for suicide gene therapy is that it does not need the 
administration of a prodrug. Additionally, an efficacious concentration of the prodrug
is not always achievable for in vivo applications and yet some cells that contain TK 
might be resistant to GCV killing
80
. Nevertheless, given the problems in the
production of virus, we had to abandon this option for our suicide gene therapy and 
focus on the HSV/TK strategy. 
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3.1.8.2 The HSV-TK approach 
To determine if the HSV-TK/GCV suicide gene strategy would work with our 
Sindbis/anti-FITC lentiviral vector to kill specifically the target cells, a spliced form of 
the TK gene (TK.007)
175
was cloned into the lentiviral vector FUW. Because of the 
possible problems associated with the positioning of the TK gene in the lentiviral 
vector plasmid
14
, three different constructs were designed to further evaluate 
expression and choose the best one for our purpose. The goal was to obtain a good 
expression of both transgenes, DsRed and TK, cloned into the FUW backbone. In two
of the constructs, the transgenes are in fusion: DsRedTK and TKDsRed. In the third 
vector, TK expression is internal ribosomal entry site (IRES)-dependent: 
DsRedIRESTK. These plasmids were transfected in 293T cells and analysed for 
DsRed, 65 hrs post-transfection, and for AlamarBlue fluorescence intensity, 5 days 
post-transfection and in the presence of 1 µg/mL of GCV (Figure 24). Although TK 
expression was quite similar among them, FUW/DsRedIRESTK showed the highest 
expression of DsRed, and was the construct chosen for this suicide gene approach. Of 
notice is the fact that GCV, at that concentration, was not toxic to untransfected 293T 
cells. 
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Figure 24. Fluorescence intensity of the DsRed and TK constructs. Cells were transfected with the 
indicated FUW plasmids and subjected to GCV treatment (1µg/mL) for 5 days, after which cell viability 
was analysed by alamarblue fluorescence. DsRed fluorescence was measured approximately 65 hours 
post-transfection. TK.007 and DsRed plasmids were included as controls. 
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To perform a titration of the GCV concentration, 293T cells were transfected with the
FUW/DsRedIRESTK plasmid and, on the following day, it was added different 
concentrations of GCV, above and below the one initially used. Cell viability was 
measured by alamarblue assay, 5 days after transfection. A decrease in cell viability 
was observed with a GCV concentration as low as 0.25 µg/mL (Figure 25). 
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Figure 25. GCV sensitivity of 293T cells expressing DsRedIRESTK assessed by Alamarblue assay. 
Cells were transfected with the FuW/DsRedIRESTK plasmid and treated with different concentrations 
of GCV for 5 days, after which cell viability was analysed by Alamarblue assay. This is a representative 
of two independent assays.
Furthermore, to confirm TK gene expression and DsRed expression, another 
experiment was carried out where FUW/DsRedIRESTK transfected cells were treated 
with the same increasing concentrations of GCV over a period of 5 days, after which 
they were analysed for DsRed expression by flow cytometry (Figure 26). DsRed
positive cells were plotted for forward and side scatter thus allowing to distinguish live 
and dead cell populations. The killing effect of HSV-TK/GCV was demonstrated by a 
clear reduction in the percentage of live DsRed
+
cells (from 79.9% to 4.86%). 
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Figure 26. GCV titration in 293T cells expressing DsRedIRESTK by flow cytometry. Cells were
transfected with the FUW/DsRedIRESTK plasmid and treated with different concentrations of GCV for 
5 days, after which cells were analysed by flow cytometry. Cells were gated for DsRed and the DsRed
+
cells were then plotted for forward and side scatter. Specific killing was assessed by observing a 
reduction in the percentage of live DsRed
+
cells.
While this system is functioning well in 293T cells, it would be important to verify 
that the same is true in Jurkat cells. VSV-G-pseudotyped viral vectors expressing this 
construct were used to transduce Jurkat and titrate the amount of GCV needed to kill 
the cells, again over a period of 5 days (Figure 27). GCV treatment started on the day 
after transduction and whenever the cells needed to be split, a new medium with the 
respective concentration of GCV was added. One can observe that an amount as low as 
0.25 µg/mL was already enough to kill most of the cells (88%). According to these 
results, the concentration of GCV chosen to be used in further experiments was 1
µg/mL, that allowed 91.6% of cell killing.
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Figure 27. GCV titration in Jurkat cells expressing DsRedIRESTK. Jurkat cells were transduced 
with VSV-G-pseudotyped lentiviruses expressing DsRedIRESTK and treated with the indicated
concentrations of GCV during a period of 5 days, after which they were analysed by flow cytometry.
Cells were gated for DsRed
+
(transduced) and this population was then plotted for forward and side 
scatter. The killing was assessed by observing a reduction in the percentage of live DsRed
+
cells.
Finally, it was performed a targeting experiment using pseudotyped Sindbis/anti-FITC
M1234 lentiviruses expressing DsRedIRESTK. Viruses were produced and Jurkat cells
transduced, using the same conditions as for the assays on the previous section. After 
the low pH treatment, medium was replaced by another containing 1µg/mL of GCV,
over a period of 12 days. Specific killing was assessed by observing a reduction in the 
percentage of DsRed positive cells (transduced cells), by flow cytometry analysis.
Several time points were performed for analysis of the transduced cells over the time 
period of GCV treatment and a gradual reduction in the percentage of DsRed positive 
cells was observed up to day 8, after which it was maintained at 5% transduced cells 
(Figure 28). Therefore, these results demonstrate that Sindbis/anti-FITC M1234
lentiviruses can kill specifically and efficiently the target cells, although not 
completely, since a small number of cells remain unaffected. An explanation for this 
can be that the GCV dose may be insufficient for total eradication or, that it only acts
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upon dividing cells and some of the transduced cells might be growth suppressed. The 
existence of cryptic splice sites is not an issue in our case, as HSV-TK (TK.007) is a 
new gene variant devoid of splicing sites. There was no unspecific killing of the non-
transduced population due to GCV treatment, for each time point analysed (see 
Appendix F for analysis corresponding to day 8).
Figure 28. Ganciclovir treatment can kill transduced Jurkat cells expressing DsRed. Jurkat cells 
were transduced with pseudotyped Sindbis/anti-FITC M1234 lentiviruses expressing DsRedIRESTK
and treated with 1µg/mL GCV during 12 days. Specific killing was assessed by observing a reduction in 
the percentage of DsRed
+
cells (transduced cells). The percentage of DsRed fluorescence is shown 
relative to the control (transduced cells without GCV treatment). Assay was performed in triplicate and 
error bars indicate the standard deviation. 
Alternative splicing site in the TK gene, resulting in the expression of a non-functional 
TK in the minority of transduced cells, was a major limitation in clinical trials with TK 
cells. The HSV-TK employed in this work was already tested in clinical trials
42
. The 
activity of this new suicide gene was superior to the conventional HSV-TK, mediating
considerably faster and higher absolute killing at low GCV concentrations, with 
reduced nonspecific toxicity, when used for donor-lymphocyte modification in 
adoptive immunotherapy models
175
. A recent report has indeed demonstrated an 
improved anti-tumour activity of TK.007 and a considerably stronger bystander effect 
as compared to conventional HSV-TK 
174
. 
The immunogenicity of viral-derived TK protein can be also a problem, however when 
TK cells are infused to immunosuppressed patients they are well tolerated and persist 
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in the long term
217, 139
. In our model system, this immunogenicity would not be a 
problem given that it will be used immundeficient animals. 
Although we used an IRES linking the two transgenes, most of the studies that used a 
HSV-TK suicide gene therapy used a fusion between the TK and the other reporter 
gene (for example,
126
). The fusion between reporter gene and TK would have an 
advantage, enabling to confirm that the elimination of cells resulted directly from TK 
action and not spontaneous death due to prolonged culture. Most of the vectors 
developed have the TK gene cloned as C-terminal fusion to EGFP gene
161, 85
. 
Nevertheless, Bennour and colleagues14 reported expression of only one of the genes 
(CD34) in a fusion between tCD34 and cHSV-TK because of a posttranslational effect 
leading to breakage of the fusion protein, which renders the cells resistant to GCV. In 
our case, the construct DsRedIRESTK allowed higher cap-dependent expression of 
DsRed than the fusion DsRedTK, but similar levels of TK expression. Fehse and 
coworkers reported an unexpected higher expression of TK from the second position in 
an IRES vector as compared with the fusion protein (in Jurkat cells)
66
. On the contrary, 
in another study, lower expression was found when the gene was under IRES-
dependent expression than when under cap-dependent expression (LTR-driven)
145
.
Hoggarth and colleagues 
85
obtained a reduction to 4% in viable GFP
+
Herpesvirus 
saimiri transduced Jurkat cells when exposed to 100 ng/ml of GCV for 7 days, whereas 
in our Sindbis/anti-FITC lentiviruses system, DsRed
+
cells were reduced to 5% in 12 
days using 1000 ng/ml GCV. Nevertheless, we had observed that 250 ng/ml, the 
minimum GCV concentration tested, was enough to get essentially the same 
proportion of cell death and besides that they used a different viral vector with a high 
multiplicity of infection (MOI of 100), while we used an MOI of approximately 20 
(200 ng HIV p24). 
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3.2 In vivo gene therapy
The in vitro results shown in the previous section indicated that this strategy of gene 
therapy could target specifically leukemic target cells in culture and deliver the 
transgene. These results provided us enough, and promising, evidence to move forward 
with this gene therapy model, i.e., to move to pre-clinical tests. To demonstrate that 
our strategy has potential for in vivo applications it was used in a mouse model of 
leukaemia. The chimeric Sindbis/anti-FITC envelope employed in this part of the work 
was the mutant M1234, which has a reduced non-specific transduction in vivo, as also 
demonstrated by others
152
. 
3.2.1 The choice of gene reporter (transgene) for detection of transduced cells
To evaluate transduction in vitro (gene transfer efficiency), we have detected the 
percentage of DsRed
+
cells. To check if the same marker could be used for the in vivo
studies, its expression had to be tested in a CCD camera (IVIS Lumina) that is widely 
used for in vivo imaging, particularly for the detection of bioluminescent signals. 
Supposedly, the red fluorescence can also be assessed in this camera. Therefore, Jurkat 
cells expressing DsRed were prepared by transduction with VSV-G-pseudotyped 
lentiviruses (VSV-G/DsRed) with an efficiency of 99%
1
. Serial dilutions of 
Jurkat/DsRed were prepared in a 24-well plate and red fluorescence was detected 
under the CCD camera (Figure 29), with a strong signal corresponding to 1×10
7
cells.
Given that it was possible to detect that signal in a culture plate, the next step was to 
check if it could also be detected in a mouse. Ten million Jurkat/DsRed cells were 
inoculated subcutaneously on the right and then on the left side of a Balb/c mouse but 
no red fluorescence was detected, except for a non-specific “spot” on the right side 
(Figure 30). Actually, most of the in vivo studies using a CCD camera for real-time 
whole body imaging rely on bioluminescent proteins, as a biofluorescent marker 
requires a higher level of expression for IVIS Lumina detection, as it is less sensitive, 
compared with bioluminescent luciferases. Curiously, the studies using this type of 
instrumentation for imaging with fluorescent proteins are performed in nude mice (for 
example
228
), as fluorescence imaging of cancer cells do not produce good images due 
1
Cells were 96% DsRed
+
after 1 month in culture.
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to significant autofluorescence caused by the presence of hair
179
. Moreover, cells are 
usually injected subcutaneously due to low tissue penetration of the fluorescent light. 
Therefore, it is not surprising that we have not observed any signal in the mouse.
Figure 29. Imaging of fluorescence of Jurkat/DsRed cells in a cell culture plate. Several tenfold 
dilutions of Jurkat/DsRed cells, ranging from 1×10
7
to 100, were plated on a 24-well plate, followed by 
Jurkat cells, at the same range of dilutions, used as a control. Fluorescence was detected in a CCD 
camera. The p/sec/cm
2
/sr represents photons/sec/cm
2
/steridian.
A B
Figure 30. Imaging of fluorescence of Jurkat/DsRed cells in a Balb/c mouse. Ten million cells were 
injected subcutaneously on the right side (A) and on the left side (B) of a Balb/c mouse and imaged on 
the IVIS Lumina.
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Thus, the option was to choose also bioluminescence to detect the transduction 
efficiency, in addition to the engraftment of leukemic cells. This is possible using two 
luciferase proteins, firefly and renilla, the former for cell detection and the latter for 
transduction, which have different substrates for luminescence detection. Therefore, it 
was generated the construct FUWDsRedIRESRenilla, that would allow detection of 
transduced cells either by real-time live imaging on a CCD camera (to detect renilla 
luminescence) or by flow cytometry of cells removed from organs (to detect DsRed 
fluorescence). 
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3.2.2 Establishment and validation of the animal model for cell engraftment 
The immunodeficient NOD/SCID mouse was shown to be highly receptive to 
engraftment of primary childhood ALL cells
203, 20
and appear to retain the phenotypic 
and genotypic characteristics of the original patient sample
20
. The NOD/SCID 
xenograft mouse model is one of the most successful models to study ALL in which
patient bone marrow leukaemia cells are directly transplanted into NOD/SCID mice
123
. 
The kinetics of engraftment reflects the human disease, leading to bone marrow 
infiltration, followed by migration to the spleen, peripheral blood and other 
haematopoietic organs
158, 123
. They have impaired T- and B-cell lymphocyte 
development, impaired natural killer (NK) cells and no complement activity, which 
facilitates xenografts
197
. Therefore, the animal model initially planned for the in vivo
work was the NOD/SCID mice engrafted with MOLT-4 leukemic cells expressing 
GFP-Fluc to facilitate the detection of the engraftment. However, we have observed 
that Molt-4 cells are not as efficiently transduced as Jurkat cells either with VSV-G 
lentiviruses (Table VI from section 3.1.5) or with Sindbis/anti-FITC/DsRed 
lentiviruses (15% for Molt-4 versus 52% for Jurkat, Appendix D). Therefore, and 
given that the in vitro targeting assays were performed in Jurkat cells, we would have 
to use an animal model for T-ALL based on Jurkat cell engraftment. In parallel with
the injection of 6 NOD/SCID mice with Jurkat/GFP-Fluc, 4 mice were also injected 
with Molt-4/GFP-Fluc, both with 20 million cells and through the tail vein. Four
NOD/SCID mice died immediately after Jurkat/GFP-Fluc injection. One week later, 
the mice that survived were visualized on the IVIS Lumina to verify cell engraftment 
(one NOD/SCID/Molt-4/GFP-Fluc mouse died during anaesthesia) but only the Molt-
4/GFP-Fluc injected NOD/SCID mice engrafted, as showed by the luminescent signal
in the femurs (Figure 31). After 5 weeks there was no signal detected in the two 
Jurkat/GFP-Fluc injected NOD/SCID mice that had survived, both by the IVIS 
Lumina and by flow cytometry of peripheral blood cells (data not shown). 
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Figure 31. Firefly luciferase imaging in NOD/SCID mice, one week after injection with Molt-4
cells. NOD/SCID mice were injected through the tail vein with 20 million MOLT-4/GFP-Luc and cells 
were observed in the IVIS Lumina 1 week later (3 mg luciferin/mouse). A luminescent signal could
already be detected in the femurs. 
Despite the weak efficiency of in vitro transduction of Molt-4, we attempted an in vivo
targeting experiment. For that, Sindbis/anti-FITC lentiviruses encoding 
DsRedIRESRenilla were produced in 100 mm culture plates and concentrated by 
ultracentrifugation. Four hundred ng (HIV p24) were incubated with anti-CD7-FITC 
(15 µg/mL) for 2 hours at room temperature and injected through the tail vein of each 
of the 2 engrafted mice, 2 weeks after cell injection. The third mouse was injected with 
virus only. The probability of success of this targeting experiment was expected to be 
very low, not only because of the difficulty in transducing this type of cells, but also 
due to the low amount of virus used. Morizono and collegues have reported in vivo
targeting using 3 µg (HIV p24) of Sindbis-pseudotyped lentiviruses
152
. Nevertheless, it 
would be useful to test the renilla substrate coelenterazine. One week later (tree weeks 
after cell injection), this substrate was administered through retro-orbital injection (100 
µg, directly from the supplied stock solution) and two mice died immediately. The 
third one was injected intraperitonially with the same coelenterazine and the image 
was acquired 15 minutes later. No renilla luminescence was detected, apart from the 
spot corresponding to site of the injection, indicating that no cell transduction 
occurred, despite the strong signal of the firefly luciferase detected in the femurs 
(Figure 32), that confirmed the good engraftment of Molt-4. Bone marrow cells were 
harvested from the femurs of the three mice and analysed by flow cytometry for GFP
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(engraftment) and DsRed (tranduced cells) staining. The percentage of GFP was 20%
and there was none for DsRed.
Firefly luciferase
(D­luciferin)
Renilla luciferase
(Coelenterazine)
Figure 32. Luciferase imaging in NOD/SCID mouse three weeks after injection with Molt-4 cells.
Mouse was injected through the tail vein with 20 million MOLT4/GFP-Luc and two weeks later 
injected through the same route with 400 ng (HIV p24) of Sindbis/anti-FITC M1234 lentiviruses 
encoding DsRedIRESRenilla, plus 15 µg/ml anti-CD7-FITC. Mouse was imaged in the IVIS Lumina 
one week later (3 weeks after cells injection). On the left is the image obtained after i.p. injection with 3 
mg of D-luciferin and on the right is the image obtained after i.p. injection with 100 µg of 
coelenterazine.
To discard any problems with the renilla substrate coelenterazine, one Balb/c mouse 
was injected intraperitonially with 1.44 µg (HIV p24) of VSV/DsRedIRESRenilla 
lentiviral vector and imaged for renilla luciferase 4 days later (Figure 33). A good 
expression of renilla was observed in several organs beside the strong signal 
corresponding to the site of substrate injection. This indicated that this coelenterazine 
solution is good for i.p. injection, as the mouse did not die, and allows detection of
transduced cells. However, this site of injection is not ideal as the luminescence 
associated with it can interfere with the detection of virus distribution (transduced 
cells). 
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Figure 33. Renilla luciferase imaging in a Balb/c mouse. Mouse was injected intraperitonially with 
1.44 µg HIV p24 VSV/DsRedIRESRenilla virus and imaged under the IVIS Lumina 4 days later (100 
µg coelenterazine injected). Images were acquired 15 min after injection. Scale bar indicates luciferase 
counts.
Back to the issue of Jurkat cells engraftment, we decided to try the injection of new 
Jurkat cells in another strain, as the other Jurkat/GFP-Fluc were causing the death of 
mice (probably because they were contaminated with mycoplasm) and did not show 
any ability for engraftment. However, the engraftment of Jurkat cells in NOD/SCID 
mice has been described. NOD/SCID mice injected with 20 × 10
6
Jurkat cells showed
25% of human CD45
+
cells in the blood of 83% of mice, 10 days after injection
169
.
High V1302 Jurkat cells engraftment levels (15×10
6
cells injected i.p.) were also 
achieved in irradiated NOD/SCID IL2Rγ
-/-
mice (30% engraftment in the spleen and 
11% in the bone marrow of 75% of transplanted mice) 
7
. The other strain of mice that 
we had available at the time was the Rag2 
-/-
IL2Rc -/-. Thus, mice were injected with
both the new and the old Jurkat cells. As those cells have no reporter gene, 
engraftment would have to be detected by staining mouse cells with an antibody for a 
human leukemic cell marker and further analysed by flow cytometry. Analysis of a 
sample of blood collected from mice would be enough to get an idea of the 
engraftment without the need to sacrifice them, as leukaemia cells are considered to 
have successfully engrafted if the proportion of human CD45
+
cells in the murine 
peripheral blood reach 1%
158
. Four weeks after injection, mice were sacrificed and 
bone marrow, spleen and blood were removed, stained with CD45-FITC antibody and 
analysed by flow cytometry (Figure 34). In the mice injected with the new Jurkat, there 
were human cells detected in all tissues analysed (except for the spleen of the two male
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mice) but the highest percentage of engraftment was in the bone marrow. The old 
Jurkat cells were not able to engraft in this strain as well (data not shown).
Bone marrow Blood Spleen
Female
Male 1
Male 2
Figure 34. Percentage of human cells in Rag2 -/- IL2Rc -/- mice injected with Jurkat. Three Rag2 
-/-
IL2Rc -/- mice were injected by the tail vein with 20 million Jurkat cells. Four weeks later, they were 
sacrificed and the collected organs were stained with anti-CD45-FITC antibody and analysed by flow 
cytometry.
Given that the new Jurkat could be engrafted in the Rag2 
-/-
IL2Rc -/-, the cells were 
then transduced with VSV/GFP-Fluc lentiviruses, sorted by FACS and expanded. The 
expression of firefly luciferase from these cells was confirmed in a tissue culture plate 
analysed under the CCD camera (Figure 35). Subsequently, fifteen million cells were 
injected into two NOD/SCID mice. Four weeks later mice were imaged on IVIS 
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Lumina for firefly luciferase expression but there was no signal of cell engraftment 
(Figure 36).
Figure 35. Imaging Jurkat/GFP-Fluc cells fluorescence in a culture plate. Eighty-thousand 
Jurkat/GFP-Fluc cells were plated on a 96-well plate in triplicate (right side). Jurkat cells (2×10
5
) were 
included on the left side as a negative control. Fluorescence was detected in a CCD camera.
Figure 36. Firefly luciferase imaging of tumour cells distribution in NOD/SCID mice. Two 
NOD/SCID mice were injected by the tail vein with 15 million Jurkat/GFP-Luc and imaged 4 weeks 
later in the IVIS Lumina (3 mg luciferin/mouse). Scale bar indicates luciferase counts.
These results indicated that the Rag2 
-/-
IL2Rc -/- was the best strain to proceed with 
the in vivo targeting experiments. Since it was not possible to obtain more of these 
mice, a similar one was purchased, the NOD-Rag1
-/-
IL2r -/-, a radioresistant strain that 
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support higher levels of engraftment than the parental NOD-SCID
164
, as irradiation 
before cell injection facilitates engraftment.
Twenty million Jurkat/GFP-Fluc (98% GFP
+
) cells were injected into 5 irradiated 
NOD-Rag1
-/-
IL2r -/- mice and 10x106 Jurkat/DsRedIRESRenilla (94% DsRed+) were 
injected in another two irradiated mice. These ones were used for tests with 
coelenterazine (working solution, route of administration and time after injection). A 
working solution, diluted in PBS (containing only 5 mM of NaCl) immediately before 
retro-orbital injection, gave the best result and was less toxic to mice. A peak in renilla 
luminescence was observed when imaging 35 seconds after injection 1(data not 
shown). Mice injected with Jurkat/GFP-Fluc were analyzed in the IVIS Lumina for 
firefly luciferase expression one week later and all had a good engraftment (Figure 37), 
which was even higher than the one observed for NOD/SCID injected with Molt-
4/GFP-Fluc, detected after the same period (Figure 31). Therefore, for the next
experiments, our in vivo model of T-ALL will be based on the engraftment of 
Jurkat/GFP-Luc cells in irradiated NOD-Rag1
-/-
IL2r -/- mice. 
1
Due to a bad reaction observed in some mice in subsequent experiments, which needed resuscitation 
procedures, we chose to perform image acquisition 1 minute after coelenterazine injection for all the 
animals in analysis.  
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Figure 37. Firefly luciferase imaging in NOD-Rag1
-/-
IL2r-/- mice one week after injection with
Molt-4 cells. Mice were injected through the tail vein with 20 million Jurkat/GFP-Luc and cells were 
observed in the IVIS lumina 1 week later (3 mg luciferin/mouse). A strong luminescent signal can 
already be detected in the femurs. Scale bar indicates luciferase counts.
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3.2.3 In vivo targeting of leukemic cells
Two weeks after Jurkat/GFP-Fluc injection in the first NOD-Rag1
-/-
IL2r -/- mice 
tested for engraftment, 700 ng of Sindbis/anti-FITC M1234 expressing 
DsRedIRESRenilla were administered to each of the five mice. The lentiviruses (from 
a total amount of 3.6 µg) were obtained from transfection of 293T cells in 100 mm 
culture plates. Three mice were injected with virus plus 15 µg/ml anti-CD7-FITC and 
two were injected with virus only. Renilla expression was analysed 3 days and 7 days 
later but no luminescence signal was detected on the CCD camera (data not shown). 
This is probably related to the low amount of virus injected. As already mentioned, the 
total virus produced (3.6 µg) should be the quantity used for one mouse. This meant 
that viral production had to be scaled-up for in vivo use if we wanted to observe some 
targeting. Besides that, the fact that viruses are being injected some time after the 
injection of the cells may be influencing the result.
Another experiment was initiated, in which two irradiated NOD-Rag1
-/-
IL2r -/- mice 
were injected through the tail vein with 20 million Jurkat/GFP-Fluc cells. Lentiviruses 
were produced in 150 mm tissue culture plates by a new protocol, concentrated by 
Lenti-X concentrator, followed by ultracentrifugation. Three days after cell injection, 
approximately 3 µg Sindbis/anti-FITC pseudotyped lentiviruses plus anti-CD7-FITC
(15 µg/ml) and 1.5 µg VSV-G pseudotyped lentiviruses (used as a control), both 
expressing DsRedIRESRenilla, were injected by the same route. Mice imaging for 
detection of virus and cell distribution was performed 4 days after virus injection, 
which corresponds to one week after cell injection. There was co-localization of 
transduced cells expressing renilla luciferase (top of panel A, Figure 38) with the 
engrafted cells expressing firefly luciferase (top of panel B, Figure 38) in the femurs 
and the sternum (bone marrow), indicating that there was specific transduction of 
engrafted cells. Three days later, another imaging of these mice was performed and the 
signal from both luciferases was increased (bottom of each panel, Figure 38). The 
pictures on the left correspond to the mouse injected with VSV where it is also 
detected a signal in the spleen, besides the one observed in the bone marrow. We were 
expecting more background transduction for the mouse injected with VSV
pseudotyped lentiviruses considering its broad tropism and the results obtained by 
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Morizono and colleagues
152
, where it was also reported transduction of the liver and 
lungs. Curiously, this mouse had not only a higher level of transduction but also a 
higher level of cell engraftment.
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Day 10
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Figure 38. Sindbis/anti-FITC M1234 pseudotyped lentiviral vector can target specific leukemic 
cells after systemic delivery in mice. Three days after cell injection (20 million per mouse), NOD-
Rag1
-/-
IL2r-/- mice were injected through the tail vein with VSV-G pseudotyped lentiviruses alone (left 
pictures) or Sindbis/anti-FITC pseudotyped lentiviruses plus 15 µg/mL anti-CD7-FITC antibody 
(pictures on the right), both expressing DsRedIRESRenilla. Four days later, the level of engraftment 
was determined by imaging the expression of firefly luciferase (top of A) and virus infection was 
determined by imaging the expression of renilla luciferase (top of B). On the bottom of each of the 
panels A and B are the images acquired three days later (day 10). Scale bars indicate luciferase counts.
These results indicated that the Sindbis/anti-FITC M1234 lentiviruses were able to 
target the leukemic cells in vivo. In order to have an idea of the percentage of 
transduction within that cell population it was necessary to perform a flow cytometry 
analysis of the bone marrow cells and for that, it was essential to have a control mouse 
injected only with cells. Therefore, Jurkat/GFP-Luc cells were injected in two 
irradiated NOD-Rag1
-/-
IL2r -/- mice as described before and three days later 
Sindbis/anti-FITC M1234 lentiviruses plus anti-CD7-FITC were injected in one 
mouse. Seven days after cell injection, mice were imaged on the IVIS Lumina to verify 
the engraftment, which was considerably lower in the mouse that was given the virus 
(Figure 39A). The renilla signal (transduced cells) (Figure 39B) was much weaker than 
the previously obtained (Figure 38), even at day 10. Nevertheless, the femurs were 
removed and bone marrow cells were collected for flow cytometry analysis. According 
to Figure 40, the engraftment was more than10 times lower for the mouse injected with 
virus than for the mouse injected only with cells (2% versus 22% of GFP
+
cells, 
respectively), as was expected from the images obtained in the CCD camera. Within 
this engrafted population, there were 2.58 % of DsRed
+
cells (transduced cells). 
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Figure 39. Sindbis/anti-FITC M1234 pseudotyped lentiviral vector can target specific leukemic 
cells after systemic delivery in mice. Three days after cell injection (20 million per mouse) in two 
NOD-Rag1
-/-
IL2r-/- mice, one of them was injected through the tail vein with Sindbis/anti-FITC
pseudotyped lentiviruses expressing DsRedIRESRenilla plus 15 µg/mL anti-CD7-FITC antibody while 
the other one was left untreated. Four days later, the level of engraftment was determined by imaging 
the expression of firefly luciferase (top of panel A) and virus infection was determined by imaging the 
expression of renilla luciferase (top of panel B). On the bottom of each of the panels A and B are the 
respective images acquired three days later (day 10). Scale bars indicate luciferase counts.
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Cells only 22%
Virus injected 2%
% GFP+ cells in live gate: % DsRed+ cells  in GFP+ gate:
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Figure 40. Efficiency of in vivo transduction of leukemic T cells with Sindbis/anti-FITC M1234 
pseudotyped lentiviral vector. The femurs from two mice, the one injected with Sindbis/anti-FITC 
M1234 lentiviral vector and the non-injected one (cells only), were removed and bone marrow cells 
were analysed for engraftment (GFP
+
) and transduction efficiency (GFP
+ 
DsRed
+
) by flow cytometry.
The data so far indicated that Sindbis/anti-FITC M1234 lentiviruses were able to 
transduce the leukemic T cells when injected 3 days after cell administration. To check 
if the viruses would have a better ability to target the cells if injected earlier on, i.e. 
before tumour cells started to expand, an experiment was performed in which the virus 
was injected on the day following cell injection. As it can be observed in Figure 41, 
tumour cells were also transduced in this way. Although the intensity of both luciferase
signals are lower than those obtained on a previous experiment (Figure 38), the ratio 
between engrafted and transduced cells is not so marked, which might indicate a better 
efficiency of transduction. To quantify that efficiency by flow cytometry, the femurs 
were removed and bone marrow cells were analysed for GFP
+
(tumour cells) and 
within this population were gated for DsRed
+
(transduced cells). The percentage of 
transduced cells was 15.2% within an engrafted population of 0.22% (Figure 42). This 
was almost 10 times lower than previous data indicating 2% engrafted cells. Actually, 
this is in accordance with the IVIS Lumina data, as the signal intensity for firefly 
luciferase in this experiment is almost 10 times lower than the previous one (Figure
38).
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Day 7
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A B
Figure 41. Sindbis/anti-FITC M1234 lentiviral vector can target specific leukemic cells after 
systemic delivery in mice. One day after cell injection (20 million per mouse), one mouse was injected 
through the tail vein with Sindbis/anti-FITC plus 15 µg/mL anti-CD7-FITC antibody. Six days later, the 
level of engraftment was determined by imaging the expression of firefly luciferase (panel A) and virus 
infection was determined by imaging the expression of renilla luciferase (panel B). On the bottom of 
each of the panels A and B are the images acquired ten days after cell injection. Scale bars indicate 
luciferase counts.
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% GFP+ cells in live gate:
Cells only Virus injected
% DsRed+ cells in GFP+ gate:
9.71
0.22
Figure 42. Efficiency of in vivo transduction of leukemic T cells with Sindbis/anti-FITC M1234 
pseudotyped lentiviral vector. The femurs from the Sindbis/anti-FITC M1234 lentiviral vector injected 
mouse were removed and bone marrow cells were analysed for engraftment (GFP
+
) and transduction 
efficiency (GFP
+
DsRed
+
). On top are GFP gated cells and on bottom are DsRed
+
within that population.
This data demonstrated not only the in vivo capacity and efficiency of this 
Sindbis/anti-FITC targeting strategy but also gave an indication of the best timing for 
its application. The effectiveness of targeting tumour cells is dependent upon factors 
such as the ratio of vector to tumour cells and accessibility of tumour cells to the 
vector. Therefore, the number of vector particles should be adequate to infect a 
significant percentage of leukemic cells in vivo. As smaller tumours contain fewer 
cells, the same amount of virus should result in better rates of infection, and 
consequently greater tumour regression would be expected when an in vivo suicide 
strategy is applied. Therefore, the best option is to start the virus injection earlier on.
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Although these in vivo targeting experiments were performed to demonstrate that we 
could achieve a significant targeting efficiency and to optimize conditions for the in 
vivo suicide gene therapy (next section), they should have been performed with more
mice per each condition to have a statistically significant result. Different results
observed between mice could be attributed to variability from mouse to mouse and 
differences in injection efficiency within the groups of animals (for each condition).
However, the NOD-Rag1
-/-
IL2r -/- mice were very expensive and this prevented us 
from carrying out these initial targeting experiments using a larger number of animals.
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3.2.4 In vivo killing of leukemic cells
We have demonstrated that the Sindbis/anti-FITC M1234 lentiviruses encoding HSV-
TK and DsRed (DsRedIRESTK) can kill the transduced leukemic cells in vitro. 
However, to show the efficiency of this suicide gene in vivo, that reporter gene would 
have to be substituted by renilla in order to monitor its luminescence signal after 
treatment with GCV. The lentiviral plasmid FUW/RenillaIRESTK was generated and 
its expression was confirmed in 293T transfected cells, both by alamarblue and by 
luciferase assay (Appendix E). Therefore, lentiviral vectors were produced and 
concentrated. Mice were injected with Jurkat/GFP-Fluc cells and on the following day, 
a group of 4 mice were injected with viruses (approximately 3 µg HIV p24 per each 
mouse) and a group of 8 were injected with same amount of viruses plus anti-CD7-
FITC (15 µg/ml). The latter group would be further divided into two, one to which 
would be administered GCV (10 mg/Kg) and other that would be left untreated. Ten 
days after cell injection, mice were analysed on IVIS lumina for renilla (transduction) 
and firefly (engraftment) luciferase expression. As it is shown in Figure 43 (it includes 
only the 2 groups to which was given virus plus antibody), there was a good cell 
engraftment but no specific transduction was detected and consequently, GCV was not 
administered. A week later, mice were observed again but without any progress, i.e., 
they remained without signs of cell transduction, and therefore, they were sacrificed. If 
the transduction efficiency was at least 2 times the maximum value obtained 
previously (15.2%), we could observe the effect of GCV by monitoring the reduction 
of the engraftment (reduction in signal intensity of firefly luciferase), which would 
likely be even higher due to its known bystander effect.
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Figure 43. Sindbis/anti-FITC M1234 lentiviral vector expressing RenillaIRESTK was not able to 
target specific leukemic cells upon systemic delivery in mice. One day after cell injection (20 million 
per each mouse) mice were injected through the tail vein with Sindbis/anti-FITC RenillaIRESTK 
lentiviruses (3 µg/ml HIV p24 per mouse) incubated with anti-CD7-FITC (15 µg/ml). One week after 
cell injection, they were analysed on the IVIS lumina for firefly (A) and for renilla (B) expression. Scale 
bars indicate luciferase counts.
A
B
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Figure 43. Continued (2
nd
group of mice). 
This result was not expected at all, as it was demonstrated in several experiments
before that Sindbis/anti-FITC M1234 lentiviruses could target and deliver the 
A
B
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transgene. The problem would probably reside on the renilla expression from the 
FUW/RenillaIRESTK lentiviral plasmid. To compare the efficiency of transduction 
mediated by the two lentiviral vectors encoding RenillaIRESTK or 
DsRedIRESRenilla, Sindbis-anti-FITC M1234 lentiviruses with both constructs were 
produced in parallel and each one (plus labelling antibody) was injected in two mice, 
the day after cell injection. Fifteen days later, mice were analysed on the IVIS lumina 
for firefly and renilla expression. One of the mice injected with Sindbis/anti-FITC 
M1234 encoding DsRedIRESRenilla died during coelenterazine administration. As 
shown in Figure 44, it was detected expression of renilla from the mouse injected with 
virus expressing    DsRedIRESRenilla but not in the mice injected with the other virus. 
Thus, mice were killed and femurs were removed. Bone marrow cells were harvested 
and genomic DNA was extracted and kept frozen for further analysis. Vector DNA 
integration gives an indication (quantitative) of the efficiency of transduction and can 
be more accurate than analysis of transgene expression in target cells or tissues that 
may be influenced by variability in vector expression levels
185
. To check if the viruses 
were able to integrate or not, it was performed a real-time PCR with primers to amplify 
renilla luciferase gene from the genomic DNA. Vector copy numbers are indicated on 
Table IX. The mice injected with the virus encoding RenillaIRESTK had unexpectedly 
higher vector copy numbers integrated on its genome (138 and 151 copies) than the 
mouse injected with the virus encoding DsRedIRESRenilla (33 copies). This 
demonstrates that both viruses could target the cells and indicate that there was a 
problem with the expression of renilla from the RenillaIRESTK virus. To confirm this, 
Jurkat cells were transduced with VSV-G pseudotyped lentiviruses encoding each of 
the constructs RenillaIRESTK and DsRedIRESRenilla. Three days later, cells were 
plated in a 96-well plate for analysis of renilla luciferase expression in the IVIS 
lumina. As expected, there was no luminescence signal from the 
Jurkat/RenillaIRESTK while there was a signal for the Jurkat/DsRedIRESRenilla 
(Figure 45). It was shown that an unusual very high expression of the IRES-driven 
second transgene may result in down regulation of expression of the first transgene, or 
exert a direct toxic effect on target cells
66
. That might have been what happened with 
our construct. The lentivirus that had integrated more copy numbers on the genomic 
DNA was the one that showed no renilla expression. The renilla expression levels from 
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the RenillaIRESTK construct was probably so weak that could not be detected in the 
IVIS lumina. However, the FUW/RenillaIRESTK plasmid expressed high levels of the 
first transgene in an in vitro assay in 293T cells (Figure 50, Appendix E) and this led 
us to consider that it would also express properly upon transduction in Jurkat cells.
Although it was shown on section 3.1.8.2 that the TK construct, which allowed the 
highest expression of the other transgene was the one where TK expression was 
mediated by an IRES, other constructs, with different positioning of the renilla and TK 
genes, should be cloned and its expression tested in transduced Jurkat cells in order to 
overcome this problem with the renilla expression. 
RenillaIRESTK RenillaIRESTK DsRedIRESRenilla
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Figure 44. Comparison of the efficiency of in vivo targeting between Sindbis/anti-FITC 
pseudotyped lentiviral vectors expressing DsRedIRESRenilla or RenillaIRESTK. One day after 
cell injection (20 million per mouse) mice were injected through the tail vein with 3 µg/ml Sindbis/anti-
FITC M1234 expressing DsRedIRESRenilla or RenillaIRESTK plus anti-CD7-FITC (15 µg/ml). 15 
days later, mice were injected with coelenterazine for analysis of renilla expression (transduction, 
Bottom) and with D-luciferin for analysis of firefly expression (engraftment, Top). Scale bars indicate 
photonic flux (photons/sec/cm
2
/steridian).
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Table IX. Copy numbers of lentiviral vectors expressing DsRedIRESRenilla or RenillaIRESTK. 
Genomic DNA was extracted from bone marrow isolated from femurs of the mice indicated in Figure 
44. 
Jurkat
Jurkat/
DsRedIRESRenilla
Jurkat/
RenillaIRESTK
Figure 45. Comparison of the renilla luminescence from Jurkat cells expressing 
DsRedIRESRenilla or RenillaIRESTK. One hundred µl of Jurkat cells transduced with VSV-
G/DsRedIRESRenilla or VSV-G/RenillaIRESTK lentiviruses were plated in triplicate on a 96-well plate 
and 100 µl of a 20µM coelenterazine solution was added to each well. Untransduced Jurkat cells were 
included as a negative control. Renilla luminescence was immediately analysed in the IVIS lumina
(exposure time: 1 min, binning large, f/stop 1).
Mouse Vector Copy number/10
4
cells
2 DsRedIRESRenilla 33
3 RenillaIRESTK 138
4 RenillaIRESTK 151
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4. Conclusions and perspectives
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For in vivo gene therapy applications, it is very important that the method of delivery 
would target only specific cells or tissues while sparing the surrounding ones. This is 
essential not only to provide an efficient gene therapy application, but also to enhance 
its safety, as inadvertent infection of irrelevant cells or tissues can result in serious 
adverse effects in clinical trials 
112
. Targeting of the viral vector can be accomplished 
most often by modifying the envelope structure through the display of recognition 
sequences on the surface or applying tissue specific promoters. The insertion of a 
ligand or a scFv with higher affinity for target molecules increases the affinity of the 
envelope protein and results in higher transduction efficiency. Since specificity is 
advantageous for in vivo gene therapy strategies, it is preferable to use antibodies as 
targeting strategy given the specificity with which they recognize their targets. In this 
study, we used an anti-FITC scFv incorporated on the Sindbis virus envelope for 
specific targeting of FITC-labelled cells. This is the first time that an anti-FITC scFv is 
used as a targeting strategy for gene therapy. It could be easily displayed at the surface 
of the Sindbis viral envelope and the lentiviruses can have a relatively high titer. 
Mutations in the envelope glycoprotein were further introduced to reduce in vivo non-
specific transduction, as shown by Morizono and colleagues
152
, although it slightly 
reduced the viral titer comparing to wt (without mutations).
This strategy of targeting an organic molecule with a scFv has advantages over others, 
such as redirecting vectors through antibody conjugation, which is a problem in 
immunocompetent animals due to competition with plasma antibodies. Moreover, it 
avoids cloning of new scFv whenever one wants to target a new cell receptor, as there 
are FITC-conjugated antibodies for many receptor molecules. 
We have shown that an HIV-derived lentiviral vector pseudotyped with this 
Sindbis/anti-FITC specifically infects T cells that are labelled with a CD7 FITC-
conjugated antibody, but not CD19 labelled cells, that is a B cell receptor. The 
lentiviral vector Sindbis/ST6 that displays a scFv recognizing other cell receptor 
(CCR5) could not transduce the same T cells. The highest specific targeting efficiency
of Jurkat/CD7-FITC cells reached was 82.8% for Sindbis/anti-FITC Wt lentiviruses 
(Figure 19A) and 44.5% for Sindbis/anti-FITC M1234 lentiviruses (Appendix C), both 
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expressing a DsRed reporter. Furthermore, the lentiviruses binding ability for 
Jurkat/CD7-FITC cells could be reduced by competition with an anti-FITC soluble 
antibody, demonstrating that the targeting is specifically mediated by the scFv display
and the need of binding to FITC for viral entry. These results altogether demonstrate 
that the Sindbis envelope pseudotyped lentiviral vectors containing anti-FITC scFv 
specifically and preferentially infect cells displaying a FITC-conjugated molecule.
A HSV-TK/GCV based suicide gene strategy was employed to specifically kill the 
leukemic T-ALL cells. Previously, Dr. Meruelo group has demonstrated the potential 
of this kind of suicide gene therapy for targeting using a cell type-specific recombinant 
Sindbis virus vector and an antibody system
87
. Others have demonstrated specific 
targeting and induction of apoptosis of T-ALL cells using a scFv against human CD7
fused to an immunotoxin, more precisely the catalytic domain of Pseudomonas 
exotoxin A fragment
165
. Using our Sindbis/anti-FITC pseudotyped lentiviral vector 
system we were able to target leukemic Jurkat cells and deliver the HSV-TK gene that, 
in the presence of 1 µg/mL GCV, lead to a gradual reduction in the percentage of 
transduced cells (Figure 26). In fact, using this HSV-TK/GCV suicide gene strategy, 
we were able to kill 95% of the transduced cells. However, in vivo, and in a clinical 
setting, the inability to totally kill the tumour cells for any strategy considered alone 
indicates the need for combined therapies in order to achieve a satisfactory treatment 
of the tumour.
As an in vivo proof of concept of this strategy, we used an animal model of T-ALL. It 
was reported that childhood ALL cells retain the phenotypic and genotypic 
characteristics of the original patient sample after being engrafted in NOD/SCID 
mice
20
. In our model system, the tumour was generated by intravenous injection of 
Jurkat T-ALL cells into immunodeficient NOD.Rag1
-/-c-/- mice and it could be 
detected one week later. Using Sindbis/anti-FITC M1234 expressing 
DsRedIRESRenilla we were able to transduce 15.2% of the tumour cells. An
inefficient production and purification of the lentiviral vector may account for the 
relatively low efficiency of the in vivo transduction. Hence, to improve the in vivo
efficiency of our gene therapy strategy, it would be better to use clinical-grade vector 
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manufacturing. Moreover, it should be considered the further scaling-up of vector 
production, replacing the time-consuming and labour-intensive small-scale vector 
production in cell culture dishes.  
To test whether our system could deliver the suicide gene HSV-TK in vivo, Sindbis-
pseudotyped lentiviruses encoding RenillaIRESTK were injected in mice on the day 
following cell injection (thus, before the tumour established). Even if only a small 
fraction of the tumour cells were transduced and expressing the HSV-TK gene it 
would be observed a significant reduction in the tumour size after GCV treatment due 
to its bystander effect. Nevertheless, we could always re-administer another dose of the 
virus to enhance the efficiency of this gene therapy. However, due to a problem with 
the expression of the renilla reporter gene in our lentiviral system, that prevented the 
detection of the transduced cells in the IVIS lumina, the treatment with GCV was not 
initiated. 
Taken together, these results indicate that our gene therapy system is suitable for 
systemic delivery and can be applied for disseminated diseases and other disease 
settings for which there is an available surface receptor or ligand FITC-labelled 
antibody. For instance, it can be applied to any cancer cell, which normally have 
certain receptors overexpressed and to which there are antibodies available, such as the 
case of epidermal growth factor receptor (EGFR) that is commonly overexpressed in 
several tumour cell lines. The availability of other cell-specific surface molecules 
conjugated with FITC will broaden its application in therapy and research.
As already mentioned, for a successful gene therapy it is important to achieve a high 
efficiency of transduction to the desired cell types, which will reduce the dose needed 
for effective therapy, thereby reducing undesirable side effects. Hence, even though 
the strategy of gene therapy here proposed has great potential for future applications, it 
could be further improved, particularly the delivery of the scFv. Other means could be 
used to deliver this scFv. For instance, it could be chemically coupled to liposomes, 
nanoparticles, or fused to cationic polymers such as protamine. However, although 
non-viral vectors should probably be less toxic to the cells, they might not be as 
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efficient as viral vectors (lentiviral vectors in this case) to deliver the scFv. Other 
approach would be to substitute the Sindbis viral envelope by another one. 
Pseudotyping by measles virus (H and F proteins) have emerged as alternative 
approaches for lentiviral vector targeting
77, 78, 6
and have been also shown to 
incorporate a scFv and display it at the viral surface. As previously mentioned, Sindbis 
entry relies on the low pH within the endosomes to mediate fusion to achieve targeted 
transduction. The direct fusion entry mechanism of measles virus has the advantage of 
avoiding the step of endosome escape. Nevertheless, in an immunocompetent host, an 
endosomal entry could potentially protect viruses from the host immune system. 
Measles and Sindbis virus envelopes have the binding and fusion functions separated 
into different glycoproteins, and therefore are a good choice for scFv or other ligand 
incorporation for retargeting as it can be generated binding-deficient but fusion 
competent mutants
152, 77
. In a study by Funke and colleagues
77
, they targeted the cell 
surface molecules EGFR and CD20 through display of the EGF ligand or a scFv as a 
C-terminal extension of the H measles virus glycoprotein in a lentiviral vector cell 
entry targeting system. They report lower background transduction on control cells 
than that in the study by Yang and colleagues 
240
also targeting CD20 but using a 
Sindbis-pseudotyped lentiviral vector. The Sindbis glycoproteins are restricted to 
target cell surface molecules that need to undergo rapid endocytosis.  More recently, 
they targeted different cell surface molecules on different cell types taking advantage 
of scFv for those molecules and where natural receptor usage is prevented by mutation 
of the relevant residues in the HA protein receptor recognition domain. However, for 
future clinical applications in humans the therapeutic efficacy may be reduced due to 
pre-existing Measles virus neutralizing antibodies. Exchange of envelope 
glycoproteins of the oncolytic virus with those of the closely related canine distemper 
virus (CDV) could allow viral escape and achieve in vivo targeted therapy
142
. 
Nevertheless, measles virus pseudotyped lentiviral vectors have not been applied so far 
for systemic delivery in vivo in animal models. 
Another aspect that could be further improved in our model system is to increase 
avidity therefore, enhancing binding to target cells, using for instance a bi-specific 
diabody or even a higher multivalent scFv. An enhanced avidity has been shown to be 
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beneficial for in vivo tumour targeting in many antibody-based therapeutic strategies 
106
. 
The work presented here, including the optimizations for viral production, cell 
transduction and suicide gene strategy, will have important implications for future 
projects in the field of gene therapy, in particular those being developed at this 
laboratory.
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Appendix A – list of primers
Table X. List of the primers used for sequencing. 
Name Purpose Primer sequence (5’
 3’)
5’-FITC 5’anti-FITC sequencing primer 
(Reverse direction)
AGA TAC CAC CTC AGG TAG
4MFwd 3’ anti-FITC sequencing primer 
(Forward direction)
AGC GTG TAC CTG CAG ATG
UbiFwd FUW forward primer TCA GTG TTA GAC TA G TAA ATT G
E2.end (S) Sindbis E2 sequencing TGG CCC CAA ACG CCG TAA TCC
E1.end (AS) Sindbis E1 sequencing TTC GTG TGC TAG TCA GCA TCA TG
Table XI. List of the primers used for Sindbis envelope mutagenesis. It includes the purpose (which 
mutant) and the primer sequence. The template was Sindbis/anti-FITC Wt. In bold are the mutation
sites.
Name Purpose (Mutant) Primer sequence (5’
 3’)
159KE160AA.S 159KE160AA (M3) CAGTGTACGACCGTCTGGCAGCAACAACTG
CAGGCTACATC
159KE160AA.AS 159KE160AA (M3) GATGTAGCCTGCAGTTGTTGCTGCCAGACG 
GTCGTACACTG
SLKQ68-
71AAAA.S
SLKQ68-71AAAA (M2) CAAGTACCGCTACATGGCGGCTGCGGCGG
TAACCGGAGGCGG
SLKQ68-
71AAAA.AS
SLKQ68-71AAAA (M2) CCGCCTCCGGTTACCGCCGCAGCCGCCATG
TAGCGGTACTTG
delE362-64.S delE362-64 (M1) GCGGTGCGGATCGTCTGGCAGCGTCATTGA
CGACTTTACC
delE362-64.AS delE362-64 (M1) GGTAAAGTCGTCAATGACGCTGCCAGACGA
TCCGCACCGC
226AK227SG.S 226AK227SG (M4) TAGGCTACTCAAGCCTTCCAGCGGGAACGT
GCATGTCCCGTAC
226AK227SG.AS Mutant 226AK227SG
(M4)
GTACGGGACATGCACGTTCCCGCTGGAAGG
CTTGAGTAGCCTA
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Table XII. List of the primers used for cloning. It includes the name of the construct and the gene 
being amplified, the primer sequence and the template. Underlined are the START, or an in frame start, 
and STOP codons; in bold are the restriction sites.
Name Name of construct
(gene amplified)
Primer sequence (5’
 3’) Template
DsRed.NheI (S) DsRed-Vpr (DsRed) ATGCTAGCCACCATGGATAGCAC
TGAG
pIRES2DsRed
-Express2
DsRed.HindIII 
(AS)
DsRed-Vpr (DsRed) CAAGCTTCTGGAACAGGTGGTGG
C
pIRES2DsRed
-Express2
Vpr (S) DsRed-Vpr (Vpr) CCTGTTCCAGAAGCTTGAACAAGC
CCCAGAAG
pEGFP-Vpr
Vpr. XbaI (AS) DsRed-Vpr (Vpr) GTGGATCCTCTAGACTAGGATCT
ACTGGCTCC
pEGFP-Vpr
RFP.BamHI (S) FUW-RFP GGATCCGTCGCACACCATGGCCT #318/RFP
RFP.EcoRI
(AS)
FUW-RFP AGAATTCGAAGCTTGAGCTCGAG
ATC
#318/RFP
Luc. BamHI (S) FUW-Luc TGGATCCACCATGGAAGACGCCA
AA
pGL3-Basic
Luc. EcoRI 
(AS)
FUW-Luc CGCGAATTCTCTAGAATTACACG
GCGATC
pGL3-Basic
IRES2-DsRed 
(S)
FUW-IRESDsRed TCGAATTCTGCAGTCGACGGTACC pIRES2DsRed
-Express2
IRES2-
DsRed.EcoRI 
(AS)
FUW-IRESDsRed TAGAATTCGGCCGCCTACTGAAC
AGG
pIRES2DsRed
-Express2
DsRed.BamHI 
(S)
FUW- DsRed ATGGATCCCACCATGGATAGCAC
TGAG
pIRES2DsRed
-Express2
DsRed (AS) FUW-
DsRedIRESRenilla 
(DsRed)
CTACTGGAACAGGTGGTGGCG pIRES2DsRed
-Express2
DsRed.IRES 
(S)
FUW-
DsRedIRESRenilla 
(IRES)
CCACCACCTGTTCCAGTAGGCCCC
TCTCCCTCCC
pIRES2DsRed
-Express2
IRES.Renilla 
(AS)
FUW-
DsRedIRESRenilla 
(IRES)
GTCGTACACCTTGGAAGCCATGGT
TGTGGCCATATTAATCATCGTG
pGL4.70
Renilla (S) FUW-
DsRedIRESRenilla 
(Renilla)
ATGGCTTCCAAGGTGTACGAC pGL4.70
Renilla.EcoRI 
(AS)
FUW-
DsRedIRESRenilla 
(Renilla)
GACGAATTCATTACTGCTCGTTCT 
TCAG
pGL4.70
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Table XII. (Continued)
Name Construct (gene 
amplified)
Primer sequence (5’
 3’) Template
IRES.TK (AS) FUW-DsRedIRESTK
(IRES)
TGACAGGGGTAGCTGGCCATGGTT 
GTGGCCATATTATCATCGTG
pIRES2DsRed
-Express2
TK (S) FUW-DsRedIRESTK
(TK)
ACCATGGCCAGCTACCCCTGTCA TK.007
TK.EcoRI (AS) FUW-DsRedIRESTK
(TK) 
TGTTAAGAATTCATCAGTTGGCCT 
CGCCCATCT
TK.007
DsRed.DTA 
(AS)
FUW-DsRedTK 
(DsRed)
CTGGAACAGGTGGTGGCGG pIRES2DsRed
-Express2
DsRed.TK (S) FUW-DsRedTK
(TK)
CGCCACCACCTGTTCCAGGCGGCC 
AGCTACCCCTGTCACC
TK.007
TK.BamHI (S) FUW-TKDsRed
(TK)
GAGGATCCCACCATGGCCAGCTA
C CCCTGT
TK.007
TK.DsRed (AS) FUW-TKDsRed
(TK)
GCCTCGCCCATCTCCCGGGCGAAG TK.007
TK.DsRed (S) FUW-TKDsRed
(DsRed)
GAGATGGGCGAGGCCAACGCGGA
TAGCACTGAGAAC
pIRES2DsRed
-Express2
DsRed. EcoRI 
(AS)
FUW-TKDsRed
(DsRed)
AGAGTGAATTCCGCCTACTGGAA
C AGGTGGTGG
pIRES2DsRed
-Express2
Renilla.BamHI 
(S)
FUW-
RenillaIRESTK
(Renilla)
GTTGGATCCGCCACCATGGCTTCC 
AAG
pGL4.70
Renilla (AS) FUW-
RenillaIRESTK
(Renilla)
GACTCTAGAATTACTGCTCGTTCT
TCAGCAC
pGL4.70
Table XIII. Primers used for real-time PCR.
Name Primer sequence (5’
 3’)
Actin (S) CTGGAACGGTGAAGGTGACA
Actin (AS) AAGGGACTTCCTGTAACAACGCA
Renilla.nt 551(S) TCGAGTCCTGGGACGAGTGG
Renilla.nt 700 (AS) CAGCGAACTCCTCAGGCTCC
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Appendix B – optimization of transduction
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Figure 46. Optimization of in vitro viral transduction using Sindbis/ZZ pseudotyped lentiviral 
vectors expressing DsRed. Two different conditions, with different amounts of plasmids were used for 
viral production. (Blue: 1 µg Gag/pol; 0.32 µg Rev; 1.4 µg FuWDsRed; 0.7 µg Sindbis/ZZ); Black: 1.2 
µg Gag/pol; 0.38 µg Rev; 0.38 µg FuWDsRed; 1.2 µg Sindbis/ZZ). Each virus (130 ng HIV p24) was 
used to transduce Jurkat cells with or without retronectin treatment to the plates (60 µg/mL) and each of 
this subjected or not to an acidic pH treatment. Anti-HLA-FITC (5µg/ml) was used for redirecting viral 
infection. Forty-eight hours after medium change, cells were analysed by flow cytometry. 
Lentiviral target-specific strategy for molecular therapy
150
D
sR
e
d
FITC
RetronectinCells
10
0
10
1
10
2
10
3
10
4
10 0
10
1
10
2
10
3
10
4
0.85
0.64
0.1398.4
RetronectinCells+Black+pH
10 0 10 1 10 2 10 3 10 4
10
0
10 1
10
2
10 3
10
4
0.54
42.1
55.81.64
RetronectinCells+Black-pH
10
0
10
1
10
2
10
3
10
4
10 0
10
1
10
2
10
3
10
4
0
31.7
68.20.087
RetronectinCells+Blue+pH
10 0 10 1 10 2 10 3 10 4
10 0
10
1
10 2
10
3
10
4
0.85
85
13.60.58
RetronectinCells+Blue-pH
10 0 10 1 10 2 10 3 10 4
10 0
10
1
10 2
10
3
10
4
0
80.3
19.60.094
Figure 46. Continued.
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Appendix C – comparison of viral concentration methods
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Figure 47. Comparison between transduction efficiency mediated by virus concentrated by 
ultracentrifugation or by Lenti-X concentrator. Sindbis/anti-FITC M1234 pseudotyped lentiviruses 
were produced in 293T cells and viral supernatant was divided in two parts that were concentrated either 
by ultracentrifugation or by the Lenti-X concentrator. Same volume of virus was used to transduce
Jurkat cells in retronectin treated plates and subjected to an acidic pH treatment. Anti-CD7-FITC 
(5µg/ml) was used for redirecting viral infection. Forty-eight hours after medium change, cells were 
analysed by flow cytometry for the percentage of DsRed
+
cells.
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Appendix D
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Appendix D – comparison of the transduction efficiency 
between Molt-4 and Jurkat cells
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Figure 48. Comparison between transduction efficiency of Molt-4 and Jurkat mediated by 
Sindbis/anti-FITC Wt pseudotyped lentiviruses. Sindbis/anti-FITC Wt pseudotyped lentiviruses were 
produced in 293T cells and viral supernatant was concentrated by ultracentrifugation. Approximately 
200 ng (HIV p24) of virus were used to transduce Molt-4 cells (A) or Jurkat cells (B) in retronectin 
treated plates (40 µg/mL) and subjected to an acidic pH treatment. Anti-HLA-FITC (5µg/ml) was used 
for redirecting viral infection. Forty-eight hours after medium change, cells were analysed by flow 
cytometry for the percentage of DsRed
+
cells.
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Appendix E – analysis of reporter gene expression from the 
plasmids FUW/DsRedIRESRenilla and 
FUW/RenillaIRESTK, in 293T cells
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Figure 49. Analysis of the reporter gene expression of several FUW/DsRedIRESRenilla clones in 
vitro in 293T cells. Eight clones were selected for transfection of 293T cells and further analysis of the 
renilla luminescence and DsRed fluorescence, on the Infinite 200 device. FUW/DsRed was included as 
a control. Clone number eight was the one chosen for the future experiments.
Lentiviral target-specific strategy for molecular therapy
156
0
5000
10000
15000
20000
25000
30000
35000
40000
45000
50000
1 2 3 4 6 7 8 9 10 293T 293T 
w/o 
GCV
F
lu
o
re
s
c
e
n
c
e
 in
te
n
s
it
y
RenillaIRESTK clones
0
1000000
2000000
3000000
4000000
5000000
6000000
7000000
8000000
1 2 3 4 6 7 8 9 10 293T 
L
u
m
in
e
s
c
e
n
c
e
 in
te
n
si
ty
RenillaIRESTK clones
A
B
Figure 50. Analysis of the reporter gene expression of several RenillaIRESTK clones in vitro in 
293T cells. Ten clones were selected for transfection of 293T cells and further analysis of the renilla 
luminescence (A) and the cell viability by AlamarBlue assay (B), on the Infinite 200 device. Non-
transfected 293T cells were included as a negative control. Clone number one was the one chosen for 
the future experiments.
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Appendix F – analysis of the sensitivity of the untransduced 
cell population to GCV treatment
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Figure 51. GCV has no effect on the untransduced cell population. Untransduced Jurkat cells 
corresponding to day 8 of the experiment on Figure 28 were plotted for forward and side scatter. There 
were basically no changes in the percentage of dead cells. 
Lentiviral target-specific strategy for molecular therapy
158
